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T he v e s t ib u la r  s c h w a n n o m a  (VS) h a s b e e n  re c o g n iz e d  sin c e  th e  la te  18th cen tu ry , 
w h e n  it w a s  d e scrib e d  on  th e  b a sis  o f  p o s tm o rte m  d a ta .1 It w a s  fo rm e r ly  ca lle d  
'a co u stic  n e u ro m a ' in  lig h t o f  f in d in g s  p u b lish e d  in  1908 b y  V erocay, w h o  n o te d  th a t 
it c o n sis te d  o f  p a ra lle l fibers th a t  h e  th o u g h t w e r e  a x o n e s .2 T he tu m o r h a s a lso  b e e n  
c a lle d  'a co u stic  n e u rin o m a ' a n d  'a co u stic  n e u rile m m o m a '. E v e n tu a lly , in  1942, 
M u r ra y  a n d  Stout p ro v e d  th a t th e  tu m o r o r ig in a te s  fro m  S c h w a n n  cells. T h ese  are 
su p p o rtin g  cells at th e  ou ter a sp e ct o f  p e rip h e ra l n e rv e s  a n d  are  resp o n sib le  for th e  
m y e lin  sh e a th  th a t  in su la te s  th e  n e rv e s .3 The correct n o m e n c la tu re  for th is  sp ecific  
c e re b e llo p o n tin e  a n g le  tu m o r sh o u ld  th e re fo re  b e  'v e s tib u la r  n e r v e  sc h w a n n o m a '. 
N o w a d a y s , th e  tu m o r is c a lle d  'v e s tib u la r  sc h w a n n o m a '. The c lin ic a l s ign s a n d  
sy m p to m s h a v e  b e e n  re c o g n ize d  sin ce  th e  en d  o f  th e  19th cen tu ry , w h e n  th e  d iagn osis 
w a s  b a se d  s o le ly  on  c lin ic a l d ata . The m o st c o m m o n  p r im a r y  sy m p to m s are 
u n ila te r a l h e a r in g  loss, t in n itu s  a n d  b a la n c e  p ro blem s. L arge tu m o rs  c a n  cau se  
fa c ia l n u m b n e ss  or e v e n  h y d ro ce p h a lu s . X -ray d ia g n o s is  a p p e a re d  to  b e  h e lp fu l 2, 
th o u g h  its r e lia b ility  w a s  q u e stio n ab le . It w a s  n ot u n t il  th e  1980s th a t  th e  d ia g n o s tic  
p ro b lem s w e r e  d e f in it iv e ly  so lv ed  w it h  th e  a d v e n t o f m a g n e tic  re so n a n c e  im a g in g  
(MRI). W h ile  m a k in g  it e a s y  to  re c o g n iz e  su c h  a tu m o r, MRI c o u ld  n ot p re v en t 
m is s in g  th e  d ia gn o sis , s in ce  it w a s  n o t c lear to  w h ic h  t y p e  o f  a u d io v e s tib u la r  
sy m p to m s th is  d ia g n o s tic  m o d a lity  sh o u ld  b e  applied .
T he in c id e n c e  o f VS in  th e  n o rm a l p o p u la tio n  is a p p ro x im a te ly  1 p er 10 0,000 a year, 
a n d  m e n  a n d  w o m e n  are  e q u a lly  a ffe c te d .4 Yet th e  rea l in c id e n c e  is p ro b a b ly  m u ch  
h igh er. In te m p o ra l b o n e  stu d ies , VSs w e r e  re p o rte d  to  b e  p re sen t in  1.7 to  2.7% o f  th e  
sp e c im e n s .5, 6 M oreo ver, in  se le c te d  a u to p sy  series, th e  in c id e n c e  o f  u n d ia g n o s e d  VSs 
w a s  as h ig h  as 0 .8-0.9% .7, 8 P re s u m a b ly  th e s e  fig u re s  are  a n  u n r e a lis t ic  re p re sen ta tio n  
o f  th e  rea l in cid en ce. H o w ev er, du e to  th e  w id e r  a v a ila b ili ty  o f  M RI in  th e  last 
d ecad es, VSs h a v e  b e e n  d ia g n o s e d  m o re  fr e q u e n tly  a n d  at a n  earlier sta g e .9,10 
A s y m p to m a tic  VSs are  d isco v e re d  re g u la r ly .11 VSs u s u a lly  a rise  in  th e  in te rn a l 
a u d ito r y  c a n a l a n d  c a n  g r o w  m e d ia lly  in to  th e  c e re b e llo p o n tin e  cistern .
D ia g n o stic  p ro ced u res w e r e  in t im a te ly  re la te d  to  th e r a p e u tic  p ro g ra m s, sin ce  
d ia g n o s in g  th e  tu m o r h a s a lw a y s  m e a n t p ro ce e d in g  to  so m e t y p e  o f  th erap y. 
D ia g n o stic  m o d a litie s  e v e n tu a lly  cre ate d  o p p o rtu n itie s  to  s tu d y  th e  n a tu ra l 
b e h a v io r  o f  V S s.12, 13 T he ra tio n a le  for a ll th e ra p ie s  w a s  b a se d  on  th e  co n cep t o f  tu m o r 
p ro g re ssio n  w it h  life - th r e a te n in g  ou tcom es, as in  o th e r in tra c ra n ia l (m alig n a n t) 





re m o v a l o f  th e  tu m o r. Som e p a tie n ts  w e r e  n o t e lig ib le  for s u rg e r y  b e c a u se  o f  th e ir  
p oo r g e n e ra l con d ition , so th e y  w e r e  fo llo w e d  w it h o u t  h a v in g  h a d  th erap y . S tra n g e ly  
e n o u g h , m a n y  o f  th e s e  u n tre a te d  p a tie n ts  liv e d  lo n g  a fte r w a r d s  w ith o u t  a n y  sign s 
o f  tu m o r p ro g re ssio n .14, 15 Thus, e a r ly  on  th e r e  w a s  a lre a d y  so m e  d o u b t a b o u t th e  life- 
th r e a te n in g  n a tu re  o f  th e  d isord er a n d  th e  n e e d  for in v a s iv e  th erap y . M a n y  m ore 
q u e stio n s  a b o u t th e  n a tu r a l b e h a v io r  o f  VSs h a v e  e m e rg e d  sin ce  MRI b e c a m e  
a v a ila b le . T his im a g in g  te c h n iq u e  a llo w e d  th e  size  o f th e  tu m o r to  b e  e a s ily  a ssessed . 
The first s tu d y  o f  se r ia l M R im a g e s  d e m o n stra te d  th a t  tu m o r g r o w t h  w a s  lim ite d  or 
e v e n  a b se n t in  a su b s ta n tia l n u m b e r  o f  p a tie n ts .16
A fte r  th e  a d v e n t o f  p la in  X -ray in v e s t ig a tio n s  at th e  b e g in n in g  o f th e  20th cen tu ry , 
th e r e  h a s b e e n  s te a d y  im p ro v e m e n t in  im a g in g  m o d a litie s . O ver th e  la st five  
d ecad es, a v a r ie t y  o f  a u d io v e s tib u la r  te s ts  h a v e  b e e n  d e v elo p ed , fo c u s in g  on  sig n s o f 
re tro c o c h le a r  p a th o lo g y . T h ese  te s ts  w e r e  s p e c ific a lly  d e s ig n e d  to  d ia g n o s e  VS. 
D ia g n o stic  p ro ced u res, th e r a p e u tic  p o ssib ilitie s  a n d  d e c is io n -m a k in g  b e c a m e  
c lo s e ly  in te rre la te d  d u rin g  th e  se co n d  h a lf  o f  th e  20th cen tu ry . E ven  to d ay, th e  u se  o f 
im a g in g  to  re p la ce  a u d io v e s tib u la r  te s ts  is s t ill  su b je ct to  co n tro versy , as is th e  choice 
o f  m a n a g e m e n t a fte r  d ia g n o s in g  a VS.
Diagnosis
The m o st fre q u e n t sy m p to m s o f  a VS a re  u n ila te ra l h e a r in g  loss, t in n itu s  a n d  
b a la n c e  disorders. T his s y m p to m o lo g y  c a lle d  for th e  d e v e lo p m e n t o f  a u d io lo g ica l 
a n d  n e u ro to lo g ic a l te s ts  th a t  c a n  d e te ct re tro c o c h le a r  p a th o lo g y . D esp ite  th e  
r e la t iv e ly  h ig h  s e n s it iv ity  a c h ie v e d  b y  c o m b in in g  m u ltip le  tests, im a g in g  h as 
a lw a y s  b e e n  d e c is iv e  in  d e m o n stra t in g  th e  p re se n ce  o f  a s p a c e -o c c u p y in g  lesio n  in  
th e  c e re b e llo p o n tin e  a n g le .17, 18 So fro m  th e  b e g in n in g , th e  role o f  a u d io v e s tib u la r  
e x a m in a tio n s  h a s  b e e n  restricted , m e re ly  p ro v id in g  a rg u m e n ts  to  p ro ceed  to  so m e 
t y p e  o f  im a g in g .
Audiology
A u d io lo g ic  e x a m in a tio n s  are  u s u a lly  th e  s ta r t in g  p o in t in  th e  d ia g n o s tic  process. 
First, p u re  to n e  a u d io m e tr y  is ap p lied . Its d is c r im in a t in g  p o w e r  is ra th er  poor, sin ce  
it is o n ly  a b le  to  d e m o n stra te  u n ila te ra l s e n so rin e u ra l h e a r in g  loss, th e  p ro m in e n t
12
INTRODUCTION
fe a tu re  o f  a VS. The c u rv e  in  th e  p u re  to n e  a u d io g ra m  in  VS p a tie n ts  is u s u a lly  
d o w n -s lo p in g , th o u g h  it m a y  ta k e  o th e r sh a p es as w e ll. S econ dly, sp e e ch  a u d io m e try  
is p e rfo rm ed . R ath er c h a ra c te r is tic  re su lts  are  a f la tte n e d  cu rv e , a d isp ro p o rtio n a te ly  
lo w  m a x im u m  d is c r im in a tio n  a n d  a ro ll-o ver p h e n o m e n o n .19, 20 F ow ler's lo u d n e ss 
b a la n c e  te s t (A ltern a te  B in a u ra l L oud n ess B ala n ce , ABLB) m a y  d o cu m e n t re c ru itm e n t 
a n d  g iv e  a n  in d ic a t io n  o f  th e  p re se n ce  o f  re tro c o c h le a r  p a th o lo g y .21 The a ssessm en t 
o f  th e  Short In cre m e n t S e n s it iv ity  In d ex  (SISI) is a n o th e r w a y  to  d o cu m e n t th e  
d e g re e  o f re c ru itm e n t.22 The Tone D e ca y  te s t c a n  d e m o n stra te  a re d u c tio n  in  th e  
s e n s it iv ity  a n d  re sp o n siv e n e ss  o f  h e a r in g  a fte r  p ro lo n g e d  s t im u la tio n , a p h e n o m en o n  
th a t  is re la te d  to  re tro c o c h le a r  p a th o lo g y .23 T he s ta p e d iu s  re fle x  d e c a y  is a sim ilar, 
m o re  o b je c tiv e  w a y  to  a ssess th is  s y m p to m .24
A  s ig n ific a n t step  fo rw a rd  in  o b je c tiv e  a u d io lo g ic  in v e s t ig a tio n s  o f  re tro co ch le a r  
p a th o lo g y  w a s  th e  a d v e n t o f  B ra in ste m  E voked  R esp o n se  A u d io m e tr y  (BERA or BER) 
in  th e  1970s.25 B y  th is  m e th o d , th e  la te n c y  b e tw e e n  a n  a u d ito r y  s t im u lu s  a n d  th e  
e le c tro e n c e p h a lo g ra p h ic  re sp o n se s is th e  re p re se n ta tio n  o f  a d is tu rb e d  c o n d u c t iv ity  
in  a u d ito r y  p a th w a y s , re s u ltin g  fro m  th e  p re se n ce  o f a VS. Its o v e ra ll s e n s it iv ity  in  
d e te c tin g  a VS m a y  b e  as h ig h  as 92-95% .26, 27 D e p e n d in g  on th e  size  o f  th e  tu m o r, th is  
s e n s it iv ity  m a y  v a r y  b e tw e e n  58 a n d  100%  in  su c h  a w a y  th a t  la rg e r tu m o rs  te n d  to  
h a v e  m o re  BER a b n o rm a lit ie s  th a n  sm a lle r  on es.28-30
Vestibular examinations
The p resen ce  o f  a VS u s u a lly  lead s to  im p a irm e n t o f  th e  a ffe re n t v e s tib u la r  p a th w a y s  
as w e ll  as d a m a g e  to  th e  la b y r in th in e  stru ctu res, re su ltin g  in  d ecreased  resp on ses on 
caloric  stim u latio n . T herefore b i-th erm a l caloric  te s tin g  u se d  to  b e  a n  im p o rta n t 
d ia g n o stic  to o l in  th e  d e te ctio n  o f  p a th o lo g y  in  th e  c ereb ello p o n tin e  an g le. V ario u s 
oth er v e s tib u la r  e x a m in a tio n s  h a v e  b e e n  d escrib ed  for a n a ly z in g  la b y rin th in e  
fu n c tio n in g .31, 32 C aloric te s tin g , h o w e ve r, h as re m a in e d  th e  m a in s ta y  in  th is  field, 
a lth o u g h  its s e n s it iv ity  is rep orted  to  b e  as lo w  as abou t 75% .33 A s m e n tio n e d  earlier, 
c o m b in in g  th e  d ifferen t a u d io vestib u lar tests could stro n g ly  in crease  th e  sen sitiv ity .17, 18
Imaging
P la in  X -ray im a g in g  w a s  u se d  at th e  b e g in n in g  o f  th e  20th c e n tu ry .2 The m ajor 




a VS h a rd ly  d iffe rs  fro m  th a t  o f  th e  su rro u n d in g  b ra in  tissu e . A s  a co n se q u e n c e  th e  
tu m o r  o fte n  c a n n o t b e  d is tin g u ish e d . On th e  o th e r  h a n d , b o n y  s tru c tu re s  c a n  be 
d e p ic te d  q u ite  w e l l  u s in g  p la in  X -ray te c h n iq u e s . Per o rb ita l v i e w  ro e n tg e n o g ra m s 
m a y  re v e a l th e  p re sen ce  o f  w id e n in g  or fu n n e lin g  o f  th e  in te rn a l a u d ito r y  c a n a l.34 
(Fig. 1a)
Figure 1 Progress in  im a g in g  o f  cereb ellop on tin e  a n g le  lesions. ia . T om ogram  o f th e 
p e tro u s b o n es s h o w in g  fu n n e lin g  o f  th e  le ft  a u d ito r y  a co u stic  m ea tu s. 
lb. N o rm a l C.T. a ir  c is te rn o g ra m  i c . S m all VS d e te c te d  w it h  a ir  CT 
c is te rn o g ra p h y  id . C lear im a g e  o f  v e s t ib u la r  s c h w a n n o m a , M RI a fte r  
G a d o lin iu m  con trast.
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T he p ro b lem  is, h o w e v e r, th a t  th is  c a n a l is n ot a lw a y s  w id e n e d  in  VS p a tie n ts, 
p a r t ic u la r ly  w h e n  th e  tu m o r h a s a p ro m in e n t e x tr a m e a ta l lo ca liza tio n . M oreo ver, it 
m ig h t b e  p ro b le m a tic  to  re lia b ly  a ssess a b n o rm a lit ie s  in  th e  sh a p e  o f  th e  in te rn a l 
a u d ito r y  c a n a l s in ce  a n a to m ic a l v a r ia tio n s  in  its s ize  a n d  sh a p e  m a y  occur.
T he u se  o f  co n tra st su b sta n ce s  w a s  d e v e lo p e d  to  im p ro v e  th e  v is u a liz a t io n  o f  space- 
o c c u p y in g  lesio n s.35 For th is  p u rp o s e  s e v e r a l ra d io p a q u e  su b sta n ce s  as w e l l  as ju st 
a ir h a v e  b e e n  u sed . In tra th e c a l a d m in is tra tio n  v ia  a lu m b a r or su b o cc ip ita l p u n c tu re  
w a s  n ee d e d  to  a llo w  th e  c o n tra st m a te r ia l to  re a ch  th e  c e re b e llo p o n tin e  c istern a e. 
From  th e  p a tie n t 's  p e rs p e c tiv e  th is  w a s  a n  u n p le a sa n t a n d  u n c o m fo rta b le  
e x p e rie n ce , a n d  it w a s  n o t w ith o u t  risk .35 T herefore, th is  im a g in g  te c h n iq u e  u se d  to  
b e  a p p lied  o n ly  in  th o s e  p a tie n ts  w h o  h a d  th e  m o st c h a ra c te r is tic  s y m p to m s in 
c o m b in a tio n  w it h  a u d io v e s tib u la r  te s t re su lts  th a t  w e r e  h ig h ly  su sp icio u s for th e  
p re se n ce  o f  a sp a c e -o c c u p y in g  lesio n  in  th e  c e re b e llo p o n tin e  a n g le . S ince n e ith e r 
s y m p to m s nor a u d io v e s tib u la r  te s t re su lts  are  c o m p le te ly  re lia b le  d ia g n o stics, 
fa ilu re s  w e r e  n ot u n c o m m o n . M oreo ver, fa ls e  p o s itiv e  re su lts  o ccu rre d  fre q u e n tly . In 
o th e r w o rd s, a fte r  u n d e r g o in g  th is  b u rd e n s o m e  d ia g n o s tic  p ro ced u re , th e  p a tie n t 
tu rn e d  out to  h a v e  n o VS, a n d  n o ca u se  w a s  fo u n d  for h is u n tre a ta b le  sy m p to m s.
C o n sid era b le  p ro gress w a s  a c h ie v e d  w it h  th e  in tro d u c tio n  o f  CT s c a n n in g  in  th e  
1970s.36 CT s c a n n in g  a llo w s  b e tte r  v is u a liz a t io n  o f  th e  b o n y  s tru c tu re s  o f  th e  sk u ll 
base, a n d  m in o r d iffe re n ce s  in  ra d io lu c e n c y  o f  so ft tis su e s  c a n  b e  m a g n ifie d . W ith  
th e  c o m b in a tio n  o f  CT a n d  in tra th e c a l a d m in is tra tio n  o f  c o n tra st su b sta n ce s  (CT 
c iste rn o g ra p h y ), n e a r ly  100%  s e n s it iv ity  c o u ld  b e  a c h ie v e d .37 H o w ev er, con tra st 
c is te rn o g ra p h y  h a s re m a in e d  a r is k y  a n d  in v a s iv e  p ro ced u re. A n  e x a m p le  o f  a sm a ll 
VS d e te c te d  w it h  a ir CT c is te rn o g ra p h y  is s h o w n  in  F igu re  1c.
MRI, a v a ila b le  for a b o u t 20 y e a rs  n ow , h a s re v o lu tio n iz e d  th e  d ia g n o s is  o f c e re b e llo ­
p o n tin e  a n g le  p a th o lo g y . N o c o n tra st is re q u ire d  in  th e  c e re b e llo p o n tin e  c is te rn  a n d  
n o p o te n t ia lly  h a r m fu l X -rays are  n eed ed . The s e n s it iv ity  is 100%  i f  in tra v e n o u s ly  
a d m in is te re d  g a d o lin iu m  is u se d  as a co n tra st su b s ta n c e  (see F igu re  1d). The 
p ro ce d u re  c a n  b e  re p e a te d  as lo n g  as n eed ed , a n d  th e  size  a n d  sh a p e  o f  th e  tu m o r can  
b e  a c c u r a te ly  a sse sse d  w it h  MRI. D e sp ite  th e  a v a ila b ili ty  o f  th is  su p erb  te ch n iq u e , 
m is s in g  th e  d ia g n o s is  is n o t in fre q u e n t: th e  s ign s a n d  s y m p to m s o f  a VS m a y  v a r y  to 
s u c h  a n  e x te n t th a t  th e  d e c isio n  to  u se  it m a y  b e  p ro b lem a tic . W h e re a s m a k in g  m ore 
M RIs o f  th e  sk u ll b a se  m e a n s  d ia g n o s in g  m o re  VSs, it is d iffic u lt  to  fo rm u la te  a 





N o w a d a y s , p a th o lo g y  in  th e  c ereb ello p o n tin e  a n g le  is m a in ly  d ia g n o se d  on  th e  basis 
o f  im a g in g , g r e a tly  re d u cin g  th e  role o f  a u d io v e stib u la r  e x a m in a tio n . The p resen ce  o f 
su b je c tiv e  h e a rin g  loss a n d  th e  d e m o n stra tio n  o f  a u n ila te ra l se n so rin e u ra l deficit 
are  su ffic ie n t gro u n d s to  p ro ceed  to  MRI. E x te n siv e  a u d io v e s tib u la r  e x a m in a tio n s  
u se d  to  b e  carried  ou t for a ca d e m ic  a n d  m e d ic o -le g a l p u rp o ses  and, in  so m e p atien ts, 
to  p ro vid e  se le ctio n  crite ria  for sp e c ific  tre a tm e n t m o d a lities.
The natural behavior of vestibular schwannomas
S eria l M RI in  p a tie n ts  w i t h  a VS h a s  d e e p e n e d  th e  u n d e r s ta n d in g  o f th e  b io log ic  
b e h a v io r  o f  th e  tu m o r. It h a s  a llo w e d  th e  in d o len t n a tu re  o f  th e  tu m o r to  b e  a ssesse d  
o b jectiv e ly , a n d  m a n y  tu m o rs  h a v e  s h o w n  n o g r o w t h  a fte r  y e a rs  o f  fo llo w -u p .13 In 
th e s e  cases, it is a ss u m e d  th a t  s ta b iliza tio n  o cc u rre d  a fte r  a p e rio d  o f  p ro g re ssio n  in  
size. The p a th o g e n e tic  m e c h a n is m  o f  th is  p h e n o m e n o n  is u n k n o w n . L o n g itu d in a l 
s tu d ie s  w it h  re p e a te d  M RI in  c o m b in a tio n  w it h  a u d io lo g ic  e x a m in a tio n s  h a v e  
re v e a le d  th a t  p ro g re ssio n  in  sy m p to m s a n d  h e a r in g  d e te rio ra tio n  are  n ot co m p a tib le  
w i t h  p ro g re ssio n  in  size.39 E ven  in  p a tie n ts  w i t h  sta b le  tu m o rs, p ro g re ss iv e  d e a fn e ss 
m a y  occur. A  g r o w in g  lesio n  is n ot a u to m a tic a lly  a cc o m p a n ie d  b y  a p ro gressio n  o f 
h e a r in g  im p a irm e n t.40 N o re la tio n  c o u ld  b e  d e m o n stra te d  b e tw e e n  th e  s ize  o f  th e  
tu m o r  a n d  th e  se rio u sn ess  o f  th e  sy m p to m s, on th e  on e  h a n d , a n d  th e  d e g ree  o f  
h e a r in g  loss, on th e  other, a lth o u g h  B ra in ste m  E voked  R esp o n se  A u d io m e try  d ata  
do es s u g g e s t  a re la tio n sh ip  b e tw e e n  h e a r in g  le v e l a n d  tu m o r size.28-30 So far, n o  w e ll  
fo u n d e d  e x p la n a tio n  h a s b e e n  o ffe re d  o f  th e  p a th o g e n e tic  m e c h a n is m  th a t  is 
re sp o n sib le  for th e  d is c r e p a n c y  b e tw e e n  c lin ic a l d a ta  a n d  tu m o r  v o lu m e  or 
p ro gressio n . It is s t ill u n k n o w n  w h y  a n d  at w h a t  p a ce  so m e  tu m o rs  g r o w  a n d  oth ers 
do not. N or is it k n o w n  w h y  so m e tu m o rs  are  a c c o m p a n ie d  b y  seriou s, p ro g re ssiv e  
s ig n s  a n d  sy m p to m s w h ile  o th e rs  are  not. In short, th e  d e te rm in a n ts  o f  VS b e h a v io r  
r e m a in  la r g e ly  u n k n o w n .
Yet th e r e  is c o m p e llin g  n e e d  for su c h  k n o w le d g e  in  p la n n in g  th e  m a n a g e m e n t o f 
VSs. U n der id e a l c irc u m s ta n c e s , w e  w o u ld  h a v e  access to  in fo rm a tio n  n ot o n ly  on 
p ro g re ssio n  in  s ize  b u t a lso  on th e  co u rse  o f  c lin ic a l p a ra m eters. In sigh t in to  th e  





T he b a sis for a ll th e r a p e u tic  s tra te g ie s  h a s e v o lv e d  b e y o n d  th e  id ea  th a t  a tu m o r h a s 
to  b e  re m o ve d . P rev iou sly , a tu m o r w a s  se e n  as a p ro g re ss iv e  sp a c e -o c c u p y in g  lesion  
th a t  sh o u ld  b e  e lim in a te d . The p a ra d ig m  w a s  b a se d  on  th e  p re m is e  th a t  th e  
p a th o lo g y  h a s to  b e  re m o v e d  in  order to  re lie v e  th e  sy m p to m s a n d  a l lo w  th e  p a tie n t 
to  re tu rn  to  n o rm a lity . Thus, for m a n y  d ecad es (an d  so m e tim e s  e v e n  n o w a d a y s !) th e  
VS h a s b e e n  p u t on  a p ar w i t h  o th er in tra c ra n ia l tu m o rs. A cco rd in g ly , su rg e r y  w a s  
d e e m e d  b o th  n e c e s s a r y  a n d  ju stifie d , e v e n  i f  th e  o p e ra tio n  h a d  seriou s risks a n d  
co u ld  re su lt in  m o rta lity , m o rb id ity  or d isa b ility . T he first s u c c e ss fu l VS op era tio n  
w a s  p e rfo rm e d  b y  Sir C h arles B a la n c e  in  1894, a n d  a m o r ta lity  ra te  o f  a ro u n d  80% for 
in tra c ra n ia l su rg e r y  w a s  re p o rte d  b y  F. K rau se  in  1903.41 F acia l n e r v e  p a ra ly s is  w a s  
in v a r ia b ly  p resen t; th e  first rep o rts on p re s e rv a tio n  o f  th e  fa c ia l n e r v e  d a te  fro m  th e  
19 6 0 s.42 M oreo ver, a v a r ie t y  o f  o th er n e u ro lo g ic  d eficits  co u ld  re su lt fro m  s u rg e r y  in  
th e  c e re b e llo p o n tin e  a n g le . T he in tro d u ctio n  o f  n e w  su rg ica l te c h n iq u e s , n o ta b ly  th e  
tr a n s la b y r in th in e  ap p roach , n e w  m e a su re s  in  a n e sth e s ia  a n d  th e  a p p lica tio n  o f  
a n tib io tics , le d  to  a d e c lin e  in  m o rta lity . B ut d esp ite  th is  p ro gress, th e r e  are  s t ill  risks 
to  su rgery.
In th e  1970s, so m e  d o u b ts a ro se  a b o u t th e  v a l id it y  o f  th e  c la ss ic a l s u rg ic a l stan d p o in t. 
T here w a s  g r o w in g  e v id e n c e  th a t  n o n -tre a te d  p a tie n ts  c o u ld  s u r v iv e  th e  tu m o r a n d  
th e r e  w a s  d e c lin in g  a c c e p ta n c e  o f  d e b ilita t in g  p o s to p e ra tiv e  se q u e la e .14, 15 M o reo ver 
a n o v e l th e r a p y  b e c a m e  a v a ila b le , n a m e ly  s in g le -d o se  ste re o ta c t ic  ra d io th e ra p y  
(SR). W h ile  L ek sell h a d  in tro d u ce d  ste re o ta c t ic  ra d ia tio n  m e th o d s  in  1951, it w a s  not 
t i l l  1971 th a t  th e  first VSs w e r e  tr e a te d  b y  g a m m a  k n ife  ra d io s u rg e ry  (GKRS). A t 
p resen t, GKRS co n sists  o f  a d m in is te r in g  a s in g le  dose  o f  co b a lt ra d ia tio n  a fte r  M R 
im a g in g , 3D re c o n stru c tio n  a n d  s te re o ta ctic  p la n n in g  u s in g  a f ix e d  fra m e  on  th e  
h e a d .43 T his c a n  b e  ca rr ie d  ou t as a d a y  care  procedu re.
T he in tro d u ctio n  o f  GKRS p ro m p te d  a p ro b in g  d e b a te  on  th e  v a lu e  o f SR co m p a re d  to  
su rg ery , a n  issu e  th a t  is s t ill u n re so lv e d . It is n ot su rp r is in g  th a t  th e  m o st v e h e m e n t 
o p p o sitio n  to  SR c a m e  fro m  la rg e  su rg ica l cen te rs  a n d  th a t  th e  d iscu ssio n  w a s  m a in ly  
b a se d  on  e m o tio n s  in ste a d  o f  sc ie n tific  a rg u m e n ts . The o p p o n en ts  a rg u e d  th a t  th e  
tu m o r w o u ld  c o n tin u e  to  g r o w  a fte r  irra d ia tio n , w h e r e b y  SR im p lie d  serio u s r isk  o f  a 
ra d ia tio n -in d u c e d  m a lig n a n c y  in  la ter life .44-49 If s u rg e r y  w e r e  n e c e s s a r y  a fte r  SR, 
th e r e  w o u ld  b e  m u c h  g rea te r  r isk  o f  c o m p lic a tio n s  su c h  as fa c ia l n e r v e  d eficit.50 A lso, 




w o u ld  b e  a n  u n b e a ra b le  b u rd en  for th e  p a tie n ts. In con tra st, th e  a d v o c a te s  o f  SR 
stre sse d  th e  p oor re su lts  o f  su rgery , th e  p o s to p e ra tiv e  m o rb id ity , m o r ta lity  (in larger 
series, up to  1%), serio u s se q u e la e  a n d  loss o f  h e a r in g .51 T h e y  e m p h a s ize d  th e  h ig h  
d e g re e  o f a rre ste d  tu m o r p ro g re ssio n  a fte r  SR, th e  p re s e rv a tio n  o f  c ra n ia l n e rv e  
fu n c t io n s  (su ch  as for th e  fa c ia l n e r v e  a n d  h e a rin g ), th e  la ck  o f  serio u s r isk  a n d  th e  
p a tie n t 's  com fort.
The in tro d u c tio n  o f  MRI a llo w e d  e a s y  a n d  a cc u ra te  fo llo w -u p  o b se rv a tio n s  on  th e  
n a tu r a l b e h a v io r  o f  VS. A s a co n se q u en ce , c o n s e rv a tiv e  m a n a g e m e n t (w ait-an d - 
scan) w a s  in tro d u ce d  a n d  so on  g a in e d  w id e s p re a d  p o p u la rity . This t y p e  o f 
m a n a g e m e n t w a s  n o t b a se d  on  sc ie n tific  co n sid eratio n s e ith er: th is  s tr a te g y  w a s  
a d o p te d  b y  tr ia l  a n d  -e rr o r  a n d  e v e n tu a lly  p ro ve d  s u c c e ss fu l in  m a n y  cases. A s 
m ig h t b e  e x p e c te d , c o n s e rv a t iv e  m a n a g e m e n t w a s  se r io u s ly  c r itic ize d  b y  th e  
a d v o c a te s  o f  s u rg e r y  as w e ll  as b y  th e  su p p o rte rs  o f  ra d io th erap y , a g a in  m o stly  
w it h o u t  so u n d  sc ie n tific  a rg u m e n ts .
G ra d u a lly  th e  d iscu ssio n  s h ifte d  fro m  th e  d o m a in  o f  th e  su rg eo n s a n d  th e  SR/GKRS 
a d v o c a te s  to w a rd s  th e  d o m a in  o f  th o s e  w h o  w a n t  to  tre a t a n d  th o s e  w h o  w a n t  to 
re fra in  fro m  th erap y . B o th  th e  a v a ila b ili ty  o f  a n  in e x h a u s tib le  a m o u n t o f  VS 
in fo rm a tio n  on th e  in te rn e t a n d  a b e tte r  o rg a n iz a tio n  o f  p a tie n t a sso c ia tio n s  h a v e  
m a d e  p a tie n ts  m o re  a ssertiv e . A t th e  sa m e  tim e, th e  q u a lity  o f  life  o f  th e  VS p a tie n t 
b e c a m e  on e o f  th e  p r im a r y  o u tco m e  m ea su res.
Aim of the study
The o b je c tiv e  o f  th e  s tu d y  d e scrib e d  in  th is  th e s is  is tw o fo ld . The first a im  is to 
c o n trib u te  to  th e  u n d e r s ta n d in g  o f  th e  n a tu ra l b e h a v io r  o f  VSs. A  p a tie n t 's  tu m o r 
m a y  b e  g r o w in g  or stab le. A  g r o w in g  tu m o r req u ires so m e  ty p e  o f tre a tm e n t, 
w h e r e a s  a sta b le  on e m a y  b e  su ita b le  for c o n s e rv a t iv e  m a n a g e m e n t. T he q u e stio n  is 
w h e th e r  a r isk  p ro file  for g r o w t h  c a n  b e  d e fin e d  on th e  b a sis o f  d a ta  a v a ila b le  at th e  
t im e  o f  d ia gn o sis.
The se co n d  a im  is to  ad d  to  th e  b o d y  o f  k n o w le d g e  o f  th e  v a lu e  o f  GKRS as a th e r a p y  
for p a tie n ts  w i t h  a VS. This p a rt o f  th e  in v e s t ig a tio n  con sid ers p o st-tre a tm e n t d ata  
on  th e  s ta b iliz a tio n  o f  tu m o r d im en sio n s, on th e  p re s e rv a tio n  o f  fa c ia l n e r v e  fu n c tio n  
a n d  h e a rin g , on t in n itu s  a n d  on q u a lity  o f  life . In th e  m a jo r ity  o f  th e  G K R S-treated 
p a tie n ts, th e  th e r a p e u tic  g o a ls  are  a ch iev ed . In so m e  o f  th e s e  p a tie n ts, h o w e ve r,
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p ro g re ssio n  in  tu m o r size  m a y  occur. In th a t  lig h t, th is  s tu d y  seek s to  id e n tify  
p red icto rs o f  s u c c e ss fu l a n d  u n s u c c e s s fu l GKRS tr e a tm e n t u s in g  p re tre a tm e n t au- 
d io v e s tib u la r  data.
Study design and limitations
T he s tu d y  on  r isk  fa cto rs  o f  tu m o r g r o w t h  p e r ta in s  to  th o s e  p a tie n ts  w h o  d id  not 
h a v e  a n y  t y p e  o f  tre a tm e n t, s p e c ific a lly  th e  'c o n s e rv a tiv e ly  m a n a g e d ' or 'w a it-a n d - 
sca n ' grou p  (W & S). VS p a tie n ts  m a y  re c e iv e  c o n s e rv a tiv e  m a n a g e m e n t for a v a r ie ty  
o f  reaso n s: sm a lle r  tu m o r size, p oo r g e n e ra l co n d itio n , p ro fitab le  h e a rin g , a 
lo n g -la s tin g  h is to r y  a n d  w is h e s  o f  th e  p a tie n t, for in sta n ce . C o n seq u e n tly , th e  
co m p o sitio n  o f  th e  s tu d y  grou p  is n ot th e  re su lt o f  ra n d o m iza tio n . T his im p lie s  th a t 
th e  c lin ic a l d a ta  a n d  sy m p to m s o f  th e  s tu d ie d  p a tie n ts  m ig h t n ot b e  id e n tic a l to  
th o s e  o f  th e  p a tie n ts  w h o  d id  h a v e  su rg e r y  or SR. In th a t sen se, th e  s tu d y  d e s ig n  has 
so m e  b u ilt- in  lim ita tio n s, w h e r e b y  g e n e r a liz a tio n  o f  th e  re su lts  w i l l  h a v e  no 
s c ie n t if ic a lly  ju s t if ie d  g ro u n d s. H o w ev e r, th e  b o d y  o f k n o w le d g e  on th e  n a tu ra l 
b e h a v io r  o f  VSs is ra th er  sp arse . Thus, co m p a riso n  a n d  c o m b in a tio n  o f  our re su lts  
w i t h  d a ta  fo u n d  in  th e  lite ra tu re  m a y  n o n e th e le ss  m a k e  a w o r th y  co n trib u tio n  to  
o u r p resen t k n o w le d g e  o f  th e  su bject.
T he lim ita t io n s  o f  th e  s tu d y  on  th e  n a tu r a l b e h a v io r  o f  VSs n o te d  a b o v e  a lso  a p p ly  to 
th e  s tu d y  on  th e  v a lu e  o f  SR in  p a tie n ts  w i t h  a VS. GKRS as th e r a p y  for VS h a s b e e n  
in tro d u ce d  g r a d u a lly  a n d  m o st re su lts  h a v e  b e e n  r e tr o s p e c tiv e ly  a n a ly z e d . For 
o b v io u s  reaso n s, n e ith e r  ra n d o m iz a tio n  nor con tro l grou p s h a v e  b e e n  u se d  in  
p u b lish e d  stu d ies  on th is  su b ject. In p a rtic u la r, e th ic a l co n sid eratio n s p ro h ib it 
co n d u c tin g  p ro p erly  d e s ig n e d  s tu d ie s  on  th e  e ffe c tiv e n e s s  o f  GKRS. Yet d esp ite  th e  
la ck  o f  sc ie n tific  e v id en ce , GKRS is in c r e a s in g ly  ca rr ie d  ou t on a ro u tin e  b a sis in  
m a n y  in s t itu t io n s  w o rld w id e . T herefore, e a ch  a n d  e v e r y  e ffo r t  to  e v a lu a te  th is  
th e r a p y  co u ld  c o n trib u te  to  th e  ra tio n a le  o f  its a p p lica tio n , its  in d ic a tio n s  a n d  
lim ita tio n s.
Outline of the thesis
In th e  se co n d  ch a p te r  o f  th is  th e s is  w e  d e scrib e  a w e ll  d o c u m e n te d  case  h is to r y  th a t 




co n ce rn s a p a tie n t in  w h o m  a g ia n t VS w a s  d ia g n o s e d  18 y e a rs  ago; at th a t  t im e  it 
w a s  co n sid ered  a l ife - th r e a te n in g  situ a tio n . In terestin g ly , th is  p a tie n t h a d  re fu s e d  
th e r a p y  b u t is s t ill  a liv e  a n d  w e ll. The s tu d y  on  th e  n a tu r a l b e h a v io r  o f  VSs is 
d e scrib e d  in  C h a p ters 2.1 a n d  2.2. P a tien ts u n d e r w a it-a n d -s c a n  m a n a g e m e n t w e re  
p ro s p e c tiv e ly  s tu d ie d  w it h  re g a rd  to  p o ssib le  tu m o r  g r o w th . The re su lts  o f  au d io lo g ic  
a n d  v e s t ib u la r  e x a m in a tio n s  as w e l l  as a n a m n e s tic  d a ta  fro m  th e  t im e  o f  d ia g n o sis  
w e r e  d o cu m e n te d . S ta tis tica l a n a ly s e s  w e r e  p e rfo rm e d  on  th is  d a ta  in  order to 
fo rm u la te  a risk  p rofile  o f g r o w th  at th e  t im e  o f  d ia gn o sis  a n d  a risk  profile  for fu tu re  
g r o w th .
C h a p te rs  3.1 th r o u g h  3.4 d ea l w i t h  v a r io u s  a sp e cts  o f  GKRS in  VS p a tie n ts. The 
p a tie n ts  w e r e  p ro s p e c tiv e ly  fo llo w e d  w it h  se r ia l M RI in  order to  a ssess th e  ra te  o f 
su ccess, p a r t ic u la r ly  re g a rd in g  sta b iliz a tio n  o f  th e  size  o f  th e  tu m o r. A  n o te w o r th y  
a sp e c t o f  th is  s tu d y  is th a t  th e  v o lu m e  o f  th e  tu m o rs  w a s  d e te rm in e d  d u rin g  
fo llo w -u p . (C h ap ter 3.1)
The d a ta  on  GKRS tr e a tm e n t, a u d io lo g ic  e x a m in a tio n s  a n d  h is to r y  is d o cu m e n te d , as 
it is in  th e  s tu d y  on tu m o r p ro gressio n  in  th e  w a it-a n d -s c a n  group. A  s ta t is t ic a l 
a n a ly s is  is ca rr ie d  out in  order to  in v e s t ig a te  w h e th e r  th is  d a ta  d iffe rs  in  su c c e s s fu lly  
tr e a te d  p a tie n ts  (s ta b iliz a tio n  o f  th e  tu m o r) co m p a re d  to  th e  d a ta  on fa ilu re s  
(co n tin u e d  g r o w th ). The p u rp o s e  is to  id e n t ify  v a r ia b le s  to  p red ict su ccess a n d  
fa ilu re  o f  GKRS. In th is  a n a ly s is , sp e c ia l a tte n tio n  is p a id  to  th e  in flu e n c e  o f 
d o c u m e n te d  tu m o r g r o w t h  b e fo re  GKRS. (C h ap ter 3.2)
Third ly, th e  in flu e n c e  o f  th e  GKRS tr e a tm e n t on h e a r in g  is q u eried : W h a t is th e  
re la tio n  b e tw e e n  th e  d e g ree  o f  h e a r in g  p re s e rv a tio n  a n d  th e  ra d ia tio n  d o se  at th e  
c o c h le a  a n d  tu m o r? (C h ap ter 3.3)
The in flu e n c e  o f  GKRS on th e  q u a lity  o f  life  is r e tr o s p e c tiv e ly  in v e s t ig a te d  u sin g  
v a lid a te d  q u e stio n n a ire s . (C h ap ter 3.4) A  g e n e ra l d iscu ssio n  w it h  c o n clu d in g  
re m a rk s is p re s e n te d  in  C h a p ter 4. The re su lts  o f  th e  s tu d ie s  d e scrib e d  in  th is  th es is  
a re  co m p a re d  to  d a ta  fo u n d  in  th e  lite ra tu re . T his ch a p te r  a lso  d iscu sse s  th e  sco p e for 
g e n e r a liz a tio n  as w e l l  as so m e im p lic a tio n s  o f th e  re su lts  for c lin ic a l p ra ctice . Som e 
re c o m m e n d a tio n s  for fu tu r e  re se a rc h  a re  m ade.
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Abstract
Introduction: T re a tm e n t s tra te g ie s  for v e s t ib u la r  s c h w a n n o m a  in c lu d e  m ic ro ­
su rg ery , s te re o ta ctic  ra d io th e r a p y  a n d  c o n s e rv a tiv e  m a n a g e m e n t (w a it a n d  scan). 
To a vo id  n e u ro lo g ica l c o m p lica tio n s or e v e n  d eath , th e  p referred  tr e a tm e n t for la rg e  
tu m o rs , h a v in g  a n  e x tr a m e a ta l d ia m e te r  >3.0 cm , is su rgery.
Objective/ methods: W e p re sen t th e  case  h is to r y  o f  a m a n  w it h  a la rg e  v e s tib u la r  
s c h w a n n o m a  w h o  h a d  re fu s e d  tr e a tm e n t a n d  w a s  se e n  a g a in  e ig h te e n  y e a rs  later.
Results: This p a tie n t h a d  n o t d e v e lo p e d  sy m p to m s o th e r th a n  th e  in it ia l  h e a rin g  
loss. R ep eated  im a g in g  s h o w e d  th a t  th e  tu m o r h a d  n ot g r o w n  a n d  th e  b ra in -s te m  
co m p ressio n  h a d  n o t p ro gressed .
Conclusion: T his case  h is to r y  illu s tra te s  th e  u n p re d ic ta b le  g r o w t h  p a tte rn  o f 
v e s t ib u la r  s c h w a n n o m a s . A p p a ren tly , e v e n  la rg e  tu m o rs  in  c lose  p r o x im ity  to  th e  
b ra in  ste m  m a y  re m a in  stab le  for m a n y  y e ars . H o w ev er, th e re  s t ill  are  n o v a lid  
a rg u m e n ts  to  re fra in  fro m  th e r a p y  in  p a tie n ts  w i t h  a la rg e  v e s t ib u la r  sc h w a n n o m a , 
s in c e  re lia b le  g r o w t h  p red icto rs are  n ot a va ilab le .
A LARGE VS THAT DID NOT GROW FOR 18  YEARS
T re a tm e n t s tra te g ie s  for v e s t ib u la r  s c h w a n n o m a  (VS) in c lu d e  m icro su rgery , 
ste re o ta c t ic  ra d io th e r a p y  a n d  c o n s e rv a tiv e  m a n a g e m e n t (w a it a n d  scan). To p re v en t 
b ra in -s te m  com p ressio n , m ic ro s u rg e ry  is u s u a lly  th e  p re ferre d  tr e a tm e n t for la rg e  
tu m o rs. W e  d iscu ss  th e  h is to r y  o f  a m a n  w it h  a la rg e  v e s t ib u la r  s c h w a n n o m a  w h o  
re fu s e d  tr e a tm e n t a n d  w a s  se e n  a g a in  a fte r  e ig h te e n  y ears .
Introduction
Case report
A  65-year-old  m a le  w a s  se e n  in  1989 b e c a u se  o f  h e a r in g  loss a n d  t in n itu s  o f  h is  rig h t 
ear. H e re p o rte d  h a v in g  so m e  v e r t ig o  in  th e  p a st b u t at th a t  m o m e n t o n ly  su ffe re d  
fro m  slig h t im b a la n ce . P h y sic a l e x a m in a tio n  re v e a le d  a n o rm a l a sp e ct o f th e  
e a rd ru m  on b o th  sides. The fu n c t io n  o f  th e  c ra n ia l n e rv e s  V  a n d  VII w a s  n orm al. 
A u d io m e tr y  s h o w e d  p ro fo u n d  d e a fn e ss  on th e  r ig h t side a n d  su b n o rm a l h e a r in g  in 
h is le ft  ear (Fig. 1). T here w a s  a sp o n ta n e o u s  ro ta to ry  n y s ta g m u s  to  th e  le ft  side. 
E le c tro n y sta g m o g ra p h ic  e x a m in a tio n s  re v e a le d  a c o m p le te  r ig h t v e s t ib u la r  paresis.
B eca u se  o f  th is  a u d io v e s tib u la r  a s y m m e t r y  a m a g n e tic  re so n a n c e  im a g in g  (MRI) 
sc a n  w a s  o b ta in e d .1 T his sc a n  re v e a le d  a la rg e  c e re b e llo p o n tin e  a n g le  m a ss on th e  
r ig h t side. The m a x im a l e x tr a m e a ta l d ia m e te r  w a s  3.0 cm . The in te rn a l a u d ito ry  
c a n a l w a s  e n la rg ed . The tu m o r co m p resse d  th e  c e re b e llu m  a n d  th e  b ra in  stem , 
c a u s in g  a m in o r s h ift  o f  th e  b r a in s te m  to  th e  le ft  (Fig. 2). O b v io u s ly  th e  p re sen ce  o f  a 
la rg e  VS on  th e  r ig h t side w a s  a p p ro p r ia te ly  d o cu m e n te d .
W h e n  c o u n s e lin g  th e  p a tie n t, w e  tr ie d  to  c o n v in c e  h im  th a t h is  lesio n  w a s  p o te n t ia lly  
l ife - th r e a te n in g  a n d  s tro n g ly  a d v is e d  m ic ro su rg e ry . H o w ev er, th e  p a tie n t p e rs iste d  
in  re fu s in g  a n y  t y p e  o f  tr e a tm e n t e s p e c ia lly  su rg ery . H e e x p re s se d  a p re fe re n c e  for 
h e rb a l a n d  m a g n e tic  th e r a p y  a n d  d e lib e ra te ly  d isa p p e a re d  fro m  fo llo w -u p . In 2007 
w e  w e r e  ab le  to  g e t in  co n ta ct w i t h  h im  a g a in , a n d  on  th a t  o cca sio n  h e  w a s  w i l l in g  
to  g iv e  us so m e  re le v a n t in fo rm a tio n . B y  th e n  h e  w a s  83 y e a rs  old a n d  re p o rte d  to  be 
in  e x c e lle n t co n d itio n . W h ile  th e  d e a fn e ss  in  h is  r ig h t ear h a d  p ers isted , h e  h a d  got 
u se d  to  h is  h a n d icap , as h is  le ft-sid e d  h e a r in g  w a s  s u b je c t iv e ly  n orm al.
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Figure 2 T i-w e ig h te d  M R im a g e s  o f  th e  p o sterio r fo ssa  in  1989 s h o w in g  a la rg e  
v e s tib u la r  s c h w a n n o m a  on th e  r ig h t side.
28
A LARGE VS THAT DID NOT GROW FOR 18 YEARS
Figure 3 T 2-w eigh ted M R im a g e s o f  th e  b rain  in  2007 sh o w in g  th e  large  vestib u la r 
sc h w a n n o m a  on th e  righ t side. Part o f it had  develo p ed  a cystic  con sisten cy  
(arrow).
The p a tie n t re fu s e d  our n e w  o ffe r  o f  c lin ic a l e x a m in a tio n  a n d  a u d io m e tr y  b u t did  
a g re e  to  u n d e rg o  M R im a g in g . F ig u re  3 sh o w s  th e  resu lts . A p p a r e n t ly  th e  tu m o r  is 
s t ill th ere . T he size  o f  th e  VS h a s  n o t ch a n g ed , a lth o u g h  p a rt  o f  it h a d  d e v e lo p e d  a 
c y s tic  co n sisten cy .
R e ce n tly  (D ecem b er 2010) w e  c o n ta cte d  h im  a g a in . H e re p o rte d  to  b e  in  g o o d  h e a lth  
w it h o u t  a n y  c o m p la in ts  re la te d  to  h is  VS, in c re a s in g  h is  “s u r v iv a l w it h o u t  
tr e a tm e n t” to  a lm o s t 22 years .
Discussion
T his p a tie n t h a d  s u r v iv e d  a t le a s t  22 y e a rs  w i t h  a la rg e  VS. H is s y m p to m s  d id  n ot 
c h a n g e  d u rin g  th a t  p eriod , nor d id  th e  tu m o r c h a n g e  in  size  d u rin g  th e  f irst 18 y e a rs  
a fte r  th e  d ia g n o s is . This case  h is to ry  illu s tr a te s  th e  u n p re d ic ta b le  g r o w th  p a tte rn  o f 
VSs. It a lso  p u ts  in to  p e rs p e c tiv e  ou r e ffo r t  to  c o n v in c e  th e  p a tie n t to  h a v e  su rg e ry  
e ig h te e n  y e a rs  ago.
C o n s e rv a tiv e  m a n a g e m e n t h a s  g a in e d  p o p u la r ity  sin ce  th e  in tro d u ctio n  o f  M R 
im a g in g . M a n y  a u th o rs  h a v e  p u b lish e d  th e ir  “w a i t  a n d  sc a n ” re su lts . O n a ve ra g e , 50 
p e rc en t o f  th e  V Ss are  fo u n d  to  b e  g r o w in g  a fte r  th re e  y e a rs  o f  fo llo w -u p .2, 3 M u ltip le  
g r o w th  p a tte rn s  h a v e  b e e n  id e n tified , b u t so far it is im p o ss ib le  to  p re d ic t fu tu r e
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tu m o r  g r o w th . In th is  p a tie n t w e  se e  a p a tte rn  w h e r e b y  g r o w t h  h a d  sto p p e d  at an  
a d v a n c e d  stage.
In th e  d e c is io n -m a k in g  p ro cess on th e  p re ferre d  tr e a tm e n t m o d a lity  for VSs, o n ly  
sm a ll lesions u se d  to  be e lig ib le  for c o n se rv a tiv e  m a n a g e m e n t. The g e n era l con sen su s 
is th a t  la rg e  tu m o rs  sh o u ld  b e  trea te d . M oreo ver, it is w id e ly  a cc ep ted  th a t  th e se  
la rg e  lesio n s sh o u ld  b e  tr e a te d  b y  m icro su rg e ry . The lo c a liz a t io n  o f  th is  lesio n  in  th e  
p o ste rio r fossa , c lose  to  th e  b ra in  stem , im p lie s  th a t  p ro g re ssio n  is life -th re a te n in g . 
M o r ta lity  c a n  e n su e  fro m  co m p ressio n  o f  th e  fo u r th  v e n tr ic le  and /or th e  b ra in  stem , 
w h ic h  re su lts  in  h y d ro ce p h a lu s  a n d  at a la ter s ta g e  b ra in -s te m  h e rn ia tio n . This 
p o s s ib ility  is m e n tio n e d  in  a f e w  stu d ies  c o n ce rn in g  th e  “w a it  a n d  sc a n ” a p p ro a ch .2-5 
In th e s e  stu d ies, m o r ta lity  rates ra n g e  fro m  zero to  s ix  p ercen t. B ut g iv e n  th e  
se le ctio n  b ias a n d  th e  lim ite d  fo llo w -u p  p eriod , th e s e  d a ta  are  h a rd ly  a p p lica b le  to  
th e  n a tu r a l h is to r y  a n d  m o r ta lity  o f  VSs. The lite ra tu re  on th e  tr e a tm e n t o f  VSs is 
v a s t  a n d  in c lu d e s  e x te n s iv e  rep orts on  th e  ch a n c e s  o f  su cce ss  a n d  fa ilu re . P resu m ab ly, 
a ll la rg e  tu m o rs  w i l l  b e  tr e a te d  on ce  th e  d ia g n o s is  h a s b e e n  m a d e ; r e fra in in g  from  
o ffe r in g  th e r a p y  w o u ld  b e  co n sid ered  u n e th ic a l. O n ly  ra re ly  do la rg e  VSs go 
u n d ia g n o s e d  u n t il d e a th  b y  tu m o r p ro gressio n  is in ev ita b le .
The p a tie n t d e scrib e d  a b o v e  d id  n o t d e v e lo p  p ro g re ss iv e  sy m p to m a to lo g y . Indeed, 
h is  s u b je c tiv e ly  p e rc e iv e d  c o n d itio n  is n o w  at le a s t as g o o d  as it w o u ld  h a v e  b e e n  if  
h e  h a d  b e e n  o p e ra te d  on  e ig h te e n  y e a rs  ago. H o w ev er, h e  h a s  b e e n  u n d er c o n sta n t 
th re a t o f  p ro g re ss iv e  n e u ro lo g ica l deficits, a n d  th e  r isk  o f  a d e te r io ra tin g  c o u rse  has 
re m a in e d  th r o u g h  th e  y e a rs . In v ie w  o f  th e s e  co n sid eratio n s, w h i le  th e  a d v ic e  w e  
g a v e  to  th e  p a tie n t e ig h te e n  y e a rs  a go  is s t ill ju s tifia b le , it is h a rd  to  e x p la in  to  h im  
a fte rw a r d s . This case  h is to r y  d e m o n stra te s  th a t  e v e n  la rg e  tu m o rs  in  c lose  p ro x im ity  
to  th e  b ra in  ste m  m a y  re m a in  sta b le  for m a n y  y e a rs . It a lso  s u g g e s ts  th a t  c o u n s e lin g  
p a tie n ts  w i t h  la rg e  VSs m a y  so m e tim e s  b e  a p ro b le m a tic  a n d  u n r e w a r d in g  task.
Conclusion
This case  h is to r y  illu s tra te s  th e  u n p re d ic ta b le  g r o w t h  p a tte rn  o f  v e s tib u la r  
s c h w a n n o m a s . A p p a ren tly , e v e n  la rg e  tu m o rs  in  c lose  p r o x im ity  to  th e  b ra in  stem  
m a y  r e m a in  stab le  for m a n y  y ears . H o w ev er, th e r e  s t ill  are  n o v a lid  a rg u m e n ts  to 
re fra in  fro m  th e r a p y  in  p a tie n ts  w i t h  a la rg e  v e s t ib u la r  sc h w a n n o m a , sin ce  re lia b le  
p red icto rs o f  tu m o r g r o w t h  are  n ot a va ilab le .
30
A LARGE VS THAT DID NOT GROW FOR 18  YEARS
Reference List
(1) N ow e V, V an  de HP, Parizel PM. MRI in  p atien ts  w ith  o to vestib u la r com p lain ts o f  u n k n o w n  origin. 
B-ENT. 20073 Suppl 7:27-35.127-35.
(2) R osenberg SI. N atu ral h isto ry  o f  acou stic n eurom as. Laryngoscope. 2000 Apr;iio(4):497-5o8.
(3) Sm ouha EE, Yoo M, M ohr K, D avis RP. C on servative  m a n a g em en t o f acou stic neurom a: a 
m eta -a n alysis  and  proposed treatm en t a lgo rith m . Laryngoscope. 2005 Mar;115(3):450-454.
(4) Charabi S, Thom sen J, M an ton i M, et al. A co u stic n eurom a (vestibu lar sch w an n om a): g ro w th  and 
su rgical and  n o n su rgica l consequences o f th e  w a it-a n d -see  policy. Otolaryngol Head Neck Surg. 
1995 Jul;113(1):5-14.
(5) H ajio ff D, Raut VV, W alsh  RM, et al. C on servative  m an a g em en t o f  ve stib u la r sch w an n o m a s: third 




Prediction of vestibular schw annom a growth: 
a novel rule based on clinical sym ptom atology
Tim m er FCA 
A rtz  JCJM 
B eynon AJ 
Donders RT 
M ulder JJS 
Cremers CWRJ 
G raam ans K
The A n n als  of Otology, R h in ology &  L aryn go lo gy 2011, in  print
CHAPTER 2.2
Abstract
Objectives: The aim  of this stu d y  w as to form ulate a p redictive rule for vestibular 
sch w an n o m a g ro w th  during th e  in itia l observation  period after diagnosis.
Methods: Logistic regression m odels w ere  fitted, w ith  tum or gro w th  in th e  first year 
as th e  dependent variab le  and patient characteristics as th e  independent variables. 
B ackw ard selection  w as used to e lim in ate  superfluous predictors. The area under 
th e  receiver operating characteristic curve  w a s  tak en  as a m easure o f th e  m odel's 
d iscrim in ative  power.
Results: E ven tu ally  th e  m odel or ru le  consisted of four sign ifican t g ro w th  predictors: 
Localization (if extram eatal, +1; if  intram eatal, 0), Sudden Sensory N eural H earing 
Loss (if present, -1; i f  absent, 0), Balance sym ptom s (if present, +1; i f  absent, 0), 
Com plaints hearing loss <2yrs (if present, +1; i f  absent or present > 2yrs, 0). A  higher 
score indicates a h igher likelihood of tum or gro w th  during th e  period o f observation 
after diagnosis. If th e  to ta l score is 0 or less, th e  likelihood o f tum or g ro w th  during 
th e  first year after diagnosis is less th a n  10%. If th e  score is 3, th e  chan ce of gro w th  
during th e  first year after diagnosis is m ore th a n  70%.
Conclusion: W e w ere  able to create a u sefu l rule to predict VS gro w th  during the 
first year after diagnosis.
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Introduction
The m an agem en t of a u n ilatera l sporadic vestibu lar sch w an n o m a (VS) is still subject 
to  controversy, m a in ly  due to its unpredictable gro w th  pattern. Over th e  past 
decades, better un derstan din g of th is gro w th  pattern  has prom pted a more 
con servative  approach. In particular, im proved im a gin g  tech niques have facilitated  
in sight into VS gro w th . W hen selecting a m an agem en t strategy, carefu l clin ical 
assessm ent is m an d ato ry  since m ultip le factors are relevant. These include tum or 
gro w th , ipsi- and contralateral hearing, age o f th e  patient, audiovestibular 
sym ptom s, duration of sym ptom s, tum or size, tum or consistency, occupation, 
com orbidity, previous treatm ents, neurological sym ptom s, and last but not least 
personal preferences. Treatm ent strategies for VS include m icrosurgery, con servative 
m an agem en t (“w a it  and scan”) and radiation therapy. A lth o u gh  th e  w ait-and-scan  
p olicy  has becom e w id e ly  accepted, it does bear som e risk because som e solid VSs 
present w ith  rapid continued gro w th .1 Som e of these gro w in g  tum ors m a y  need 
m icrosurgery, preferably at an  early  stage, because larger tum ors have an increased 
risk o f surgical m orbidity. Furtherm ore, delay m igh t cost patients their e lig ib ility  for 
surgical hearing preservation. In a previous stu d y  w e  tried  to  predict g ro w th  based 
on data o f long term  follow -up.2 Since it is im p ortan t to ascertain  g ro w th  as soon as 
possible, w e  attem pted  to form ulate  a p redictive m odel b y  com piling m ultiple 
sym ptom s and clin ical data related to g ro w th  at th e  tim e o f diagnosis.
Several m ethods m a y  be applied in th e  search for p redictive factors. Sym ptom s and 
results o f clin ical in vestigations m ay provide u se fu l inform ation. A  sym ptom s-based 
ru le  can be used as a description, w h ich  m a y  in  tu rn  have p redictive properties. The 
10-point A pgar score is a good exam ple of such a rule. It w a s  introduced in  1952 by 
V irg in ia  A pgar to su m m arize  th e  physical condition o f in fan ts shortly  after delivery.3 
For such a score, a receiver-operating characteristic cu rve  (ROC) is used to determ ine 
th e  predictive properties of th e  proposed rule. It is m ade b y  p lottin g th e  false-positive 
rate on th e  x-axis and th e  tru e  p ositive rate on th e  y-axis. The accuracy o f the 
d iagn ostic rule is determ in ed b y  m easurin g th e  area under th e  curve (AUC) in the 
ROC curve. A n  area of 1 represents a p erfect test, th o u gh  obviously  th is result is hard 
to  achieve. In tern ation ally  an AUC > 0.7 is seen as sign ifican t.4
The aim  of th is study w a s  to create a “bedside” rule in dicatin g th e  p ossib ility  of 
tum or g ro w th  at the m om ent o f  diagnosis. To th is purpose, w e  tried  to use th e  m odel 
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Methods
Study population
A  retrospective stu d y of patients w ith  sporadic u n ilatera l VSs w a s  conducted at the 
D epartm en t of O torh in olaryn gology and Head and N eck Surgery o f th e  Radboud 
U n iversity  N ijm egen M edical Center, th e  N etherlands. The study population 
consisted of patients d iagn osed w ith  sporadic u n ilatera l VS from  1994 th rou gh  2006. 
The diagnosis o f VS w as based on M agn etic  Resonance (MR) im ages and characteristic 
sym ptom atology. A ll patients w ith  in itia l con servative m an agem en t and a 
follow -up w ith  a m in im u m  of one MRI scan w ere  included.
Cystic tum ors w ere  defined as solid tum ors dem onstrating cystic com ponents filled 
w ith  a fluid-like substan ce on th e  outer aspect o f th e  tum or, as v isu alized  w ith  
M agn etic  Resonance Im agin g (MRI). Patients w ith  cystic tum ors or neurofibrom ato­
sis w ere  not included.
Investigations at the time of diagnosis
Table I and II give  an o v e rv iew  of th e  data th at w as  collected upon diagnosis. 
Sym ptom s w ere  retrieved from  th e  charts.
Pure-tone audiometry
Tonal audiom etric assessm ent consisted of standard pure-tone audiom etry 
m easu rin g  all octave frequencies 0.25 to 8 kHz. For a n a ly zin g  only  th e  bone 
conduction thresholds w ere  used. The Pure tone average 1 (PTA-1) w as  defined as the 
m ean  o f th e  thresholds at 0.5, 1.0, and 2.0 kHz. W e used tw o  related indexes to take 
into account th e  h ig h  and lo w  tones. These indexes w ere  called PTA-2 and PTA-3, 
th e y  w ere  defined as th e  m ean  o f th e  thresholds at 0.5, 1.0, 2.0, and 4.0 kHz and at 
0.25, 0.5, 1.0, and 2.0 kHz, respectively. W hen no threshold  could be assessed in the 
pure-tone audiogram , it w a s  entered as 130 dB HL.
Speech audiometry
Speech audiom etry  w a s  assessed usin g stan dardized D utch consonant-vow el-con­
sonant. Several variables w ere  extracted  from  th e  speech audiogram : th e  m a xim u m  
speech recognition  score (SRSmax), th e  in ten sity  level for SRSmax (SRSmax-int), the 
Rollover Index (RI), th e  p aram eter Speech-Tone (SPTO), and th e  Slope. The RI w as 
calcu lated  as (SRSmax - SRSmin) / SRSmax as described b y  Jerger and Jerger 5. SRSmin 
is th e  low est m easured score in speech audiom etry  on a loudness level h igher th an  
SRSmax-int. To obtain  a m easure for th e  relation  b e tw ee n  th e  pure-tone audiogram
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Table 1 General descriptive statistics for the study population and there predictive 
value for tum or growth.
Variable N Growth No Growth <=iyr P
Sex (m en / w om en) 240 37/38 7 9 /8 6 0.83
M ea n  age (years) 240 58 yrs 57 yrs 0.60
T um or side (left/ right) 240 39/36 85/80 0.94
Intra-/ extra m eata l 240 40 /35 107/58 0.09
M ea n  tu m o r size m e th o d  1 52 12 m m  (30) 12 m m  (22)
M ea n  tu m o r size m e th o d  2 41 17 m m  (20) 18 m m  (21)
M ea n  size intra m eata l tum ors 147 11 m m  (62) 9 m m  (85)
All variables are defined in Methods ; N= patient number; P= P value of univariate analyses chi-square 
tumor growth after one follow-up scan as dependent.
and th e  speech audiogram , th e  p aram eter SPTO w a s  defined as th e  corresponding 
loudness level at 50% SRS m in us th e  PTA. If th e  h earing is norm al th e  SPTO should be 
25 dB SPO.
The slope is tak en  to express qu alita tive  aspects o f speech discrim ination. To obtain  
th e  Slope, SRSmax is d ivided b y  its corresponding loudness m in us 10 dB SPL. In 
persons w ith  n orm al hearing, 100% discrim in ation  is achieved  at 50 dB, so a norm al 
Slope is 100 / (50-10) = 2.5%/dB SPL.
Vestibular function testing
V estibular fu n ction  w a s  recorded b y  e lectron ystagm ograph y (ENG). Procedures 
w ere  in accordance w ith  in tern atio n ally  accepted gu idelin es.6 The test included 
assessm ent o f spontaneous n ystagm us, saccadic testing, sm ooth pursuit testing, 
optokinetic testing, a torsion test, and caloric testing.
The torsion test w as  done in th e  dark. The ve lo c ity  step response param eters that 
w ere  an alyzed  are those previously  established b y  H uygen and N icolasen in  1985.7 
Their 90% confidence in terval (CI) had b een established b y  Theunissen et al. in  1986.8 
The param eters w ere  th e  in itia l ve lo c ity  (V), tim e constant (T), and G esam tam p li­
tude (G = VT). 7 The 90% CI w a s  adapted to accom m odate usin g th e  m ean  valu e  
calculated for each response p aram eter for th e  right-beating and th e  left-beating 
n ystagm u s responses. It should be noted th at th e  param eters V, T, and G all have 
logn orm al d istributions and th at for th is reason th e  geom etric m ean  w as calculated.8 





Table 2 Descriptive statistics for the study population and there predictive value for 
tum or growth.
Variable N Growth No Growth 
<=iyr
P
Patient Tinnitus yes/n o 240 56/19 100/56 0.03
history H earing loss yes/n o 240 35/40 73/92 0.72
SSNHL yes/n o 240 6/69 27/138 0.09
B alan ce p ro b lem s yes/n o 240 46/29 63/102 <0.01
Earache yes/n o 240 4/71 7/158 0.70
H ea d a ch e yes/n o 240 4/71 4/161 0.26
C om plain ts hearing loss < 2y yes/n o 240 54/21 80/85 <0.01
Total com p la in ts f o r  < iy r  yes/n o 240 36 /39 58/107 0.06
Audiometry PTA-1 tu m o r ear 231 34 dB 37 dB 0.27
PTA-1 contrala teral ear 238 10 dB 9 dB 0.52
PTA-2 tu m o r ear 225 42 dB 43  dB 0.78
PTA-2 contrala teral ear 238 11 dB 10 dB 0.67
PTA-3 tu m o r ear 231 30 dB 32 dB 0.47
PTA-3 contrala teral ear 238 11 dB 10 dB 0.85
SRSm ax tu m o r ear 216 70 % 70  % 0.64
SRSm ax contralateral ear 217 9 8  % 9 8  % 0.57
In ten sity  a t SRSm ax tu m o r ear 216 81 dB 83 dB 0.43
In ten sity  a t SRSm ax contrala teral ear 217 68 dB 70 dB 0.87
In ten sity  a t 50%  sp eech  recognition 215 48  dB 50 dB 0.62
In ten sity  a t 50%  sp eech  recognition 217 42 dB 41 dB 0.30
SPTO tu m o r ear 168 26 dB 26 dB 0.63
SPTO contrala teral ear 217 25 dB 24 dB 0.43
Slope tu m o r ear 216 1.01 0.93 0.06
Slope contralateral ear 217 1.8 1.77 0.79
Rollover tu m o r ear 199 0.11 0.10 0.56
Rollover contrala teral ear 217 0.01 0.01 0.64
ENG Turn/ stop  n orm al/ a b n orm a l 205 35/63 36/71 0.52
D P V  category n o rm a l/a b n o rm a l 199 20/75 13/91 0.17
DPT category n o rm a l/a b n o rm a l 199 24/71 15/89 0.34
DPG  category n orm al/ a b n orm a l 199 29/66 20/84 0.43
Labyrinth d if f  n orm al/ a b n o rm a l 182 18/63 3 4 /6 7 0.08
D P V 199 -1,98 -4.75 0.39
DPT 199 -4,33 -0 .9 9 0.05
DPG 199 ,3
VO V£) 0.15
G eom etric  m ean V 199 42.01 46.6 0.06
G eom etric  m ean T 199 12.14 14.62 0.01
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Table 2 C o n t i n u e d .
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V estibular prep on d era nce

















tu m o r ear 
N o rm a l TEOAE
yes/n o 54 2/19 4 /29 0.77
BAEP
contrala teral ear 
N o rm a l BAEP response
yes/n o 48 6/12 12/18 0.46
tu m o r ear
N o rm a l BAEP response
yes/n o 85 2/23 17/43 0.05
contrala teral ear 
N o rm a l Interaural wave
yes/n o 85 21/4 56/4 0.19
V  la ten cy  d ifference  









SSNHL= sudden sensorineural hearing loss, Total complaints < 1 yr= When did your complaints (related to 
the VS) start? , TEOAE= Transient Evoked Otoacoustic Emission. All parameters derived from audiometry 
and vestibular testing are explained in the text in the section on pure-tone audiometry, speech audiometry, 
and vestibular function testing.
re la tiv e  d iffe re n c e  (i.e., a b so lu te  v a lu e )  in  a g iv e n  v e lo c ity  step  p a ra m e te r  (V, T, or G) 
b e tw e e n  th e  tw o  n y s ta g m u s  d irectio n s o f  > 25%. 8
Caloric test
T he calo ric  te s t w a s  p e rfo rm e d  w it h  th e  p a tie n t in  a su p in e  p o sitio n , th e  h ead  
e le v a te d  b y  30° fro m  th e  e a r th -h o rizo n ta l a xis , w i t h  th e  s t im u lu s  c o n d itio n s a n d  
a n a ly s is  as p re v io u s ly  d e scrib e d  b y  N ijh u is &  H u y g e n s .5 B i-th erm a l (30°C a n d  44°C) 
w a te r  irr ig a tio n  (150 m l in  20 secon ds) w a s  e m p lo ye d . The re sp o n se  p a ra m e te r  w a s  
th e  m e a n  s lo w  p h a s e  v e lo c ity  (SPV) o f  th e  p o st-ca lo ric  re sp o n se  at c u lm in a tio n . 
B ila te ra l ca lo ric  w e a k n e s s  w a s  d e fin e d  as a le v e l o f  a ll s in g le  re sp o n se s fro m  b o th  
la b y r in th s  (at c u lm in a tio n )  o f  < 7°/s. U n ila te ra l ca lo ric  w e a k n e s s  w a s  d e fin e d  as n o 
re sp o n se  at a ll or h a rd ly  a n y  re sp o n se  fro m  on e  side, or w h e n  th e  side d iffe re n ce , i.e., 
th e  re la tiv e  d iffe re n c e  in  re sp o n se  le v e l b e tw e e n  b o th  sides as d e fin e d  for 4 
irr ig a tio n s, w a s  > 20% (a ssu m e d  n o rm a l lim it). T he d iffe re n c e  b e tw e e n  th e  tw o  





fo llo w in g  form ula: VP=( Rc + Rw) - (Lw-Lc) / (Rc+Rw+Lw+Lc) x  100%, w h ere  Rc w as 
“right cold,”Rw  w a s  right w arm ,” Lc w a s  “left cold,”and Lw w a s  “left w arm .”
Analysis of tumor growth
In all patients, a standard MRI protocol w a s  used. Ti-w eighted, gadolin iu m -en ­
han ced  MR im ages w ere  used to m easure th e  tum or size. A  classification w a s  m ade 
into in tram eata l or extram eatal. The distinction  b e tw ee n  these tw o  groups w as 
m ade on th e  basis o f th e  a x ia l M R/im ages. The tum or w a s  assigned to th e  in tram eatal 
group w h en  protrusive tum or surface w as  less th a n  one th ird  of th e  in tram eatal 
tum or surface, as depicted in  th e  a x ia l p lane w ith  MRI. The size o f th e  in tram eatal 
tum ors w as  tak en  as th e  m a xim u m  diam eter along th e  len gth  of th e  internal 
auditory canal. Two m ethods w ere  used to m easure th e  d iam eters o f th e  extram eata l 
tum ors, due to  d ifferent observers. M ethod 1 w a s  to  m easure th e  m a xim u m  diam eter 
parallel to th e  petrous ridge in  th e  a x ia l plane; m eth od 2 w as to m easure the 
m a xim u m  diam eter parallel to  th e  in tern al auditory canal in  th e  a x ia l plane. The 
first scan, m ade upon diagnosis, w a s  com pared to th e  second scan, n orm ally  m ade 
after one year. The definition of gro w th  w a s  determ in ed b y  a differen ce in  tum or 
diam eter o f ffl 1 m m  in th e  a x ia l plane. G row th  w a s  determ in ed th rou gh  independent 
assessm ents b y  a radiologist and a senior otologist (J.M., C.C., and K.G.)
Transient Evoked Otoacoustic Emissions
The presence or absence o f Transient Evoked O toacoustic Em issions (TEOAE's) w as  
determ ined in  both  ears.
Brainstem auditory evoked potentials
Concerning th e  B rainstem  auditory evoked p otentials (BAEP) testin g , tw o  variables 
w ere  determ ined. First th e  p attern  o f th e  BAEP result w h ich  id eally  show s five peaks. 
Peak I, III and V  are th e  m ost explicit w aves. Each peak arises after a specific latention 
period. If th e  sign al is delayed or disrupted th e  p eak  w ill  arise after a longer latency 
or w o n 't arise at all. The second variab le  is th e  in teraural w a v e  V  la ten cy  difference.
BAEP recording w as perform ed at th e  departm ent of audiology according to a 
standard protocol. Click stim uli w ere  delivered b y  headphones. In general, stim ulus 
in te n sity  w a s  set at a level o f 50 dB above th e  in dividual's threshold  levels w ith  an 
upper lim it o f 105 dB above norm al hearing threshold. The in terval b e tw ee n  BAEP 
p eak  I and V  w a s  m easured in  th e  ipsi- and contra lateral side. The latention  tim es 
w ere  com pared to th e  lim it o f norm al for sex and age. N orm al va lu es w ere  obtained
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previously, usin g th e  sam e protocol, in a large h ealth y  population, w ith  ages 
stratified into 5 year groups b e tw ee n  th e  age of 15 and 85.
Statistical analysis
Logistic regression m odels w ere  fitted w ith  tum or g ro w th  during th e  first 
observation  period servin g as dependent variables and th e  patient characteristics 
servin g  as independent variables. To obtain  a parsim onious model, w e  used 
backw ard  selection, w h ich  e lim in ated  irrelevant predictors. A  liberal p  va lu e  of 
<=0.20 w a s  chosen for inclusion in th e  p rim a ry  model. This p va lu e  w as chosen to 
reduce th e  chan ce of m issing variables th at could be relevant. As a m easure of the 
d iscrim in ative  p ow er of th e  m odel, th e  area under th e  ROC cu rve  (labeled AUC) w as 
used. N ext, forw ard  selection  is used to select variables th at increase th e  AUC of the 
model.
First, th e  data gathered from  th e  clin ical h isto ry  and th e  MRI scan w a s  screened for 
relevan t predictors. N ext, audiom etric data w ere  screened and relevan t predictors 
w ere  added to th e  basic model. In addition, th e  data collected from  vestib u lar tests 
and data from  BAEP tests w ere  included in th e  analysis. A fter each step, th e  AUC w as 
determ ined. This step w ise  bu ild in g  o f th e  m odel concurs w ith  clin ical practice.
In th is w ay, a prognostic rule could then  be form ulated  from  th e  analysis based on 
th e  final model.
Results
Study group
A  to ta l o f 382 VS cases w ere  considered, 283 of w h o m  w ere  in itia lly  g iven  con servative 
treatm ent. The rem ain in g 99 patients w ere  g iven  p rim a ry  treatm ent con sistin g of 
m icrosu rgery (n=84), stereotactic radiotherapy treatm ent (n=10), or a com bination 
o f surgery and stereotactic radiotherapy (n=5).
A fter exclusion of patients for w h o m  a second scan w a s  not available  at our 
in stitu tio n  (n=32) and patients w ith  cystic tum ors (n=11), eve n tu a lly  th e  stu d y group 
com prised 240 patients w ith  a sporadic u n ilatera l VS (Table 1). The m ean  len gth  of 
tim e b e tw ee n  diagnosis and th e  first follow -up scan w a s  12.7 m onths. Tumor gro w th  





Risk of growth, creating a predictive rule for tumor growth during the 
initial follow-up period
Taking tum or g ro w th  a fter one follow -up scan as th e  dependent variab le  and the 
patient characteristics as in depen dent variables, u n ivariate  logistic regression w as 
perform ed to screen the general, anam n estic, and im a gin g  data for predictors. 
M ultiple variables w ere  found to be relevant. The distribution  o f the potential 
predictors can be found in Table 1 and 2. A  m odel w as  created based on four variables. 
(Table 3) This m odel consisted o f four variables. The area under th e  curve for a 
prediction based on four o f these variables w a s  0.72. (Figure 1) T inn itus w a s  also 
foun d to be a relevan t predictor w ith  th e  un ivariate  analysis. H owever, tin n itu s is 
not selected to be part o f the rule because it did not increase the fit and th e  p redictive
Figure 1 ROC cure of the presented rule. The area under the curve is 0.72.
ROC Curve for Model
Area Under the Curve = 0.7218
0.00 0.25 0.50 0.75 1.00
1 - Specificity
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Table 3 A n alysis  o f M a xim u m  Likelihood Estim ates Relevant variables th at w ere 




Intra-/ extra m ea ta l 0.5111 0.3069 0.09
SSNHL -1.2895 0.5018 0.09
B alan ce problem s 1.0451 0.3052 0.00
Com plaints hearing loss < 2yr 1.1868 0.3190 0.00
Figure 2 Parameters and their contribution to the rule.
A higher score gives an increasing likelihood of tumor growth during the first observation period. (See Table 
4.) SSNHL = sudden sensorineural hearing loss.
accuracy o f the m odel. Predictive in form ation  present in the variab le  tin n itu s is also 
present in the predictors th at do enter into the m odel and hence tin n itu s does not 
have an y added value.
A fte r adding the audiom etry variables, the patient num ber dropped and possible 
selection bias w a s  introduced. However, b y  exp andin g the m odel to include SRSmax 
tum or ear, In ten sity  at SRSmax tum or ear, and SRSmax contralateral ear, the AUC 




v a r ia b le s  fro m  th e  e le c tro n y sta g m o g ra p h y . The ru le  c re a te d  fro m  th e  p a ra m e te rs  
Intra- / e x tra m e a ta l, C o m p la in ts  h e a r in g  loss < 2yr, PTA-1 tu m o r  ear, PTA-1 
c o n tra la te ra l ear, Turn  / stop, DPV, DPG, G e o m e tric  m e a n  V, G e o m e tric  m e a n  T, a n d  
th e  L a b y r in th  d iffe re n c e  re s u lte d  in  a n  AU C o f  0.9. U n fo rtu n a te ly , a fte r  a d d in g  
a u d io m e tr ic  a n d  v e s t ib u la r  d ata , th e  re lia b ility  w a s  g r e a tly  redu ced . This is 
a ttr ib u te d  m a in ly  to  th e  d e c re a s in g  size  o f  th e  p a tie n t gro u p  as m o re  v a r ia b le s  are 
in clu d e d . W e fo rm u la te d  a b a sic  ru le  b a se d  on  th e  s ig n ific a n t v a r ia b le s  d e riv e d  from  
th e  a n a m n e sis  a n d  im a g in g . From  th e  d a ta  in  Table 3, th e  fo llo w in g  ru le  w a s  created. 
(F igure 1)
Table 4 sh o w s th e  p o ssib le  o u tco m es o f  th is  ru le  w i t h  th e  co rresp o n d in g  g r o w th  
p e rc e n ta g e s  a fte r  1 y e a r  fo llo w -u p : -1, 0, 1, 2, a n d  3.
Table 4 Possible outcom e, ch an ce  o f tu m o r g ro w th  w ith  th e  corresp on din g confidence.
Score N Growth <=1 Yr No Growth <=1yr Confidence interval %
-1 1 0 (0%) 1 (100%) 0.0 - 97.5
0 44 4 (9%) 4 0 (91%) 2 .5 -21.7 %
1 109 29 (27%) 80 (73%) 18.6 -35.9 %
2 63 26 (41%) 37 (5 9 %) 2 9 .0 -54.4 %
3 23 16 (70%) 7 (3 0 %) 47.1-86.8%
Total 240 75 165
4 4
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Discussion
Based on th e  variables collected b y  m eans of h istory-taking and im agin g, it w as 
possible to create a rather u se fu l rule for estim atin g  th e  chan ce of tum or g ro w th  in 
th e  first year after diagnosis in our clinic. The decision on th e  m an agem en t strategy 
in  each in d ivid u al patient u su a lly  is based on a v a r ie ty  of factors. This rule can only 
provide additional argum ents. W e found evidence that a m ore accurate ru le  could be 
created w h en  audiovestibu lar data is collected m ore m eticulously.
Predicting vestib u lar sch w an n o m a gro w th  has been  an im p ortan t issue since it 
becam e clear that m a n y  d ifferent gro w th  p atterns exist in VSs.1, 9 W e assu m ed that 
th e  key to th is gro w th  prediction w o u ld  lie in th e  com bination of m ultip le variables 
collected b y  h istory-taking, im agin g, and audiovestibu lar investigations.
In th e  presented stu d y group, tum or g ro w th  during th e  in itia l period of observation 
after tum or diagnosis w a s  observed in 75 patients (31%). This is com parable to the 
results published b y  other authors in  th e  past.1 In this study g ro w th  w a s  defined as 
ffl1 m m  progression in  size m easured on MRI. Recent studies foun d evidence th at an 
increase of is significant. W e used ffl1 m m  because w e  used to be convinced
o f th e  q u a lity  o f our m easurem en ts during th e  years of th is study. (1994 to 2006) In 
th is ligh t it is im portan t to m ention  th at 70 of th e  75 gro w in g  tum ors grew  ffl 2mm 
during th e  observation  period.
M a n y  authors h ave  tried  to find relations b e tw ee n  an am n estic  or objective variables 
and tu m o r-gro w th  behavior, th o u gh  w ith o u t m uch success. Recently, a system atic 
re v ie w  b y  Nikolopoulos et al. su m m arized  all represen tative studies on th is subject 
th at had been published over th e  past ten  years.10 D iverse gro w th  p atterns have 
been  identified, and m a n y  authors have foun d one or tw o  predictors of fu tu re  tum or 
gro w th . Tumor location, tum or size, patient age, tin n itu s, vertigo, and duration of 
sym ptom s w ere  all n am ed as g ro w th  predictors. H owever, none of these outcom es 
had been reproduced b y  m ore th a n  tw o  authors.11-13 In contrast, m a n y  authors 
concluded th at no predictors could be identified am ong th e  variables derived from  
data collected at th e  tim e o f d iagnosis.14, 15
Tumor Localization (extram eatal vs intram eatal), Sudden Sensory N eural H earing 
Loss at th e  tim e of diagnosis, Balance sym ptom s and Com plaints of hearing loss <2yr 
w ere  selected to enter th e  prediction m odel for gro w th  during th e  first period of 
observation  after th e  diagnosis. (Figure 1.) The exp lan ation  w h y  these variables can 
predict fu tu re  gro w th  is not obvious. It is im p ortan t to note th at th e  regression 
w eigh ts  and p-values o f variables th at do enter th e  prediction m odel are conditional 




can m ake it hard to give  a causal exp lan ation  for th e  significance, th e  m agn itu de 
and th e  sign of th e  regression w eights.
The p ossib ility  of id en tify in g  signs of g ro w th  b y  PET and MR spectroscopy w as 
suggested  b y  Charabi in  1993, but no fu rth er research on this topic has appeared in 
th e  recent literature.16
W e h yp o th esized  th at th e  key  m a y  lie in  a com bination of variables th at can be 
extracted  from  th e  patient database. In general, m ath em atical m odels w ith  the 
sm allest num ber of param eters are preferred, as each p aram eter introduced into the 
m odel adds som e u n ce rta in ty  to it. E xcessively com plex m odels m a y  suffer from  
over fitting. Consequently, th e y  have poor predictive power, unless th e  database is 
m eticu lo u sly  put togeth er from  a large p atient group. In our previous publication  on 
th is subject, w e  introduced a risk profile for fu tu re  VS g ro w th  in th e  long term .2 We 
encountered several d isad vantages of th e  statistical analysis presented in this 
p revious publication, one bein g that w e  had to split our patient population  into 
th ree  risk groups. By doing so, a considerable n um ber of patients w ere  elim in ated. In 
th e  present study, in  contrast, w e  could take  alm ost th e  entire w ait-and-scan  group 
into account w h en  form ulatin g our rule.
The accuracy of the diagn ostic rule is determ in ed b y  m easu rin g  the area under the 
cu rve  (AUC). (perfect rule AUC=i) The presented m odel has an AUC of 0.72. The AUC 
could be fu rth er increased from  0.7 to 0.8 and even to 0.9 b y  adding m ore variables 
from  pure-tone and speech audiom etry, vestibu lar testing, oto-acoustic em issions, 
and brain stem  response m easurem ents. W ith  th e  increasing num ber o f variables, 
th e  num ber of patients suitable for analysis decreased because of incom plete 
datasets and the statistical m odel degenerated. This em phasizes the potentia l 
usefu ln ess of gatherin g audiological and vestibu lar data, even  if  such data does not 
appear to be n eeded for th e  treatm ent process. A udiological and vestib u lar data 
collected at th e  tim e of diagnosis is used p rim arily  to docum ent th e  audiovestibular 
status of a patient. The results o f th is stu d y  indicate that th is data m a y  also be used 
to  estim ate th e  risk of tum or grow th.
The n atu ral behavior o f VSs rem ains rather enigm atic. In research on th is subject, 
th e  stu d y  group is a lw a ys assem bled th rou gh  som e ty p e  o f selection, since eth ical 
considerations preclude proper random ization. W ait-and-scan studies a lw ays 
exclude patients w h o  had received m icrosu rgery or radiotherapy shortly  after the 
diagnosis and m a n y  tum ors are not d iagn osed at all.17 It is conceivable th at a 
sign ifican t share of the m ore rapidly gro w in g  tum ors are to be foun d w ith in  the 
group of patients treated w ith  stereotactic radiotherapy or m icrosurgery. Because of 
th e  increasing p ercentage of con servatively  treated VS patients, th e  w ait-and-scan
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population  is b ecom ing less biased. O nly i f  all VS patients w ere  treated con servatively  
after their in itia l diagnosis w o u ld  it be possible to  perform  this study w ith o u t bias, 
th ereb y m akin g it applicable to th e  w h ole  population.
The m ethod presented here also has som e drawbacks. The reliability  of the calculated 
risk profile is neither com plete nor un equivocal. The patients in  th is stu d y group do 
not all h ave  a sim ilar set o f audiovestibu lar data, and th e  application of the 
in vestigation s is not ran dom ly distributed. To stren gth en  th e  clin ical applicability  
th e  rule presented here, th e  patient group w o u ld  h ave  been  com posed of all 
d iagn osed VS patients. Each patient w o u ld  h ave  been scann ed at th e  sam e interval, 
all tum ors w ere  m easured in th e  sam e w a y  b y  th e  sam e observers and all patients 
w ere  subjected to  a set o f identical audiovestibu lar investigations.. Nonetheless, to 
th e  best o f our know ledge, th is is th e  first stu d y in th e  VS field w h ere  a brief ru le is 
presented for predicting VS gro w th  during th e  first observation  period after 
diagnosis.
Conclusion
A ccurate prediction of VS gro w th  w ith  com plete ce rta in ty  rem ains a challenge. 
H owever, m eticu lous registration  o f clin ical sym p to m atolo gy and audiovestibular 
data allow s for th e  form ulation  o f a ru le  th at m a y  serve as a predictor and therefore 
can be h elpfu l to determ in e th e  treatm ent strategy  in  VS patients.
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CHAPTER 2.3
Abstract
Introduction: M an agem en t o f a sporadic vestib u lar sch w an n o m a (VS) is still subject 
o f controversy, m a in ly  due to distinct and unpredictable gro w th  patterns. To em bark 
on an appropriate th erap y  it is n ecessary  to dispose o f a reliable prediction about 
tum or progression. This stu d y  aim s to design  a risk profile w ith  predictors for VS 
grow th.
M aterials and m ethods: A  to ta l o f 234 VS patients w h o  w ere  m an aged  con servatively  
w ere  included. D ata concerning (duration of) sym ptom s and localisation  of VS w ere 
a n a lysed  w ith  Cox proportional hazards regression models.
Results: Predictors for g ro w th  are u n steadiness/vertigo, no sudden onset o f hearing 
loss and short duration of hearing loss. H igh-risk patients h ave  1.: VS w ith  an 
extra m eata l localisation, short duration of hearing loss and at least one o f th e  tw o  
other predictors (unsteadiness/vertigo or no sudden sen sorin eural hearing loss) or 
2.: VS w ith  an  in tram eata l localisation  and all th ree  other predictors. Low-risk 
patients h ave  1.: VS w ith  an extram eata l com ponent and no other predictor or 2.: VS 
w ith  an  in tram eata l localisation  and at m ost one other predictor. H igh-risk patients 
h ave  a risk of gro w th  of 36.9% in  th e  first year and 64.6% in th e  second year. For 
patients w ith  a lo w  risk th is is respectively  2.5% and 12.7%.
Conclusion: Simple data gathered at th e  m om ent of diagnosis m a y  provide usefu l 
in form ation  since th e y  m a y  lead to a risk profile for grow th.
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The m anagem ent of a unilateral sporadic vestibular schw annom a (VS) is still subject 
of controversy m a in ly  due to distinct and u npredictable g ro w th  patterns. In case of 
a solid VS a w ait-and-scan -policy is o ften  appropriate because these tum ors in 
general show  no gro w th  or h ave  a slow  gro w th  pattern, v a ry in g  b e tw ee n  0.9 and 1.9 
m illim etres in  m a x im a l diam eter per year.1-4 M oreover, several studies on the 
gro w th  rate of VSs, have show n besides stability  even regression during conservative 
m an agem en t.1, 5-10 In contrast, part o f th e  solid VS's is able to present w ith  re latively  
rapid grow th, w h ich  eventually  m ight result in serious m orbidity and even m ortality 
i f  left untreated.
To em bark on th e  m ost appropriate m an agem en t of VSs it is n ecessary  to dispose 
of a reliable prediction about th e  g ro w th  of th e  tum or at th e  m om ent o f diagnosis. 
This stu d y  is aim ed to design a risk profile for VS gro w th  based on anam n estic 
and radiological data gathered at th e  m om ent of diagnosis, th at is (duration of) 
sym ptom s and localisation  o f th e  tumor.
Materials and methods
Study group
A  prospective stu d y  o f patients w ith  sporadic u n ilatera l VSs w as conducted at the 
d epartm ent of oto rh in o laryn go lo gy of th e  Radboud U n iversity  M edical Centre 
Nijm egen, The N etherlands. Patients w ith  sporadic u n ilatera l VS w ere  included from  
1994 th rou gh  2006. The diagnosis VS w a s  based on characteristic sym ptom s, audi- 
o vestibu lar data and MR im ages. Patients w h o  w ere  in itia lly  m an aged  con servatively  
w ere  included. Con servative m an agem en t consisted of a m in im al follow -up of six 
m onths and at least tw o  MRI-scans. The treatm ent protocol for VS in  our in stitu te  is 
h ig h ly  in d ivid u alized  and flexible, p articu larly  after in form in g th e  patient. The 
m an agem en t is determ in ed after considering a 10-points p aradigm  w h ich  includes: 
tum or size, u n favourable  h ealth  factors, in va lid atin g  sym ptom s, duration of 
sym ptom s, hearing level, contralateral hearing, tin n itu s, balan ce problem s, 
docum en ted tum or gro w th  and personal preferences of th e  patient. As a consequence, 
th e  m an agem en t is tailored to th e  patient in stead of bein g th e  result of a rig id ly  
shaped protocol. Patients w ith  other ear pathologies th a n  a VS and patients w ith  
neurofibrom as w ere  not selected. Patients w ith  cystic tum ors w ere  excluded. Cystic 
tum ors w ere  defined as solid tum ors dem onstrating cystic  com ponents filled  w ith  a 





The fo llo w in g patient characteristics w ere  addressed in  th is study; gender, age at the 
m om ent of diagnosis, (duration of) sym ptom s, tum or side (left or right) and 
localisation  o f th e  tum or. A  classification w a s  m ade into p u rely  in tram eata l (IAC 
group) or in tram eata l and extra m eata l (cerebellopontine angle (CPA)-group). The 
distinction  b e tw ee n  these tw o  groups w a s  m ade on th e  basis o f th e  a x ia l MR-images. 
The tum or w a s  assigned to th e  IAC group w h en  th e  protrusive tum or surface w as 
less th en  one th ird  o f th e  in tram eata l tum or surface, as depicted in th e  a x ia l plane 
w ith  MRI. The duration o f sym ptom s w a s  defined as th e  tim e  b e tw ee n  th e  onset of 
first sym ptom s and th e  diagnosis.
Analysis of tumor growth
MRI w a s  used to assess th e  size of th e  lesions. The size o f th e  IAC tum ors w a s  taken 
as th e  m a xim u m  diam eter along th e  len gth  of th e  IAC. The diam eters of th e  CPA 
tum ors w ere  m easured b y  tw o  differen t m ethods due to differen t observers. M ethod
1 consisted of m easurin g of th e  m a xim u m  diam eter p arallel to th e  petrous ridge in 
th e  a x ia l plane; m eth od 2 consisted o f tak in g  th e  m axim u m  diam eter parallel to  the 
in tern al auditory can al in  th e  a x ia l plane. It is k n o w n  th at VS have different gro w th  
patterns. Some w ill  sh ow  g ro w th  w ith in  th e  first year of observation; som e w ill 
sh o w  g ro w th  after som e years. Therefore th e  tim e to first observed gro w th  as 
assessed b y  MRI w a s  recorded. The definition o f g ro w th  w a s  determ ined b y  the 
differen ce in  tum or size o f ffl 1 m m  in  th e  a x ia l plane. G row th  w a s  determ in ed by 
m eans o f independent assessm ents b y  a radiologist and an otolaryngologist.
Pure-tone audiometry
The audiom etric assessm ents o f th e  pure tone a udiom etry  com plied w ith  th e  highest 
c lin ical standards. The Fletcher Index (FI) o f air conduction o f th e  VS-ear w as 
included. FI w a s  defined as th e  m ean  of th e  thresholds at 500, 1000 and 2000 Hz. 
W hen no threshold could be assessed in th e  pure-tone audiogram , it w a s  noted at 130 
dB HL.
Speech audiometry
Speech audiom etry  m easurem ents w ith  D utch vow el-con sonan t-vow el w ords w ere 
p erform ed up to a m a xim u m  of 125 dB SPL.
Statistical analysis
Statistical an alysis w a s  p erform ed usin g SPSS 12.0. The occurrence of gro w th  of the 
VS is dependant on th e  param eter “duration o f follow -up”. Some VS gro w  constantly;
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som e VS start to gro w  after a period of s tab ility  and som e VS stay  stable. It w o u ld  be 
in adequate to sim ply com pare VSs in  classes o f “g ro w th ” and “no g ro w th ” because 
not all VS patients had th e  sam e period o f follow -up. Therefore th e  tim e elapsed until 
th e  first observed gro w th  w a s  presented in a Kaplan-M eier curve w ith  censoring at 
th e  tim e o f th e  last MRI w h e n  no gro w th  w a s  observed.
The association  of p oten tia l risk factors w ith  th e  risk o f g ro w th  w a s  exam in ed  w ith  
Cox proportional hazards regression m odels. H azard rate ratios (HRR) w ere  calculated 
to  q u a n tify  th e  effect o f a risk factor on grow th. First, w ith in  each set o f factors like 
localisation  (IAC or CPA), sym ptom s and duration of sym ptom s, th e  risk factors w ere 
selected  usin g backw ard  elim in ation . The selected  risk factors w ere  th en  com bined 
in  another backw ard  selection  procedure to y ie ld  th e  final m odel. Based on th e  final 
m odel regression scores can be calcu lated  for each patient (p < 0.05). Patients w ere 
categorized according to quintiles o f th e  regression score, w ith  th e  low est quintile  
labelled  lo w  risk and th e  top quin tile  labelled  h igh  risk. C u m ulative probability 
curves w ere  con structed  for patients in  each of th e  quintiles w ith  th e  use of 
Kaplan-M eier m ethod.
Results
Study group
Prospectively  382 VS cases w ere  considered. Con servative treatm en t w as  in itia lly  
applied in 283 patients. The m ain  reason for conservative treatm ent w as  sm all tum or 
size (n=236). Som e patients refused a n y  treatm ent (n=8), another group w as 
m an aged  con servatively  because of co-m orbidity (n=io) and som e patients w ere 
treated  con servatively  because o f a long h isto ry  of sym ptom s su ggestin g  a slow  
g ro w th  p attern  or absence o f g ro w th  (n=26). A  sm all group (n=3) had no com plaints 
at all and w ere  therefore treated  conservatively.
The rem aining 99 patients w ere prim arily treated by m icrosurgery (n=84), stereotactic 
radiotherapy (n=io) treatm ent or a com bination of surgery and stereotactic radio­
therapy (n=5).
The indications for p rim a ry  treatm en t of th e  VS w as a large tum or size (n=63), 
personal preference o f th e  patient (n=i6), th e  aim  o f hearin g  preservation  (n=2) and 
th e  presence of debilitating audiovestibu lar sym ptom s (n=3).
A fter exclusion of patients w ith o u t a second scan (n=38) and patients w ith  cystic 




(Table 1). The m e a n  a g e  at th e  m o m e n t o f d ia g n o s is  w a s  57 y e a rs  (SD 11.79, ran ge: 
16-82 years), 55 y e a rs  (SD 12.04, ra n g e : 16-77 y e ars) for m e n  a n d  60 y e a rs  (SD 11.10, 
ra n g e : 30-82 y e ars) for w o m e n . The d is tr ib u tio n  o f  th e  tu m o r  lo c a lisa tio n  o b ta in e d  
b y  th e  first M RI w a s  as fo llo w s: 142 in tra m e a ta l a n d  92 in tra m e a ta l w i t h  e x te n s io n  
in to  th e  c e re b e llo p o n tin e  an g le . The m e a n  fo llo w -u p  o f  th e s e  p a tie n ts  w it h  
c o n s e rv a t iv e  m a n a g e m e n t w a s  28 m o n th s  (SD: 20.89, ra n ge : 4-120 m o n th s).
Table 1 Patient characteristics.
Total Localisation of VS
IAC CPA
N um ber o f patients 234 142 92
M ean age at diagnosis, years (SD) 57 (11.7 9 ) 57 (11.52) 59 (12.16)
M ean follow-up, m onths (SD) 28 (20.89) 31 (22.50) 24  (17.35)
Gender - M ale : Female 119 : 115 71 : 71 4 8  : 4 4
Side VS - Right : Left 121 : 113 76 : 66 45  :47
IAC: internal auditory canal, CPA: cerebellopontine angle (for definitions see methods).
Tumor characteristics
N o s ig n ific a n t d iffe re n c e  in  gen der, a g e  or side o f  th e  tu m o r w a s  fo u n d  b e tw e e n  
p a tie n ts  w i t h  a n d  w ith o u t  g r o w t h  o f  th e  tu m o r  or b e tw e e n  IAC a n d  CPA lo ca lisa tio n . 
The m e a n  m a x im u m  d ia m e te r  o f  th e  IAC tu m o rs  w a s  9.2 m m  (SD: 3.29, ra n g e  2.00 -
14.00 m m ). The m e a n  m a x im a l d ia m e te r  o f  th e  CPA tu m o rs  m e a su re d  w it h  m e th o d
1 w a s  12.2 m m  (SD: 4.31, ra n g e  5.00 - 23.00 m m ). The tu m o rs  m e a su re d  w it h  m e th o d
2 h a d  a m e a n  m a x im a l d ia m e te r  o f  17.2 m m  (SD: 4.92, ra n g e  10.00 - 30.00 m m ).
Clinical presentation
The sy m p to m s re p o rte d  b y  p a tie n ts  at th e  m o m e n t o f  d ia g n o s is  are  s h o w n  in  
Table 2. T he m o st re p o rte d  sy m p to m s at th e ir  first v is it  to  th e  h o sp ita l w e r e  h e a rin g  
loss, t in n itu s  a n d  u n s te a d in e s s/ v e rt ig o . A lso  su d d en  s e n so rin e u ra l h e a r in g  loss 
(SSHL) a n d  a u ra l fu lln e s s  w e r e  a ra th er co m m o n  p re s e n tin g  sy m p to m  in  re s p e c tiv e ly  
13.2% a n d  11.5% o f  th e  p a tie n ts. The m e a n  d u ra tio n  o f a ll sy m p to m s w a s  60 m o n th s 
(SD 80.42, ra n g e  1-480 m o n th s). In th e  to ta l p a tie n t p o p u la tio n  sa m p le  h e a r in g  loss 
h a d  th e  lo n g e st d u ra tio n  a m o n g s t o th er sy m p to m s (Table 3).
In th e  s tu d y  gro u p  n o o th er o to lo g ic  d isorders w e r e  presen t.
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Table 2 Frequencies of symptoms.
Symptoms Total
N = 234 (%)
Localisation of VS 
IAC
N = 142 (%)
CPA
N = 92 (%)
H earing loss 216 (92.3) 128 (90.1) 88 (9 5 .7)
Tinnitus 151 (64.5) 93  (6 5 .5) 58 (63.0)
U nsteadiness/vertigo 103 (44.0) 59  (41 .5) 4 4  (47 .8 )
SSHL 31 (13.2) 20 (14.1) 11 (12.0)
A ural fullness 27 (11.5) 19 (13.4 ) 8 (8.7)
Otalgia 10 (4 .3) 5 (3.5) 5 (5 .4 )
H eadache 8 (3.4) 3 (2.1) 5 (5 .4 )
SSHL: sudden sensorineural hearing loss.
Table 3 M ea n  duration  of sym ptom s.
Symptoms Total Localisation of VS
IAC CPA
M onths (SD) M onths (SD) M onths (SD)
H earing loss 55 (7 6 .9 ) 48 (74.84) 65  (7 9 .15)
Tinnitus 37 (5 6 .8 0 ) 31 (51.02) 47 (64.32)
U nsteadiness/vertigo 39  (6 8 .4 3 ) 38 (65.32) 4 0  (37.65 )
SSHL 28 (5 8 .3 4 ) 17 (41.84) 41 (73.90)
A ural fullness 21 (25.79) 14 (14 .9 4 ) 50 (41.68)
O talgia 7.0 (6.61) * *
H eadache 32 (48.98)
* *
SSHL: sudden sensorineural hearing loss. 'patient number < 5.
Audiometry
P u re  to n e  a u d io m e tr y  d a ta  o f  231 p a tie n ts  w a s  a va ila b le . D a ta  o f  th e  a u d io m e try  
re su lts  for th e  V S -ear are  p re s e n te d  in  Table 4. The m e a n  FI w a s  38.9 dB HL (SD 25.98 
dB HL). In s ix  p a tie n ts  to ta l d e a fn e ss  o f  th e  V S -ear w a s  fo u n d  (FI ffl 130 dB HL). Sp eech  
re c o g n itio n  a u d io m e tr y  d a ta  o f  211 p a tie n ts  w a s  a va ila b le . The m e a n  P b m a x  w a s  




Table 4 Audiometry data of the ear w ith  VS.
Total Localisation of VS
IAC CPA
M ean (SD) M ean (SD) M ean (SD)
FI (dB HL) 38.9  (25.9 8 ) 36.9 (26.18) 42.0 (25.50)
Pbm ax (%) 7 0 .0  (2 9 .85 ) 73.3 (28 .61) 65.0 (31.15)
FI: Fletcher Index, Pbmax: maximum speech recognition score.
Risk of growth
The risk  o f  g r o w t h  in  th e  first y e a r  a fte r  d ia g n o s is  re g a rd in g  th e  w h o le  s tu d y  
p o p u la tio n  sa m p le  is 17% a n d  is in c re a s in g  d u rin g  fo llo w -u p . W ith in  t w o  y e a rs  th e  
risk  in crea se s  to  38% a n d  w it h in  fiv e  y e a rs  it in crea se s  to  58%. Tum ors w i t h  a n  in it ia l 
IAC lo c a lisa tio n  h a v e  a 10% risk  o f  g r o w t h  w it h in  on e y e a r  co m p a re d  to  28% for 
tu m o rs  w it h  a n  in it ia l  CPA lo ca lisa tio n . W ith in  th re e  y e a rs  th is  risk  is 43% co m p a re d  
to  64% for r e s p e c tiv e ly  in tra m e a ta l a n d  e x tr a m e a ta l tu m o rs. W ith in  f iv e  y e a rs  th e  
risk  se e m s sta b le  for p a tie n ts  w i t h  in tra m e a ta l tu m o rs  (49%) a n d  se e m s to  in crea se  
for p a tie n ts  w i t h  e x tr a m e a ta l tu m o rs  (73%). This re su lts  in  a HRR o f  2.0 for g r o w th  
(p < 0.05) for p a tie n ts  w i t h  a VS w it h  e x te n s io n  in to  th e  c e re b e llo p o n tin e  a n g le  
co m p a re d  to  p a tie n ts  w i t h  a VS w h ic h  is lim ite d  to  th e  in te rn a l a u d ito r y  c a n a l 
(F igure 1).
Potential risk factors and predictive model
The fo llo w in g  p o te n t ia l r isk  fa cto rs  are  re ta in e d  as p red icto rs o f  g r o w t h  in  b a c k w a r d  
e lim in a t io n  m o d els: a n  e x tr a m e a ta l lo c a lisa tio n  o f  VS a n d  a m o n g  sy m p to m s: 
t in n itu s , u n s te a d in e s s/ v e rt ig o , n o  SSHL a n d  a sh ort d u ra tio n  o f  h e a r in g  loss. This 
sh ort d u ra tio n  is d e fin e d  as a h e a r in g  loss o f  ju s t  1-24 m o n th s.
The f in a l m o d e l is b a se d  on  p o p u la tio n  sa m p le  o f  224 p a tie n ts; in  10 p a tie n ts  no 
in fo rm a tio n  a b o u t d u ra tio n  o f  sy m p to m s w a s  rep orted . The fo llo w in g  p red icto rs o f 
g r o w t h  are  in c lu d e d  in  th e  m o d el: 1: e x tr a m e a ta l lo ca lisa tio n  (HRR 2.3, p < 0.0001), 2: 
SSHL (HRR 0.5, p < 0.05), 3: u n s te a d in e s s / v e rt ig o  (HRR 2.0, p < 0.001) a n d  4: short 
d u ra tio n  o f  h e a r in g  loss (1-24 m o n th s) (HRR 3.1 (p <0.0001). The s y m p to m  t in n itu s  as 
p re d ic to r o f  g r o w t h  h a d  n o c o n tr ib u to ry  e ffe c t  to  th e  m o d el. B ased  on  th is  fin a l 
m o d e l 16 c lasse s  o f  p a tie n ts  w i t h  d iffe re n t risk  p ro files c a n  b e  d efin ed . W e ca te g o rize d  
th e  p a tien ts a ccord in g  to  q u in tile s  o f  th e  regressio n  score. The c u m u la tiv e  p ro b a b ility  
o f  g r o w th  for e ach  q u in tile  is o b ta in e d  w it h  th e  K ap lan -M eier m eth od . The fo llo w in g
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Figure 1 Risk o f  g r o w th  for VS w it h  in tra m e a ta l versu s e x tra m e a ta l lo ca lisatio n  at th e 
m om en t o f  d iagnosis.
risk  p ro files w e r e  d efin ed : 1: H ig h  risk  (N = 43), 2: In te rm e d ia te  risk  (N = 139) a n d  3: 
L o w  risk  (N = 42). The p a tie n ts  w i t h  a h ig h  a n d  lo w  risk fo r g r o w t h  o f  VS are  sh o w n  
in  Table 5.
Table 5 Risk profile o f  patients w it h  VS.
High risk Low risk
1. VS w ith  an extram eatal com ponent and 1. VS w ith  an extram eatal com ponent and
• short duration o f  hearing loss and • no other predictor
• at least one o f th e other tw o  predictors
(unsteadiness/vertigo or no SSHL)
2. VS w ith  in tram eatal localisation and 2. VS w ith  an intram eatal localisation and
• all three other predictors • at m ost one other predictor.
The predictors for growth are: extrameatal localisation and among symptoms: short duration of hearing 





For patients w ith  a lo w  risk profile the risk o f g ro w th  o f a VS is 2.5% in  the first year 
and 12.7% w ith in  tw o  years. For patients w ith  a h ig h  risk profile the risk o f g ro w th  of 
a VS in the first y ea r is 36.9% and 64.6% w ith in  tw o  years (Figure 2).
Figure 2 Patients w ith  h igh and low  risk of grow th  of VS.
High risk and low risk groups are mentioned in Table 5.
Discussion
V estibular sch w an n o m as are m o stly  slow  g ro w in g  tum ors. Conservative 
m an agem en t w ith  regu larly  M RI-scanning is an appropriate approach because any 
ty p e  o f th erap y m ay result into (increased) h earin g  loss or facia l nerve deficits. 
H owever, some VS present w ith  rapid g ro w th  th at m a y lead to serious m orbid ity and 
even  m o rta lity  if  left untreated. Preferably, the g ro w th  b eh aviour o f VS should be 
predictable at the m om ent o f d iagnosis to a llo w  the best strategy. Throughout the 
years, several studies attem pted to id en tify  g ro w th  predictors o f VS's. Due to 
d ifferen t research h yp oth eses and protocols the results o f these studies are hardly 
com parable. The size o f the tu m o r at the m om ent o f d iagnosis has been  proposed as
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an indicator for grow th. Fucci et al. reported a sign ifican tly  increased g ro w th  rate of 
tum ors w ith  a m a x im a l diam eter larger th at 20 m m  at presentation.11 Som e studies 
foun d th at tum or gro w th  in  th e  first year could be in dicative for fu tu re  g ro w th .12, 13 
Furtherm ore th e  sym ptom s o f th e  patients h ave  been  considered as possible 
predictors of gro w th . Tschudi et al. foun d th at patients w ith  progressive h earing loss 
as a first sym ptom  had a sign ifican tly  low er tum or gro w th  th a n  those presenting 
w ith  tin n itu s, sudden h earing loss and vertigo.13 Other studies, how ever, revealed  no 
sign ifican t d ifferences in age, gender, tum or laterality, in itia l sym ptom s, duration of 
sym ptom s or in itia l tum or size b e tw ee n  patients w ith  gro w in g  tum ors and 
n on -grow in g tum ors.7, 11, 12, 14 A  possible predictor of g ro w th  m a y  be th e  duration of 
sym ptom s. One stu d y reported th at patients w ith  a short duration of sym ptom s had 
tum ors th at sign ifican tly  g rew  faster.15 Our stu d y  dem onstrated th at th e  sym ptom  
hearing loss w a s  present in  92.3% of th e  patient population  sam ple and that short 
duration of hearing loss w a s  indeed a predictor of gro w th  w ith  a hazard risk of 3.1 (p 
< 0.0001).
The search for predictors o f g ro w th  should result in  a m an ageable  profile w h ich  
could be im plied in practice. Such a profile can be perform ed b y  usin g statistical tests 
like regression or m ultivariate  analysis. B eenstock used a m u ltivariate  an alysis to 
in vestigate  predictors for VS gro w th .16 H owever, th is stu d y  w as based on tw o  
independent sets o f previous data w ith  a sm all num ber o f patients (N = 51 and N = 
69). Age, side of th e  tum or and reporting sym ptom s seem ed to be key variables in 
predicting stab ility  or g ro w th  o f VS. 16 If reporting sym ptom s included vertig o  and 
un steadiness tum or g ro w th  w as m ore pronounced. This could be confirm ed in  our 
study: th e  hazard risk for g ro w th  for th e  sym ptom  un steadiness/vertigo  w a s  2.0. 
B eenstock found th at p robability  o f s tab ility  seem ed to be independent of gender, 
t in n itu s and hearing loss. 16 This is also in accordance w ith  th e  results found in our 
stu d y  except for t in n itu s w h ich  w a s  retain ed  as a predictor for gro w th . In th is study 
side of th e  tum or w a s  not in dicative as a p oten tia l risk factor for grow th. Beenstock 
reported th at left side o f th e  tum or w a s  an indicator for gro w th  o f VS. Furtherm ore 
in  one data set VS g ro w th  varied  sign ifican tly  and in versely  w ith  age. 16 
This stu d y  w as able to present a risk profile o f VS g ro w th  concerning in itia l 
sym ptom s and localisation  of VS. In contrast to results o f earlier studies, w e  
dem onstrated th at sym ptom s reported b y  patients at th e  m om ent of diagnosis seem  
to  be o f great va lu e  in  predicting gro w th  behaviour of VS. M ore attention  need to be 
g iven  to in itia l sym ptom s such as un steadiness or vertigo, tin n itu s, short duration 
of h earin g loss or th e  absence of SSHL. This in  com bination w ith  th e  localisation  of 




for VS. To our kn ow led ge th is is th e  first study that presents a risk profile for VS 
g ro w th  based on in form ation  gathered at th e  m om ent o f diagnosis.
The statistical grouping of patients in  th ree  risk groups and com paring th e  h igh  and 
lo w  risk group e lim in ated  a considerable am ount of patients from  th e  study. 
H ow ever, th is grouping w a s  essential in order to d istin gu ish  relevan t differences. 
The outline o f th e  statistical an alysis w a s  shaped in such a w a y  th at th e  effects of 
th e  various determ in ants could be v isualized.
Studies concerning th e  prediction o f s tab ility  or gro w th  o f VSs should id eally  be 
done w ith  at random  patient selection. The non-random  selection  m eth od  m ight 
h ave  resulted in overstatem en t of s tab ility  o f th e  VS and un derstatem en t of in itia l 
sym ptom s. In clin ical practice, how ever, a random  selection of patients w ith  VS is 
not feasible, because som e VSs have such large size that surgery in stead of 
con servative  m an agem en t is th e  treatm ent of first choice. The differences b etw een  
th e  treated and non-treated groups of patients w ere  quite variab le  and not u n iform ly 
categorized. This m akes th at som e degree of s im ilarity  b e tw ee n  those tw o  groups is 
ce rta in ly  present. As a result th e  outcom es of this lo n gitu d in al stu d y should be 
considered as bein g representative or at least in dicative for th e  w h o le  VS population.
Conclusion
This stu d y p resents a risk profile for VS gro w th  based on sym ptom s and localisation  
of th e  tum or in a not random ised stu d y  group m an aged  b y  a “w a it  and scan” policy. 
Patients w ith  a h igh  risk profile have a risk of gro w th  of 36.9% in th e  first year and 
64.6% w ith in  tw o  years. To th is risk profile belong patients w ith  1.: VS w ith  an 
extra m eata l com ponent and short duration o f hearing loss and at least one o f th e  
tw o  predictors (unsteadiness/vertigo or no SSHL), 2.: VS w ith  in tram eata l localisation 
and all th ree  other predictors (short duration of h earing loss, un steadiness/vertigo, 
no SSHL). For patients w ith  a lo w  risk profile th e  risk of g ro w th  in  th e  first year is 2.5% 
and 12.7% w ith in  tw o  years. These patients h ave  1.: VS w ith  an  extram eatal 
com ponent and no other predictor or 2.: VS w ith  an in tram eata l localisation  and at 
m ost one other predictor.
The outcom es o f th is stu d y  cannot d irectly  be gen eralised  for th e  w h o le  VS 
population. N evertheless th e y  are in dicative for th e  behaviour o f th ese  tum ors.
A cknow ledgem ent: The authors th a n k  Mrs. S. Peer for statistical analysis.
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Objective: A  prospective long-term  follow -up stu d y  w as conducted to eva lu ate  the 
results of G am m a K nife radiosurgery  (GKRS) for vestibu lar sch w an n o m a (VS) 
patients. Both a x ia l and volu m etric m easurem ents are used to determ in e tum or size 
during fo llo w  up.
Methods: A  to ta l o f 110 VS patients w ere  referred for rad iosurgery b e tw ee n  2002 
and 2007. A ll patients w ere  treated w ith  a Leksell 4C ga m m a knife. 12.5 to 13 Gy w as 
prescribed to th e  isodose covering 90% of the tum or volum e. The resulting m arginal 
dose w a s  on average 11.0 Gy (9.3-12.5 Gy). Tumor size and tum or volu m e w ere 
determ in ed before and after GK treatm ent at regular in tervals. The m in im al 
follow -up period w a s  tw o  years.
Results: 100 patients w ere  included in th is study. Eight patients needed additional 
treatm en t after a m ean  follow -up period of 38 m onths. One patient exp erien ced  a 
tem p o rary  facia l n erve deficit. No g ro w th  p attern  could be recogn ized  for tum or 
g ro w th  after GKRS. Based on m easurem en ts of th e  largest extram eata l d iam eter the 
tum or size w o u ld  have decreased or rem ained  stable in  94%. Based on volum etric 
m easurem ent, th e  tum or size w as  decreased or rem ained  stable in  79%.
Conclusion: H igh tum or control and lo w  com plication rates m ake GKRS a good 
th erap y  for VS. If tum or g ro w th  occurs after GKRS, a con servative  m an agem en t can 
be considered because continued tum or gro w th  is un certain . The extram eata l 
diam eter on a x ia l MRI seem s to be a reliable p aram eter of th e  size o f a VS. V olum etry 
is the preferred m ethod to assess th e  dim ensions of a VS alth ough the consequences 
of strong volu m etric increase, esp ecially  in sm all tum ors, can be different, depending 
on in d ivid u al d ifferences in  tum or size.
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D ue to th e  greater a va ilab ility  o f M agn etic  Resonance Im agin g (MRI), vestibular 
sch w an n o m as (VSs) are bein g diagnosed m ore freq u en tly  and at an earlier stage.1 
Treatm ent strategies for VS include m icrosurgery, con servative m an agem en t (“w a it  
and scan”) and radiation therapy. Radiation th erap y  can take  tw o  fo rm s: fractionated  
radiotherapy and radiosurgery. R adiosurgery com prises th e  d elivery  o f a single dose 
of radiation w ith  h ig h  precision after stereotactic p lan n in g u sin g a fixed fram e on 
th e  head and MR im agin g. In G am m a K nife radiosurgery(GKRS), m ultip le radiation 
beam s derived from  cobalt sources adm inister th e  dose. There is an ongoing 
discussion on th e  preferred treatm ent of VS. At our in stitu tio n  th e  treatm ent strategy 
is tailor-m ade for each patient and determ in ed after a decision-m aking process in 
w h ich  th e  patient's personal preferences, age and occupation p lay a role. In general, 
w e  advise  p rim a ry  m icrosu rgery w h en  th e  tum or com presses th e  brainstem . If the 
tum or is relatively  large -  th at is, i f  it fills th e  cerebellopontine angle w ith o u t 
brain stem  com pression -  w e  take  into consideration th at continued gro w th  could 
e v e n tu a lly  preclude th e  application of GKRS. For th e  rem ain in g VSs, w e  advise 
patients to h ave  their tum or gro w th  m onitored b y  an n u al MRI, also referred to as a 
“w a it  and scan” (W&S) policy. W hen tum or g ro w th  (>2 m m  in  th e  a x ia l p lane on 
MRI) has been docum en ted over tim e, w e  advise th e  patient to proceed to therapy, 
either su rgery  or GKRS, depending on several considerations, in cludin g th e  patient's 
w ishes.
Introduction
D urin g a W & S period or during follow -up after GKRS, MRI scans are repeated to 
docum ent th e  size o f th e  tum or. Tumor size in  th e  a x ia l p lane can be determ ined 
according to th e  consensus reached in  Tokyo on N ovem ber 7th 2001.2 A  draw back of 
th is m eth od is th at it on ly  takes th e  largest extra m eata l d iam eter into account. Since 
VS g ro w th  can be subtle and take  place in a n y  direction, determ in in g th e  tum or's 
vo lu m e w o u ld  seem  to be a m ore exact m ethod. This topic has been addressed in  a 
num ber of published studies.3-5 U ntil n o w  it has rem ained  un certain  w h eth er 
volu m etric m easurem ents are m ore accurate for determ in in g tum or size. W hether 
th ese  m easurem en ts should be recom m ended for routine use in clin ical practice is 
still a subject of debate. In th at light, th is stu d y has a tw o fo ld  aim . It first analyzes 
th e  results o f GKRS treatm ent in  patients w ith  a sporadic VS w ith  focus on tum or 
size and possible com plications of GKRS. Secondly it evaluates th e  va lu e  of th e  tw o  





The patients included in  this stu d y  h ave  been treated b y  GKRS for u n ilatera l sporadic 
VS. This diagnosis w as  based on characteristic audiovestibu lar sym ptom s and MRI 
findings. A ll patients w ere  in itia lly  seen and exa m in ed  at th e  D epartm en t of 
O torhinolaryngology, Head and N eck Surgery of th e  Radboud U n iversity  N ijm egen 
M edical Center b e tw ee n  2002 and 2007. Patients w ere  th o ro u gh ly  in form ed about 
current treatm ent options and possible com plications. The rationale to proceed to 
GKRS w a s  rather diverse. In general, MRI-proven tum or g ro w th  (>2mm differen ce in 
m a x im a l diam eter o f th e  tum or in either direction on a xia l MRI) or personal 
preferences o f th e  patients after consultation  w ere  reasons to advise  GKRS. Patients 
w ith  a follow -up tim e <2 years and patients su fferin g  from  neurofibrom atosis ty p e
II w ere  excluded from  th is study.
Tumor location and assessment of size
In all patients, a standard pretreatm ent MRI protocol w as  used. T1-weighted, 
gadolin iu m -en h an ced  MR im ages w ere  used to m easure th e  tum or size in  th e  axia l 
p lane and to determ in e th e  tum or vo lu m e usin g th e  Leksell G am m a-Plan so ftw are  
V5.34. Follow-up im ages w ere  all obtain ed usin g th e  sam e scanner and th e  sam e 
scan n in g param eters. The slice thickness w as  1 m m  for th e  great m ajority  o f the 
patients. Follow-up im ages w ere  sent to th e  ga m m a kn ife  computer, w h ere  im age 
fusion  w a s  perform ed w ith  th e  Leksell G am m a-Plan softw are. A ll tum or volum es 
w ere  determ in ed in an  identical w ay.
The continuation  of th e  line of th e  petrous ridge depicted on serial a x ia l MR im ages 
provided a clear d istinction  b e tw ee n  th e  intra- and extra m eata l portion  o f the 
tum or. The tum or w as reported as an in tram eata l lesion w h en  there w as  no tum or 
extension  beyon d th e  p lane form ed b y  that line. Tumor size in th e  a x ia l p lane w as 
determ in ed according to th e  consensus th at w a s  reached in Tokyo on N ovem ber 7th 
2001.2 This m eth od is restricted to an assessm ent of th e  largest extra m eata l diam eter 
in  m illim eters.
Tumor g ro w th  w a s  defined as an  increase in th is d iam eter of m ore th a n  2 m m ; this 
is an arbitrary lim it based on data in  th e  literature.2 M oreover, th e  tum or volum e 
w a s  determ in ed usin g th e  Leksell G am m a-Plan so ftw are  after th e  tum or w as 
poin ted out on th e  corresponding im ages. A n  increase or decrease of 10% w as 
considered significant.
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Complications and audiovestibular symptoms
S e v e ra l c o m p lica tio n s o f  GKRS h a v e  b e e n  rep orted : re c u rre n t or c o n tin u e d  tu m o r 
g r o w th ; se n so rin e u ra l h e a r in g  im p a irm e n t; v e s t ib u la r  disorders; fa c ia l n e rv e  
deficit; t r ig e m in a l n e r v e  d y s fu n c tio n ; h e a d a ch e; ra d ia tio n -in d u c e d  m a lig n a n c ie s ; 
an d  com plication s fro m  in sta llin g  th e  stereotactic fram e  on th e  head. The com plications 
th a t  o cc u rre d  d u rin g  fo llo w -u p  w e r e  d o cu m e n te d .
Gamma knife settings, procedure and cochlear radiation dose
A  L ek sell t i ta n iu m  ste re o ta ctic  fra m e  w a s  in s ta lle d  on  e a ch  p a tie n t 's  h e a d  a fte r  
in je c tin g  lo ca l a n e sth e s ia  su b c u ta n e o u s ly  a b o v e  th e  s c r e w  p o in ts  in  th e  skull. 
The p atien t w a s  th e n  placed in  a Philips T1.0 MRI scanner. A x ia l T 1 1.0 m m  MR im ages 
w e r e  m a d e  b efore  a n d  a fte r  a d m in is te r in g  g a d o lin iu m  con trast. T hen  3D TSE 0.7 m m  
im a g e s  w e r e  produ ced.
U sin g  Leksell G a m m a  Plan  s o ftw a r e  V5.34, th e  tu m o r w a s  d e lin e a te d  on  th e  
co rresp o n d in g  im a g e s  u s in g  th e  TSE a n d  T 1-w eigh ted  g a d o lin iu m  co n tra st e n h a n c e d  
im a g e s. A  ra d ia tio n  p la n  w a s  m a d e  b y  p la c in g  ‘iso cen te rs ' or 'shots' in  th e  tu m o r 
v o lu m e , g u id e d  b y  p rescrib ed  dose  (PD), m a r g in a l dose, a n d  co n fo rm ity . The ra d ia tio n  
dose  w a s  p re scrib e d  to  th e  iso d o se  c o v e r in g  90%  o f  th e  tu m o r v o lu m e . In p a tien ts 
w h o  w e r e  s till u s in g  th e ir  a ffe c te d  ear on  th e  te lep h o n e, a dose  o f  12.5 G ray  (Gy) 
w a s  p rescrib ed . The PD for p a tie n ts  w h o  d e c lared  th e ir  a ffe c te d  ear to  b e  u se less  w a s
13.0 Gy. The re s u ltin g  m a r g in a l do se  w a s  on  a v e ra g e  11.0 G y  for a ll p a tie n ts  (range 
9 .3 -12.5 Gy).
S te re o ta c tic  s u rg e r y  w a s  p e rfo rm e d  u s in g  a L ek sell 4C G a m m a  K n ife . P a tien ts w e re  
d is c h a rg e d  fro m  th e  h o sp ita l th e  sa m e  day.
Tumor control / successful treatment
In th is  stu d y, a d d it io n a l tr e a tm e n t is th e  o u tc o m e  m e a su re  th a t  d is tin g u ish e s  
b e tw e e n  a s u c c e ss fu l o u tco m e  a n d  fa ilu re . The n e e d  for a d d it io n a l tr e a tm e n t is 
n ot s ta n d a rd iz e d . If c o n tin u e d  tu m o r g r o w t h  is o b serv ed , a d d it io n a l tre a tm e n t 
(rep eated  GKRS or m icro su rg e ry )  is con sid ered . M u ltip le  fa cto rs  (m ass e ffe c t  on th e  
b ra in , n e u ra l sign s, p a tie n t age, g r o w t h  sp eed, tu m o r size, p a tie n ts  o p in io n  etc.) are 
ta k e n  in to  c o n sid era tio n  to  d ecid e  w h ic h  th e r a p y  is applied .
Follow-up
F ollo w -u p  M RI sca n s w e r e  g e n e r a lly  m a d e  a fte r  1, 2, 3 a n d  4 y ears . T he m in im a l 




G roup c o m p a riso n s w e r e  m a d e  w it h  th e  n o n -p a ra m e tr ic  M a n n -W h itn e y  test.
Results
A  to ta l o f  110 VS p a tie n ts  w e r e  re ferre d  for ra d io s u rg e ry  b e tw e e n  2002 a n d  2007. 
T h ree  p a tie n ts  w i t h  n eu ro fib ro m a to s is  t y p e  II a n d  se v e n  p a tie n ts  w i t h  less th a n  2 
y e a rs  o f  fo llo w -u p  w e r e  e xc lu d e d . A  to ta l  o f  100 p a tie n ts  (54 m a le  a n d  46 fem ale) 
w i t h  u n ila te r a l  VS c o u ld  b e  in c lu d e d  in  th e  stud y. T he m e a n  a g e  at th e  d a te  o f  GKRS 
w a s  57 y e a rs  (ran ge  25-80 years). The tu m o r w a s  lo ca te d  on  th e  le ft  side in  59 cases 
(59%). T he re a so n  for GKRS w a s  p ro v e n  tu m o r g r o w t h  a fte r  a W & S  p e rio d  (>2 m m  
a x ia l  p lan e) in  67 cases (67%). In 29 cases (29%) th e  p a tie n t h a d  GKRS b e c a u se  o f  a 
r e la t iv e ly  la rg e  tu m o r a n d  th e  co n se q u e n t re s tr ic te d  w in d o w  o f  o p p o r tu n ity  to  
a p p ly  GKRS. Four p a tie n ts  (4%) c h o se  GKRS tr e a tm e n t ra th er th a n  a W & S  p ro to co l 
d u e  to  p e rs o n a l p referen ces . N o VS s h o w e d  c y s tic  co m p o n en ts  at th e  su rfa c e  o f  th e  
tu m o r. The d e s cr ip t iv e  d a ta  o f  th e  s tu d y  group, th e  tu m o r  size  a n d  ra d ia tio n  
p a ra m e te rs  are  lis te d  in  Tables 1 a n d  2.
Table 1 N u m b er o f in clu ded  p atients per year (N).
Year 2003 2004 2005
N 6 (6%) 8 (8%) 23 (23%)
2006 2007 Total
33 (33%) 30 (30%) 100
Table 2 Tum or size an d  radiation  param eters.
N=100 (range)
Intram eatal vs extram eatal 2 vs 98
M ean tum or size Tokyo 2003 guidelines 17 m m  (6- 41)
M ean tum or volum e 2825 m m 3 (63- 17800)
M ean m ax dose tum or 19.9 Gy (16.0- 25.5)
M ean m arginal dose tum or 11.1 Gy (9.3- 12.5)
M ean dose 90% 12,7 Gy (12.0-13.2)
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The m ean  follow -up w a s  38 m onths (range 24-73 m onths). A  tum or w a s  considered to 
h ave responded to  treatm ent w h en  a loss o f contrast en h an cem en t w a s  seen on the 
MRI, w h ich  occurred for 57 patients (57%).
Figure 1 represents the relationship betw een  the volum etric and axial measurements. 
Figure 1
The dotted line equals 4/3 x pi x r3 which is the equation to calculate the volume of a sphere. The solid 
line represents the line fitted to our data.
The dotted line in th e  figure represents 4/3 x  n  x  r3 w h ich  is th e  equation  for the 
volu m e o f a sphere (r=o.5 x  largest diam eter). The correlation b e tw ee n  th e  calculated 
and the m easured vo lu m e is sign ifican t (p<0.05). Yet, as Figure 1 clearly shows, 
app lying th e  standard equation  for th e  vo lu m e o f a sphere w ou ld  overestim ate the 
tum or volum e. That discrepan cy w o u ld  increase along w ith  tum or size.
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Table 3 g iv e s  th e  tu m o r  v o lu m e  a n d  m a x im a l e x tr a m e a ta l tu m o r  d ia m e te r  at th e  
t im e  o f  GKRS, at th e  first fo llo w -u p  sc a n  (m ean  FU t im e  = 12 m o n th s; ra n g e  3-15) a n d  
at th e  m o st recen t fo llo w -u p  sc a n  (m ea n  FU t im e  = 38 m o n th s; ra n g e  24-73).
In Tables 4 a n d  5 th e  m o st re cen t sc a n  is co m p a re d  to  th e  in it ia l  sc a n  at th e  m o m e n t 
o f  GKRS. Tum or con tro l re su lts  c a n  b e  d e riv e d  fro m  th e s e  tables.
Table 3 The vo lu m e an d  m a x im a l d iam eter before GKRS at th e  first scan  a fte r GKRS 
an d  at th e  m ost recent scan.
N=100 Mean (mm3) Range (mm3) Mean follow
-up (months)
Tumor volum e before GKRS 2825 m m 3 63 -  17800 m m 3 -
M axim al diameter before GKRS 17 mm 6 -  41 mm -
Tumor volum e at first follow-up scan 2590 m m 3 35-17800 m m 3 12 (3-15)
M axim al diameter at first follow-up scan 16.8 m m 6 -  41 m m 12 (3-15)
Tumor volum e m ost recent follow-up scan 2043 m m 3 24 -  13200 m m 3 38 (24 -73)
M axim al diameter most recent follow-up scan 15.1 mm 5 -  38 m m 38 (24 -73)
Table 4 M a x im a l d iam eter d ifferen ce  b e tw e e n  th e  scan  at th e  tim e  of GKRS an d  at the 
m o st recent scan.
M axim al diam eter < -2 m m  -2 m m  -1 m m  0 +1 m m  + 2 m m  > +2mm 
N= 100 45 (45%) 9 (9%) 13 (13%) 13(13%) 7 (7%) 7 (7%) 6 (6%)
An increase or decrease of >2mm is considered significant.
Table 5 M a x im a l v o lu m e differen ce  as a p ercen tage o f th e  in itia l tu m o r volu m e 
b e tw e e n  th e  scan  at th e  tim e  of GKRS and at th e  m o st recent scan.
Volum e change < -50% -50% to -25% to  -10% to  >+10% to +25% to > +50%
-25% -10% +10% +25% + 50%
N=100 36 (36%) 16 (16%) 16 (16%) 11 (11%) 7 (7%) 4 (4%) 10 (10%) 
An increase or decrease of 10% is considered significant.
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Some tum ors, how ever, can  gro w  during the first period a fter GKRS and rem ain  the 
sam e size over subsequent years o f follow -up. In Figures 2 and 3, a ll fo llow -up scans 
are depicted in  a diagram . It show s th a t som e tum ors shran k during the period 
covered b y  th ree  con secutive follow -up scans but th en  g re w  after th e  fo u rth  scan.
In th is series w e  foun d th a t 31 o f the 100 tum ors show ed a sign ifican t increase in 
th eir volu m e (>10%) at the first follow -up MRI scan. A lm o st a ll o f these "in itia lly  
g ro w in g ” tum ors (29 of 31) stabilized  or decreased in  volu m e during fu rth er 
follow -up. No relation  w a s  foun d b e tw e e n  the in itia l tu m o r sw e llin g  and loss of 
central tu m o r en h an cem en t on the follow -up MRI scan  (Chi-square p=o.63).
Figure 2 A  diagram  representing the largest extra m eata l d iam eter chan ge in  all 
fo llow -up scans.
I Larger com pared 
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Growth > 2 mm in the largest extrameatal diameter was considered significant. One hundred patients 
were treated with GKRS. At the first follow-up scan the tumor had grown in five patients and shrunk or 
remained stable in 95 patients. All patients underwent at least two follow up scans.
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Figure 3 A  diagram , the sam e as figure 2 but n o w  representing the tum or volum e 
chan ge in  a ll follow -up scans.
A volume change of 10% was considered as significant.
As Figure 4 shows, w e  calcu lated  the volu m e difference as a percentage o f the 
volum e at the tim e o f GKRS.
One patient had a sm all in tracan icu lar tu m o r th at g rew  from  6 to 9 m m . The volum e 
chan ge in th is in d ividual w a s  exceptional: +440% at 55 m onths o f follow-up. 
A lth o u gh  g ro w th  after GKRS has been  docum en ted in th is patient, no additional 
th erap y  w a s  given  to date. This decision w a s  based on the sm all tum or size and 
patient preferences.
In Figure 5, the data are presented in  a box plot. A ll follow -up scans w ere  included in 
a box.
Up till now, eight patients have received additional treatm ent after the in itia l GKRS. 
The details for these patients are sum m arized  in Table VI.
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Figure 4 The tum or volu m e differen ce as a percentage o f the volu m e at the tim e of 
GKRS.
Before GKRS, tum or g ro w th  w a s  docum ented w ith  MRI in 67 patients. The rem ainin g 
33 patients u n d erw en t GKRS because o f tum or size or personal preferences. No 
sign ifican t d ifferen ce w a s  found b e tw ee n  the outcom es for these groups 
(M ann-W hitney p  = 0.36).
Complications and audiovestibular symptoms
The com plications and audiovestibu lar sym ptom s w ere  described previously, 
w h ereb y  cochlear radiation dose and post-GKRS h earin g w ere  related to the q u ality  
o f life a fter GKRS. In short, one patient experienced a tem p orary  facia l nerve paresis, 
w h ich  com pletely disappeared w ith in  3 m onths. No life-th reaten in g com plication 
occurred.
H earing w a s  considered to be preserved (m ax +1 class, Tokyo classification 2) in 52 of 
the 69 patients w h o se  h earin g w a s  better th a n  the threshold o f 90 dB before GKRS.
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Figure 5 Box plot representing the volu m e chan ge as a percentage com pared to the 
volu m e at the tim e of GKRS.
n=the number of patients in the box. The box represents 50% of all data. The superior and inferior lines 
represent the highest and lowest score in the group. The horizontal line in the box represents the 
median. The numbers represent outliers.
However, just 32 of all the patients had h earin g in Tokyo class A, B, or C (serviceable 
hearing) before GKRS. O f those 32, 13 patients (41%) had a h earin g class A, B, or C after 
GKRS. In other words, w h en  serviceable h earin g w a s present, it could be preserved in 
41% of the cases. The subjective audiovestibu lar sym ptom s are outlined in Table 7.
A fter the additional (2nd) GKRS treatm ent, one patient developed a facia l nerve 
paresis (H ouse-Brackm ann (HB) grade III) and a trig em in al n erve deficit. This patient 
did not recover com pletely from  either com plication. One of the 3 patients w ho 
u n d erw en t additional m icrosurgery (largest extram eata l tum or diam eter: 38 mm) 
had a total loss of facia l n erve fu n ction  (HB grade VI) and a trig em in al nerve deficit. 
The other tw o  m icrosurgery patients did not have  an y com plications.
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Table 6 Data on the patients who received additional treatm ent after GKRS.











M 43 4700 mm3 1500 mm3 1200 mm3 4600 mm3 49 m onths 2nd GKRS
22 m m 16 m m 14 m m 24 m m
M 51 1700 mm3 1500 mm3 1200 mm3 1600 mm3 3100 mm3 62 m onths 2nd GKRS
17 m m 16 m m 15 m m 16 m m 19 m m
F 5400 mm3 5700 mm3 9200 mm3 7200 mm3 31 m onths 2nd GKRS
65 25 m m 23 m m 27 m m 26 m m
F 1100 mm3 1600 mm3 2800 mm3 2800 mm3 3100 mm3 33 m onths 2nd GKRS
47 15 m m 13 m m 17 m m 17 m m 17 m m
F 520 mm3 812 mm3 1200 mm3 1900 mm3 41 m onths 2nd GKRS
72 9 m m 12 m m 14 m m 17 m m
M  50 10200 mm3 9400 mm3 6500 mm3 12300 mm3 55 m onths M icrosurgery
34 m m 33 m m 32 m m 38 m m
M 44 5800 mm3 7300 mm3 8800 mm3 11600 mm3 9400 mm3 37 m onths M icrosurgery
27 m m 28 m m 28 m m 27 m m 27 m m + 2nd GKRS
F 65 2700 mm3 3800 mm3 8600 mm3 8700 mm3 38 m onths M icrosurgery
17 m m 19 m m 25 m m 27 m m + 2nd GKRS
Tumor size is represented as volume and maximal diameter according to the Tokyo consensus.
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Table 7 Subjective symptoms before and after GKRS.
N=91 Patients before GKRS 8 Patients after GKRS 9
Tinnitus 75 (82%) 82 (90%)
Dizziness 62 (68%) 68 (75%)
H eadache 4 4  (48%) 53 (5 8 %)
Discussion
In th is  fo llo w -u p  s tu d y  w it h  a m e a n  fo llo w -u p  p e rio d  o f  38 m o n th s  a n d  a m in im a l 
fo llo w -u p  o f  2 y ears , w e  fo u n d  a sta b le  o u tco m e  (d efin ed  as n o a d d it io n a l tre a tm e n t 
n eed ed ) in  92 o f th e  100 VS p a tie n ts  w h o  h a d  GKRS.
C o m p lica tio n s w e r e  ra re  a fte r  th e  first GKRS tre a tm e n t. O n e p a tie n t e x p e rie n c e d  a 
te m p o r a r y  fa c ia l n e r v e  p aresis . N o p a tie n ts  d e v e lo p e d  o th e r se v e re  side e ffec ts . 
A fte r  a d d it io n a l GKRS, on e o f  th e  7 p a tie n ts  d e v e lo p e d  a n  N.V a n d  N.VII deficit. O ne 
p a tien t u n d e rw e n t com plete  tu m o r re m o va l an d  did not recover fro m  a p osto p erative  
N.V a n d  N.VII d eficit (HB g ra d e  VI).
B esides y ie ld in g  th e s e  fig u res  on tu m o r co n tro l a n d  co m p lica tio n s, th is  s tu d y  h as 
c le a r ly  s h o w n  th a t tu m o r g r o w t h  or s h r in k a g e  a fte r  GKRS is u n c e r ta in  a n d  th a t no 
g r o w t h  p a tte rn  c a n  b e  re c o g n iz e d  in  g r o w in g  tu m o rs  a fte r  GKRS. (Figure 2&3)
In th e  p ast, v o lu m e tr ic  m e a su re m e n t w a s  co n sid ered  th e  m o st a cc u ra te  w a y  to 
a ssess g r o w t h  in  VS. M e a su re s  u se d  form erly , n a m e ly  th o s e  b a se d  s o le ly  on 
m e a s u r in g  th e  d ia m e te r  in  a c e r ta in  p la n e  on MRI, are  th o u g h t to  b e  in a c cu ra te . The 
re a so n  is th a t  e v e n  m in o r c h a n g e s  in  d ia m e te r  c a n  re su lt in  s ig n ific a n t c h a n g e s  in  
v o lu m e . T herefore, th e  a p p lica tio n  o f  v o lu m e tr ic  a sse ssm e n ts  co u ld  h a v e  
co n se q u e n c e s  for th e  o u tco m e  fig u re s  a fte r  GKRS, e s p e c ia lly  in  th e  case  o f  sm a ll 
tu m o rs . For e xa m p le , w h e n  a 12-m m  tu m o r  (larg est e x tr a m e a ta l d ia m eter) g ro w s  to 
14 m m , its d ia m e te r  h a s  in cre a se d  b y  17%. H o w ev er, th e  v o lu m e tr ic  in cre a se  c o u ld  be 
as grea t as 59%, a s s u m in g  th e  lesio n  ta k e s  th e  sh a p e  o f  a sphere. (((4/3’ n ’ 73 -4/3’ n ’ 63) 
/ 4 /3*n*63)*1 0 0 %).
If our re su lts  w e r e  b a se d  on  th e  la rg e st e x tr a m e a ta l d ia m e te r  a n d  i f  a c h a n g e  in  
tu m o r  size  c h a n g e  w e r e  d e fin e d  as >2 m m , th e  tu m o r size  w o u ld  h a v e  d e cre a sed  or 
re m a in e d  stab le  in  94%  o f  th e  p a tie n ts  in  th is  s tu d y  (Table 4). T his p e rc e n ta g e  is 
co m p a ra b le  to  th e  re su lts  fo u n d  b y  o th e r au th ors. 7-9
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The accuracy of vo lu m etric m easurem ent has been in vestigated  b y  several authors 
in  th e  past fe w  years.3-5, 10 Com pared to a x ia l m easurem ent, vo lu m etric m easurem ent 
w a s  found to be m ore precise, esp ecially  for larger tum ors. Each tim e it appeared to 
be difficult to m easure th e  volu m e of sm all in tram eata l tum ors. If w e  fo llo w  the 
Tokyo guidelines and consider volu m etric m easurem ent to be sign ifican t if  a volum e 
ch an ge of 10% is found, th e  tum or size w o u ld  have decreased or rem ained  stable in 
79% (Table 5). In th is study, th e  15% differen ce b e tw ee n  th e  tw o  m easurem ent 
options is m a in ly  accounted for b y  sm all tum ors th at increased less th a n  2 m m  in 
a x ia l d iam eter but show ed a significant p ercen tage increase after volum etry. If w e  
accept vo lu m etry  as th e  gold standard, th is outcom e suggests th at g ro w th  evaluation  
according to th e  Tokyo guidelines usin g th e  largest extram eata l d iam eter w ou ld  
un derestim ate tum or grow th. Because m ultip le follow -up scans are m ade before the 
diagnosis of “progressive tum or gro w th  after GKRS” is m ade, th is un derestim ation  
o f tum or g ro w th  w o u ld  have little  consequence in  d a ily  practice.
Tumor gro w th  is often  referred to  as an increase in  th e  tum or's d iam eter at im agin g 
b y  a certain  am ount, expressed in m m /year. No biological exp lan ation  has been 
offered to support th e  hyp oth esis th at th e  increase in  volu m e of a tum or can be 
expressed as a linear increase in  its diam eter. The results o f th is stu d y confirm  that 
recurrent or continued tum or gro w th  (or shrinkage) after GKRS is variab le  and does 
not seem  to fo llo w  a w ell-defin ed  p attern  (Figures 2 and 3). This m eans th at additional 
treatm en t strategies m a y  include “w a it  and scan”, repeated GKRS and m icrosurgery. 
The un defin ed n ature of tum or behavior after GKRS suggests th at follow -up 
scan n in g should be repeated regularly, even  after longer periods w ith o u t grow th.
A n  increase in tum or vo lu m e during th e  first year after GKRS can be interpreted  as 
either reactive sw e llin g  or progressive gro w th . In th is series w e  foun d th at 31 of the 
100 tum ors show ed a significant increase (>10%) in  their vo lu m e at th e  first follow -up 
MRI scan. A lm ost all o f these in itia lly  gro w in g  tum ors (29 o f 31) stabilized  or 
decreased in  volu m e during fu rth er follow -up. H ow ever, th is vo lu m e increase 
during th e  in itia l period after GKRS can be of great sign ifican ce if  th e  tum or is 
a lready large and com pressing th e  brainstem . Based on th e  largest extram eatal 
d iam eter (>2mm), 5% of th e  patients show ed in itia l tum or grow th. The difference 
b e tw ee n  th ese  tw o  m easurem ents can be exp lain ed  along th e  lines m entioned 
earlier in  th is text.
No relation w a s  found b e tw ee n  th e  in itia l tum or sw e llin g  and loss o f central tum or 
enhan cem en t on th e  follow -up MRI scan. M oreover, no relation w a s  found b etw een
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th e  tum or sw e llin g  after GKRS and proven tum or gro w th  prior to GKRS.
Pollock described 30 patients w ith  tum ors th at w ere  enlarged by at least 2 m m  after 
radiosurgery.10 He suggested  th at tum or expansion  after VS radiosurgery rarely 
denotes a failed  procedure and that th e  m ajority  o f patients only require furth er 
im agin g. A ccording to  his exten sive  experience, additional tum or treatm ent should 
be reserved for patients w h o  dem onstrate progressive tum or enlargem ent upon 
con secutive im agin g. W e can support th is opinion b ased on th e  results o f th e  present 
study.
M ultiple authors have reported th e  results o f treatm ent b y  repeated GKRS. Studies 
b y  D ew a n  and Noren and b y  Kano et al. have both  sh o w n  tum or regression in  most 
patients.11, 12 None of th e  patients developed sym ptom atic adverse radiation  e ffects or 
n e w  neurological sym ptom s after a second GKRS in  th e  study published b y  Kano et 
al. D ew a n  found 8 out o f 11 VSs to decrease in size after re-treatm ent. In 2 patients the 
tum or continued to grow. Facial n erve fu n ction  rem ained stable in  all patients; 2 of 
th e  11 cases described w ere  com plicated b y  slight cerebellar oedem a. In our study, 
one patient developed a facia l n erve deficit and decreased sen sib ility  o f th e  face after 
additional GKRS. These data give  som e indication  th at com plications could occur 
m ore freq u en tly  after repeated GKRS.
Surgery after GKRS seem s to be m ore difficult due to  scarring and adhesions. Roche 
et al. and Shuto et al. found th at th e  effectiven ess of tum or rem oval and facia l n erve 
p reservation  m igh t be im paired b y  radiosurgery in  h a lf  o f their cases.13, 14 However, 
no large series have been presented so far. In th e  current study, one patient 
un d erw en t m icrosu rgery w ith  to ta l tum or rem oval; 2 patients u n d erw en t surgery 
w ith  incom plete tum or rem oval fo llow ed  by a second treatm ent of GKRS on the 
tum or rem nant. The patient w h o  u n d erw en t com plete tum or rem oval had a 
postoperative N.V and N.VII deficit (HB grade VI), w h ich  did not go aw ay. In th e  other
2 patients w h o  had m icrosu rgery after GKRS, th e  procedure w en t w e ll and there 
w ere  no problem s. Since surgery w a s  perform ed on only  3 patients after GKRS, it is 
im possible to m ake a n y  significant com m ents on th is topic yet.
The effectiven ess o f GKRS should preferably be judged  in  light o f data from  long-term  
follow -up. This is p articu larly  tru e  for th is study, since th e  radiation dose currently 
applied is low er th a n  th e  dose schem es th at had been used in itially. In this stu d y  12.5 
-  13.0 Gy w a s  prescribed to th e  isodose line covering 90% o f th e  tum or volum e. Since 
th e  1990s, th e  prescribed doses have been p eriod ically  low ered to m in im ize  side 
effects. M a x im a l radiation doses in  our stu d y  ran ged from  16 to 26 Gy, and peripheral
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doses (m arginal or m in im al dose) ran ged  from  9.3 to 12.5 Gy. Before 1992, how ever, 
th e  m a x im a l doses ty p ica lly  ran ged  from  50 to 70 Gy, and th e  peripheral doses 
ran ged  from  25 to 35 Gy.15 Low ering th e  doses e ffe ctiv e ly  reduced th e  side effects, but 
long-term  follow -up is still w arra n ted  to assess th e  im pact on long-term  tum or 
control.
This stu d y  has sh o w n  th e  GKRS outcom e in a large group w ith o u t a n y  lost to 
follow -up. Since th e  n atu ral course of VS g ro w th  is h ig h ly  unpredictable, a longer 
follow -up tim e is needed. A  random ized tria l com paring GKRS and W & S w o u ld  be 
desirable, but eth ical considerations w o u ld  form  an obstacle to such research. 
A nother possible bias is th e  fact th at tum or g ro w th  w a s  observed b y  m ultip le scans 
in  a m ajority  o f th e  patients before GKRS. Some patients h o w ever w ere  treated 
w ith o u t kn o w in g  th e  g ro w th  pattern  of th e  tum or in  th e  year prior to GKRS. Since 
m ost studies don't m ention  th is d ifference at all, w e  th in k  th ese  results are 
com parable to other studies published in th e  in tern ation al literature before. 
A nother w eakn ess of this stu d y  w a s  th e  fact th at w e  w ere  unable to clearly 
d eterm in e th e  criteria for “additional treatm en t”. In th e  in tern ation al literature 
there is still no consensus about th is topic. Longer fo llo w  up and larger studies should 
be conducted and com bined to address this problem.
Conclusion
H igh tum or control and lo w  com plication rates m ake GKRS a good th erap y  for VS. If 
tum or g ro w th  occurs after GKRS, a con servative m an agem en t can be considered 
because continued tum or g ro w th  is un certain . The extra m eata l d iam eter on axial 
MRI seem s to be a reliable p aram eter of th e  size of a VS. V o lu m etry  is th e  preferred 
m eth od  to  assess th e  dim ensions of a VS alth ou gh  th e  consequences of strong 
volu m etric increase, esp ecially  in  sm all tum ors, can be different, depending on 
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Objectives: G am m a kn ife  radiosurgery (GKRS) has becom e an im p ortan t treatm ent 
m o d a lity  for vestib u lar schw an n om as. The p rim a ry  aim  of th is stu d y w as to 
in vestigate  w h eth er tum or gro w th  at th e  m om ent of GKRS has a n y  correlation to the 
outcom e. The secon dary aim  w a s  to id e n tify  clin ical predictors of radioresistance in 
VS patients treated  w ith  GKRS.
Methods: 100 vestib u lar sch w an n o m a patients, treated  w ith  GKRS, w ere  divided 
into tw o  groups: 'proven tum or g ro w th  preceding GKRS’ and 'previous h isto ry  of 
g ro w th  u n k n o w n ’. GKRS outcom e w a s  defined in  tw o  w ay s. A ccording to th e  first 
definition, GKRS is said to h ave  failed  w h en  additional treatm ent had taken  place. 
A ccording to th e  second one, a vo lu m e decrease >20% after tw o  years m arked 
successfu l treatm ent. Correlations b e tw ee n  outcom e and gro w th  status w ere 
determ in ed w ith  SPSS. Furtherm ore, th e  stu d y assessed h o w  different variables 
(patient data, history, tum or characteristics, im agin g, and audiovestibular 
exam in ations) correlated w ith  th e  outcom e o f GKRS.
Results: No significant d ifferen ce regarding success and failu re of GKRS w a s  found 
b e tw ee n  th e  tw o  patient groups. The m ean  reduction in  tum or volu m e after GKRS 
w a s  less pronounced in  patients in  w h o m  tum or g ro w th  w a s  dem onstrated before 
treatm ent, but th is findin g w a s  not significant. No significant predictors (P <0.05) 
could be identified in  this dataset.
Conclusions: This stu d y  found no indication  th at g ro w th  at th e  m om ent of GKRS 
influences its therapeutic outcom e, nor did it id e n tify  a n y  predictors of th e  outcom e 
after GKRS in  VS patients.
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One feature o f a u n ilatera l vestib u lar sch w an n o m a (VS) is th at this tum or has 
variou s gro w th  patterns. As Sm ouha et al. dem onstrated in 2005, only 43% o f the 
tum ors had gro w n  after a m ean  follow -up of 3.2 years.1 At present, there are three 
m an agem en t options: m icrosurgery; stereotactic radiotherapy, in cludin g gam m a 
kn ife  rad iosurgery  (GKRS); and con servative m an agem en t w ith  an n ual MRI 
scann ing, k n o w n  as 'w a it and scan ’ (W&S). So far, no consensus has been  reached on 
th e  preferred m anagem en t. Our p olicy  is to advise m icrosu rgery w h en  th e  tum or 
com presses th e  brainstem , as visib le  w ith  MRI, w ith  or w ith o u t neurologic signs. If 
th e  tum or is relatively  large -  th at is, fillin g th e  cerebellopontine angle  w ith o u t 
brain stem  com pression -  w e  also refrain  from  con servative  m anagem en t. In that 
case, w e  proceed to m icrosu rgery or GKRS. For th e  rem ain in g VSs, w e  advise  a W & S 
policy. Once tum or gro w th  (ffl2 m m  in  th e  a x ia l p lane on MRI) is docum ented over 
tim e, w e  advise  th e  patient to proceed to therapy. W e recom m end either m icrosurgery 
or GKRS, depending on several considerations, in cludin g th e  p atie n t’s w ish es.
G iven th is protocol, tw o  differen t groups of patients are referred for GKRS. One 
consists of patients w ith  a tum or th at has been gro w in g  during th e  last year or more 
o f a certain  follow -up period. The second group com prises patients w h o se  h isto ry  of 
tum or g ro w th  is un kn o w n . Tumors in  th e  first group are u su a lly  sm aller th a n  those 
in  th e  second group. M a n y  tum ors in  th e  latter group are presum ed to be stable. We 
h yp o th esized  th at these tw o  groups could have a d ifferent outcom e after GKRS due 
to  th e  different p rop en sity  for gro w th . The p rim a ry  aim  o f our stu d y w as to test this 
hypothesis. M ost tum ors ten d  to decrease in size a fter GKRS. H owever, som e continue 
to  gro w  or sh ow  delayed grow th. A lth o u gh  VSs w ere  first treated b y  GKRS in 1971, it 
is still not possible to  d istin gu ish  tum ors th at are radioresistant. Thus, th e  secondary 
a im  o f th is stu d y  w as to id e n tify  clin ical predictors o f radioresistance in  VS patients 
treated  w ith  GKRS.
Methods
Study group
The patients included in th is stu d y h ave  been treated  b y  GKRS for a un ilateral 
sporadic VS. This diagnosis w as  based on characteristic audiovestibu lar sym ptom s 






O to rh in olaryn go lo gy -  Head and Neck Surgery of th e  Radboud U n iversity  N ijm egen 
M edical Center b e tw ee n  2002 and 2007. GKRS w a s  perform ed in  th e  G am m a Knife 
Center Tilburg, St Elisabeth Hospital, Tilburg. Inform ation w a s  provided to th em  on 
treatm en t options and possible com plications. Patients w ith  a follow -up tim e <2 
years and patients sufferin g  from  neurofibrom atosis ty p e  II w ere  excluded.
Assessment of tumor size
The continuation  of th e  line o f th e  petrous ridge depicted on a xia l MR im ages 
provided a clear d istinction  b e tw ee n  th e  intra- and extra m eata l portion  o f the 
tum or. The tum or w a s  classified as an in tram eata l lesion w h en  there w a s  no tum or 
extension  beyond th e  p lane form ed b y  th at line. The size o f in tram eata l lesions w as 
determ in ed b y  m easurin g th e  largest diam eter p arallel to th e  course o f th e  internal 
auditory canal. In extram eata l lesions, th e  size o f th e  tum or w as represented b y  the 
largest extram eata l d iam eter in m illim eters according to th e  Tokyo gu idelin es.2 
Tumor g ro w th  w a s  defined as an increase o f th is d iam eter o f >2 m m . This is an 
arb itrary  lim it based on data in th e  literature.2 In th e  W & S group, g ro w th  w as 
assessed usin g th is m ethod. V olum etric m easurem ents w ere  used to m easure tum or 
size during th e  work-up for GKRS and during follow-up.
A  stan dardized pretreatm ent MRI protocol w a s  follow ed. T1-weighted, 1-mm slice, 
gadolin iu m -en h an ced  MR im ages w ere  used to m easure th e  tum or in  th e  axia l 
p lane and to determ ine th e  tum or volu m e u sin g Leksell G am m a-Plan so ftw are  V5.34 
(Elekta, Stockholm , Sweden). A ll follow -up im ages w ere  obtained usin g th e  sam e 
scanner and th e  sam e scan n in g param eters. Follow-up im ages w ere  transferred  to 
th e  ga m m a kn ife  computer, w h ere  im age fusion  w a s  perform ed w ith  Leksell 
G am m a-Plan softw are.
Gamma knife settings, procedure, and cochlear radiation dose
A  Leksell titan iu m  stereotactic fram e (Elekta, Stockholm , Sweden) w as  in sta lled  on 
each p atien t’s head after in jectin g a local an esth etic su bcu tan eou sly  above the 
screw  points in  th e  skull. The patient w as  th en  placed in  a Philips T1.0 MRI scanner 
(Philips H ealthcare, Andover, M A, USA). A x ia l T1 1.0-m m  MR im ages w ere  m ade 
before and after ad m in isterin g  gadolin iu m  contrast. Then 3D TSE 0.7-mm im ages 
w ere  produced.
Leksell G am m a-Plan so ftw are  V5.34 w as used to delineate th e  tum or on the 
corresponding im ages, th at is on TSE and T1-w eighted gadolin iu m  contrast-en­
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han ced  im ages. A  radiation plan  w a s  m ade b y  p lacin g 'isocenters’ or 'shots’ in  the 
tum or, gu ided b y  p lan n in g o f p rescribed dose (PD), m arg in al dose, and conform ity. 
The radiation dose w as  p lan ned  to th e  isodose covering 90% of th e  tum or volum e. 
For patients w h o  w ere  still usin g their a ffected  ear on th e  telephone, a dose o f 12.5 
Gray (Gy) w a s  prescribed. For th e  rem ain in g patients, th e  PD w as 13.0 Gy. The average 
resulting m argin al dose w as  11.0 Gy for all patients (range 9.3-12.5 Gy). Stereotactic 
radiosurgery w a s  then  p erform ed usin g a Leksell 4C G am m a K n ife  (Elekta, 
Stockholm , Sweden).
Outcome
The outcom e w a s  defined in tw o  w ays. A ccording to outcom e m easure one, GKRS 
w a s  said to have fa iled  w h en  additional treatm ent had tak en  place. This is th e  usual 
defin ition  for GKRS failure. A ddition al treatm ent, w h ich  could be either m icrosurgery 
or repeated GKRS, w a s  recom m ended w h e n  continued or recurrent g ro w th  w as 
observed. A ccording to  outcom e m easure tw o, a volu m e decrease >20% after tw o  
years w a s  considered successfu l treatm ent. This is an arbitrary criterion since no 
stan dardized lim its are k n o w n  to define successfu l outcom e of GKRS.
Variables from medical history
V ariables w ith  regard to th e  p atien t’s audiological h isto ry  w ere  docum en ted at the 
m om ent of GKRS. These include tin n itu s, vertigo, otalgia, aural fullness, sen sitiv ity  
face (N. V), headache, and facia l n erve fu n ction  (N. VII)
Pure-tone audiometry
Tonal audiom etric assessm ent consisted o f standard pure-tone audiom etry 
m easurin g all octave frequencies from  0.25 to 8 kHz. O nly bone conduction thresholds 
w ere  used in  th e  analysis. Pure-tone average 1 (PTA-1) w as  defined as th e  m ean of the 
thresholds at 0.5, 1.0, and 2.0 kHz. PTA-2 w a s  defined as th e  m ean  of th e  thresholds at 
0.5, 1.0, 2.0, and 4.0 kHz. W hen no threshold  could be assessed in th e  pure-tone 
audiogram , it w a s  entered as 130 dB HL.
Speech audiometry
Speech audiom etry  w as  assessed usin g a standardized D utch consonant-vow el-con­
sonant protocol. Several variables w ere  extracted  from  th e  speech audiogram : the 
m a xim u m  speech recogn ition  score (SRSmax); th e  in te n sity  level for SRSmax 
(SRSmax-int); th e  Rollover Index (RI); th e  p aram eter Speech-Tone (SPTO); and th e  





a n d  Jerger.3 SR Sm in is th e  lo w e s t m e a su re d  score in  sp e e ch  a u d io m e tr y  on  a lo u d n ess 
le v e l h ig h e r  th a n  SR Sm ax-int. To o b ta in  a m e a su re  for th e  re la tio n  b e tw e e n  th e  
p u re -to n e  a u d io g ra m  a n d  th e  sp e e c h  a u d io g ra m , th e  p a ra m e te r  SPTO w a s  d e fin e d  
as th e  co rresp o n d in g  lo u d n e ss le v e l at 50% SRS m in u s  th e  PTA. If h e a r in g  is n orm al, 
th e  SPTO sh o u ld  b e  25 dB SPL. The slop e is ta k e n  to  e x p ress  q u a lita t iv e  a sp e cts  o f 
sp e e c h  d is cr im in a tio n . To o b ta in  th e  Slope, SR Sm ax is d iv id e d  b y  its co rresp o n d in g  
lo u d n e ss m in u s  10 dB SPL. In p e rso n s w it h  n o rm a l h e a rin g , 100%  d is c r im in a tio n  is 
a c h ie v e d  at 50 dB, so a n o rm a l S lope is 100 / (50 - 10) = 2.5%/dB SPL.
Vestibular testing; caloric test
The calo ric  te s t w a s  p e rfo rm e d  w it h  th e  p a tie n t in  a su p in e  p ositio n , th e  h ea d  
e le v a te d  b y  30° fro m  th e  e a rth -h o rizo n ta l axis. The stim u lu s  con d ition s a n d  a n a ly s is  
w e re  as p re v io u sly  described b y  Nijhuis and H u ygen .4 The results of th ese  e xa m in ation s 
w e r e  sco red  as n o rm a l or ab n o rm al.
Statistical analysis
SPSS w a s  u se d  for th e  s ta t is t ic a l a n a ly s is . In th e  first p a rt o f  th is  stud y, a ll v a r ia b le s  
w e r e  te s te d  for th e ir  a b ility  to  p re d ic t tu m o r g r o w th . The p ro b a b ility  w a s  te s te d  
w it h  th e  n o n -p a ra m e tr ic  M a n n -W h itn e y  te s t a n d  F ish er’s e x a c t  test.
Results
A  to ta l  o f 110 VS p a tie n ts  w e r e  re ferre d  for GKRS b e tw e e n  2002 a n d  2007. T hree 
p a tie n ts  w i t h  n e u ro fib ro m a to s is  t y p e  II a n d  se v e n  p a tie n ts  w i t h  less th a n  t w o  y e a rs  
o f  fo llo w -u p  w e r e  e xc lu d e d . E v e n tu a lly  100 p a tie n ts  (54 m a le  a n d  46 fe m a le )  w i t h  a 
u n ila te r a l  VS co u ld  b e  in clu d ed . T he m e a n  a g e  at th e  d a te  o f  GKRS w a s  57 y e a rs  
(ran ge  25-80 years). The tu m o r  w a s  lo ca te d  on th e  r ig h t side in  59 cases (59%). The 
re a so n  g iv e n  for GKRS w a s  d o c u m e n te d  tu m o r g r o w t h  a fte r  a W & S  p e rio d  in  67 
cases (67%). In 33 cases (33%), GKRS w a s  p e rfo rm e d  so o n  a fte r  d ia g n o sis , so w ith o u t  
a W & S  p eriod . For th e s e  33 p a tie n ts, th e ir  p re v io u s  h is to r y  w it h  re g a rd  to  p ossib le  
tu m o r  g r o w t h  w a s  u n k n o w n . Table I p re sen ts  d e scrip tiv e  d a ta  on  th e  p a tien ts, 
d iv id e d  in to  t w o  grou p s: 'p ro ve n  tu m o r  g r o w t h ’ a n d  'p re v io u s h is to r y  o f  g r o w th  
u n k n o w n ’.
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Table I Descriptive data on the study population (n=ioo), divided into tw o groups.
Proven tumor growth 
(n=67)
Previous history of growth unknown 
(n=33)
P
Sex (male/ female) 35/32 19/14
Age 61 years (38-80) 49 years (25-77) <0.001
Side (left/ right) 29/38 12/21
Mean largest extrameatal diameter 16 m m  (6-41) 22 m m  (17-34) <0.001
Mean tumor volume 2150 m m 3 (72-17800) 4200 m m 3 (63-14900) <0.001
Mean maximal tumor dose 20 Gy (16-25) 20 Gy (16-23)
Mean m arginal tumor dose 11 Gy (9-12) 11 Gy (10-12)
Mean dose on 90% of the tumor volume 12.8 Gy (12-13) 12.6 Gy (12-13)
Mean follow-up time 26 months (24-48) 27 months (24-37)
Mean volume change -11% (-88 - + 218) (median-22%) -30% (-82 - + 52) (median -41%) 0.24
Mean largest extrameatal diameter change -2.3 mm (-19 - +10) (median -1) -3.4 mm (-10 - +4) (median -3) 0.21









N o s ig n ific a n t d iffe re n c e  re g a rd in g  su ccess a n d  fa ilu re  o f  GKRS w a s  fo u n d  b e tw e e n  
th e  'p ro ve n  tu m o r g r o w t h ' a n d  'p re v io u s h is to r y  o f  g r o w t h  u n k n o w n ' grou p s. In 
Fisher's e x a c t  test, P=0.78 a cco rd in g  to  th e  first d e fin it io n  a n d  P= 0 .4 0  a cco rd in g  to  
th e  se co n d  d e fin itio n . This d a ta  is s h o w n  in  Tables II a n d  III.
Table II O utcom e according to d efin ition  1.
Method 1 GKRS success GKRS failure Total
Proven tum or grow th  before GKRS 62 5 67
Previous h istory o f grow th  unknow n 30 3 33
GKRS failure is defined as the occurrence of additional treatment. After Fisher's exact test, P= 0.78.
Table III O utcom e according to defin ition  2.
Method 2 GKRS success GKRS failure Total
Proven tum or grow th  before GKRS 36 31 67
Previous h istory o f grow th  unknow n 21 12 33
GKRS success is defined as > 20% volume decrease at the moment of 2-year follow-up. After Fisher’s exact 
test, P=0.40.
For th e  se co n d  p a rt o f  th is  stud y, w e  co m b in e d  a ll p a tie n ts  in to  o n e  group. A  lis t  o f 
th e  v a r ia b le s  p re sen t at th e  m o m e n t o f  GKRS w a s  r e v ie w e d  in  a n  a tte m p t to  e sta b lish  
a co rre la tio n  w it h  th e  GKRS ou tcom e. T he sa m e  t w o  o u tco m e  m e a su re s  as d escrib ed  
a b o v e  w e r e  u sed . H o w ev er, n o  s ig n ific a n t p red icto rs (P <0.05) c o u ld  b e  id e n tif ie d  in 
th e  d a ta se t. T his d a ta  is p re se n te d  in  Table IV.
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Table IV Descriptive statistics for the study population and the P value of their 





General Sex (men/ women) 54/46 0.82 0.95
Mean age (years) 57 (25-85) 0.68 0.45
Tumor side (left/ right) 41/59 0.34 0.34
Imaging Size (mm) 17.9 (6-41) 0.18 0.23
Volume (mm3) 2.8 (0.06-17.8) 0.22 0.13
Tumor location intra-/ extracanalicular 2/98 0.68 0.34
Anamnesis Tinnitus-affected ear yes/no 86/4 0.70 0.23
Vertigo yes/no 57/43 0.28 6.30.
Otalgia yes/no 7/93/ 0.60 0.40
Aural fullness yes/no 21/79 0.54 0.63
Sensibility (N V) yes/no 11/89 0.97 0.70
Headache yes/no 15/85 0.36 0.50
Facial nerve paresis yes/no 4/96 0.57 0.20
Audiometry PTA-1 tumor ear 57 (5-130) 0.44 0.41
PTA-1 contralateral ear 15 (-3-87) 0.97 0.36
PTA-2 tumor ear 59 (5-130) 0.43 8.30.
PTA-2 contralateral ear 18 (-1-86) 0.93 0.54
SRSmax tumor ear 71 %(0-100) 0.61 0.39
SRSmax contralateral ear 98 %(80-100) 0.36 0.71
Intensity at SRSmax tumor ear 90 dB(50-110) 0.63 0.28
Intensity at SRSmax contralateral ear 64dB(40-120) 0.81 0.98
Intensity at 50% speech recognition 
tumor ear
63 dB(0-106) 0.97 0.13
SPTO tumor ear 11.6dB (-59-60) 0.26 0.48
Slope tumor ear 0.96(0-2.5) 0.48 0.87
Rollover tumor ear 0.14 (0-0.97) 0.20 0.91
GKRS Dose 90% tumor volume (Gy) 12.8 Gy (12.0-13.2) 0.20 0.19
Marginal dose 11.1 Gy (9.3-12.5) 0.80 6.30.
Maximal dose 19.9 Gy (16.0-25.5) 0.20 0.24
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Discussion
This s tu d y  found no indication  th at tum or g ro w th  at th e  m om ent of GKRS has a 
correlation to th e outcom e o f th is therapy. It did find  th at th e m ean  reduction in 
tu m o r vo lum e after GKRS w a s  less pronounced in  th ose  patients in  w h o m  tum or 
g ro w th  w a s  d em onstrated  prior to treatm ent. H ow ever, th is find ing w a s  not 
sign ifican t. A part from  th is, w e  did not find  a n y  predictors for th e outcom e after 
GKRS in VS patients.
The goal o f usin g  GKRS to treat VS is to arrest tum or grow th . W hile th is goal is 
ach ieved  in  m a n y  patients, it is d ifficu lt to determ ine h o w  m uch o f th is success m ay  
be attribu ted  to GKRS. There is con vincing evidence th at m a n y  VSs either do not 
g ro w  or becom e stable in  size after a (short) period o f gro w th  w ith o u t an y  treatm ent.1 
This m eans th at th e 'success' o f GKRS is gu aran teed  in m a n y  cases. The m ain  problem  
is th at w e  do not h ave  th e tools to predict th e course o f th e  biologic beh avior o f a VS 
in  in d iv id u a l cases. In it ia lly  a ll tum ors can  be considered as gro w in g  lesions, but in 
m a n y  cases g ro w th  com es to an  arrest and  th e size o f th e  tum or rem ain s stable. In 
th is  stu d y w e  addressed th e result o f GKRS in  relation  to a certa in  m om ent in  the 
developm ent o f th e  tum or: is there a d ifferent result in  g ro w in g  tum ors com pared to 
stable lesions? This is th e  key  question, th at su rp risin g ly  is not addressed in  the 
literature  u n til now : th e literature  on GKRS o f VSs u su a lly  ju st d isp lays th e results 
in  term s o f tum or stabilization  w ith o u t tak in g  into consideration pretreatm ent 
spontaneous arrest o f grow th .
There are d iverse  m an agem en t protocols for VS patients. A  reg im e o f an n ual 
fo llow -up w ith  MRI scan n in g  is o ften  pursued  u n til tum o r g ro w th  is docum ented -  
th e  W & S strategy. It a lso  rather freq u en tly  occurs th at n e w ly  d iagnosed  patients are 
sub jected  to GKRS w ith o u t k n o w in g  w h eth er th e tum or is stable or still grow ing. 
Som e authors h ave  m entioned th at a portion  o f th e ir irrad iated  VS patients had 
docum ented  tu m o r g ro w th  b efore undergoing GKRS.5 There is no in fo rm atio n  in  the 
literature, how ever, about d ifferent GKRS outcom es for gro w in g  tum ors com pared to 
non -gro w in g tum ors.
For our study, w e  did not perform  GKRS on patients in  w h o m  th e sta b ility  o f the 
tu m o r w a s  docum ented  w ith  seria l M RI scann ing. GKRS in  th e W & S group w a s  
p erform ed  exc lu sive ly  w h e n  gro w th  h ad  been  substan tiated . This a llow ed  us to 
perform  a retrospective  stu d y com paring tw o  groups: 'proven tum or g ro w th ' and 
'previous h isto ry  of g ro w th  un know n'. No d ifferen ce in GKRS outcom e could be
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detected. It h as b een  d em onstrated  th at 57% o f th e n e w ly  d iagnosed  tum ors do not 
g ro w  during th e first th ree  years  a fte r d iagnosis.1 Thus, w e  m a y  expect to find around 
43% o f th e tum ors in  our 'previous h isto ry  o f g ro w th  u n k n o w n ' group to be grow in g.
A  strik in g  fin d in g  is th at th e  average  tum o r vo lum e decreased b y  30% in  the 
'previous h isto ry  o f g ro w th  u n k n o w n ' group, com pared to 8% in  th e 'proven tum or 
g ro w th ' group. W hile th is  could im p ly  th at GKRS is less su ccessfu l in  gro w in g  
tum ors, th is fin d in g w a s  not sign ifican t (P=0.24).
The effects o f GKRS h ave  been  d em onstrated  in  m ultip le  studies. Com pared to 
co n servative  m an agem en t, a sign ifican t reduction in  tum or size w a s  found.6-10 Some 
VSs do not regress a fter GKRS and som e sh o w  continued tum or gro w th . No reliable 
predictors for th e outcom e o f GKRS in  VS patients are m entioned in  th e literature. 
Nor are th e factors in flu encing rad ioresistan ce understood. R adiation dose m ight 
p la y  a role, but its in flu ence is u n certain . D ose-response studies even  show ed 
su rv iv in g  cells in  specim ens treated  w ith  as m uch as 150 Gy.11
Som e authors found  correlations b etw e e n  th e outcom e o f GKRS and  th e num ber of 
isocenters used  in  th e GKRS.8 A  m a rg in a l dose (ffi13 Gy) w a s  found  to correlate w ith  
a n egative  resu lt.8 None o f th ese  find ings could be repeated, how ever, and  m an y  
authors found no predictors at a ll.12, 13 In our study, th e ran ge o f th e  rad iation  dose 
w a s  v e ry  sm all. Therefore, it had to be exp ected  th at w e  w o u ld  not be able to id en tify  
a n y  dose-related outcom e predictors. We also looked for predictors in  patien t data, 
aud io vestibu lar variab les, tum or ch aracteristics, im ag in g , and  history, th ough  
w ith o u t a n y  success.
The fo llow -up period w a s  rather short but th is  w a s  not an  im p airm en t for our study. 
Two years  of fo llow -up w a s  d eliberately  chosen since in itia l sw e llin g  resu ltin g  from  
edem a is considered to p la y  no role a n y  m ore a fter such  a period. A fter tw o  years  w e  
can obtain  fa c tu a l figures on th e presence or absence of continued g ro w th  o f a 
tum or. The a im  of th is stu d y  w a s  not to present long term  results o f GKRS.
Som e w eak n esses in  th e d esign  o f th is stu d y should be addressed. First, there is 
selection  b ias in  th e 'proven tum or g ro w th ' and  'previous h isto ry  o f gro w th  
u n k n o w n ' groups. Both th e  m ean  age and  th e tum or size are s ign ifican tly  d ifferent. 
G iven  som e in trin sic  im p airm en ts o f th e  stu d y  design, it w a s  not possible to d irectly  
com pare th e results o f GKRS in  groups o f patients w ith  gro w in g  and non -grow ing 
tum ors. H ow ever, th e “previous h isto ry  o f g ro w th  u n k n o w n ” group certa in ly  
includes n on -gro w in g tum ors, in  contrast to th e “proven  tum or g ro w th ” group. This
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m ean s th at th e overall g ro w th  p attern  o f both  groups m ust be d ifferent, a lth ough  
th e  exact figure  o f th is d ifferen ce rem ain s u n know n.
There w e re  d ifferences in  tum or sizes o f both  groups o f patients. In th e an a ly sis  of 
th erap eutic  resu lts o f m icrosu rgery  o f VSs th e size o f th e  tum or is an  im p o rtan t issue 
since th e results use  to be better in  sm aller lesions. This is not th e case in  results o f 
GKRS: there is no u n eq u ivocal and  proportional relationship  b etw e e n  tum or size 
and  success or fa ilu re  of GKRS.8, 14
It h as to be em phasized  th at in  fu tu re  research  ran dom ization  in  th e application of 
GKRS in  tw o  groups w ith  and  w ith o u t a h isto ry  o f recent g ro w th  w ill  be v ir tu a lly  
im possib le due to eth ica l considerations. Future studies w ith  larger series o f patients 
in  w h o m  GKRS has b een  applied  exc lu sive ly  a fter docum ented  tum or progression 
m a y  in  som e w a y  elucidate to w h a t extent a th erap eutic result can  be ascribed to 
rad iation  on tum or cells.
Conclusion
W e found  no indication  th at g ro w th  at th e  m om ent o f GKRS in fluences the 
th erap eutic  outcom e. We looked for but did not id en tify  a n y  other predictors for the 
outcom e after GKRS in  VS patients.
A ck n o w le d g e m e n t: The authors th a n k  Mr. W. Lem m ens for th e statistica l analysis.
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Abstract
Introduction: This stu d y w a s  designed  to eva lu ate  h earin g  p reservation  after 
g a m m a  k n ife  rad io su rgery  (GKRS) and to determ ine th e relation  b etw een  h earing 
preservatio n  and  cochlear rad iation  dose in  patients w ith  a sporadic vestib u lar 
sch w an n o m a (VS).
M ateria ls and  m ethods: Prospective stu d y  in vo lv in g  patients su ffe rin g  from  VS 
w h o  received  GKRS from  Ju n e  2003 till N ovem ber 2007. Pure tone and  speech 
au d iom etry  w ere  conducted before and a fter GKRS. The thresholds at pure tone 
au d iom etry  w ere  taken  as a m easu re  o f hearing. Pure tone average  (PTA) w a s  defined 
as th e m ean  threshold  at 0.5, 1.0, 2.0, and  4.0 kHz. H earin g w a s  c lassified  according to 
th e  2003 consensus m eetin g  in  Tokyo. Stereotactic su rg e ry  w a s  p erform ed  u sin g  a 
Leksell 4C G am m a Knife.
Results: A  to ta l o f 69 patients w e re  included  in  th e study. M ean  tum or size w a s  17 
m m . M ean  m a rg in a l dose at th e  tum or w a s  11.0  G y (range 9.3-12.3 Gy), m ean  m a x im a l 
dose w a s  19.7 G y (range 16-25.5 Gy). M ean  m a x im a l dose at th e  cochlea w a s  10.27 Gy 
(range 3.1-16.1 Gy), and  m ean  m in im a l dose at th e  cochlea w a s  2.6 G y (range 0.9-7.4 
Gy). M ean  PTA before GKRS w a s  43 dB (SD 20 dB), m ean  PTA a fter GKRS w a s  63 dB (SD 
30 dB). M ean  in te rv a l b etw e e n  pre-GKRS au d io m etry  and  GKRS w a s  8.0 m onths. 
B etw een  GKRS and post-GKRS audiom etry, m ean  in te rv a l w a s  14.2 m onths. H earing 
w a s  considered to be preserved  (M ax + 1 class, Tokyo classification) in  52 (75%) o f 69 
patients. H ow ever just, 32 patients h ad  class A, B, or C (serviceable hearing) before 
GKRS. W ith in  th is group, on ly  13 patients (41%) h ad  a h earin g  class A, B, or C after 
GKRS. A  sign ifican t relation  w a s  fo und  b etw e e n  th e m a x im a l cochlear dose and  the 
d ifferen ce in PTA before and  a fte r GKRS.
Conclusion: H earing p reservation  is correlated to th e m a x im a l rad iation  dose at the 
cochlea. The p urp ose o f developing GKRS tech niques w a s  to avoid  collateral dam age 
in  h ea lth y  tissues. This stu d y  em phasizes th e need for exact rad iation  p lan n in g  in 
order to reduce th e cochlear rad iation  dose i f  th e h earin g  is to be preserved.
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Introduction
D ue to th e in creased  a v a ila b ility  o f M agn etic  Resonance (MR) im ag in g , VSs are 
d iagn osed  m ore freq u en tly  and  at an  earlier stage.1, 2 Regularly, asym p to m atic  VSs 
are discovered.3 In itia l treatm ent strategies include co n servative  m an agem en t 
('w ait and  scan'), m icrosurgery, and  rad iation  therapy. Radiation  th erap y  can  be 
sub d iv id ed  into fraction ated  rad io th erap y  and  rad iosurgery. Leksell in it ia lly  
in troduced stereotactic m ethods and  rad io su rgery  in  19 51.4 The first VSs w e re  treated 
b y  g a m m a  k n ife  rad io su rgery  (GKRS) in  1971.5 N o w ad ays, GKRS consists of 
ad m in isterin g  a sin gle  dose of rad iation  a fte r 3D MR im ag in g  and  stereotactic 
p lan n in g  usin g  a fixed  fram e on th e head.
Besides being th e m ost com m on presenting  sym ptom , sen so rin eu ra l h earin g  loss is 
considered a possible com plication in both rad io th erap y  and m icrosu rgery  
m an agem en t o f VS. O bviously tra n sla b yrin th in e  su rg e ry  causes deafn ess and is the 
least a ttractive  option i f  h earin g  is to be preserved. Other m icrosurgical approaches 
can p reserve  som e h earing , th o u gh  th e results v a r y  am ong in d iv id u a l surgeons and 
th e surgical approach chosen.
D ue to th e  re la tive ly  m ild  risk  profile, th e  com fort provided to th e patient, and the 
h ig h  tum or control rate o f GKRS, an  in creasin g  percen tage o f our VS patients prefer 
p rim a ry  treatm ent w ith  GKRS above m icrosurgery. H earing loss resu ltin g  from  
cochlear and cochlear n erve  rad iation  d am age is freq u en tly  observed  after GKRS, 
a lth o u gh  th e com plication rate is low.
The a im  o f th is  stu d y  is to eva lu ate  our results for h earin g  preservation  a fter GKRS. 
In th at light, it th en  explores th e relation  b etw e e n  h earin g  p reservation  and cochlear 
rad iation  dose. This is done b y  find ing correlations b etw e e n  rad iation  dose at both 
tum or and  cochlea, on th e one hand, and  h earin g  p reservatio n  on th e other.
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Patients and methods
Study group
A ll patients w e re  in it ia lly  seen  and  ex a m in ed  at th e D epartm ent o f O torh inolaryn­
gology, H ead and  N eck Su rgery  o f th e  Radboud U n iversity  N ijm egen M edical Centre. 
B etw een  M a y  2003 and N ovem ber 2007, 11 1  patients w ere  referred  for rad iosu rgery  
to th e  G am m a K n ife  Center in  Tilburg. These patients h ad  tum ors <3.0 cm  at th e first 
scan. They w ere  referred either because o f MR im ag in g  proven tum or gro w th  (>2mm 
m a x im a l d iam eter of th e  tum or in  either direction  on a x ia l MRI) or because o f their 
person al preference. Patients su ffe rin g  from  neurofibrom atosis and patients w ith  a 
Pure Tone A verage (PTA) > 90  dB before GKRS w e re  excluded from  th is  study.
Tumor location and size
Two in d iv id u al observers p erform ed  th e assessm ents o f th e  tum or size. The 
con tinuation  o f th e line  o f th e  petrous ridge depicted on seria l a x ia l M R im ages 
provid ed  a clear d istinction  b etw e e n  th e intra- and  e x tra m e a ta l portion  o f the 
tum or. The tum or w a s  reported as an  in tram eata l lesion w h e n  there w a s  no tum or 
exten sio n  beyond  that plane. Tumor size w a s  determ ined  according to th e consensus 
reached in  Tokyo on N ovem ber 7 th 2003.6 This m easu rem ent o n ly  includes th e largest 
e x tra m e a ta l diam eter. M easu rem ents according to th e gu id elines o f th e  AAO-HNS 
w e re  p erform ed  as w e ll in  order to com pare resu lts.7 In th e latter m ethod, size is the 
square root o f th e  product b etw een  th e greatest d iam eter in  th e d irection p ara lle l to 
th e  petrous ridge and  th e m a x im u m  diam eter p erp en d icu lar to th is  in  th e a x ia l 
p lain . Furtherm ore it w a s  noted w h eth er th e fu n d u s w a s  'filled ' w ith  tum or or 
'em pty'. A n  em p ty  fu n d u s sh ow ed  a h ig h  sign a l b eh in d  th e tum or in  th e fu nd u s 
on a T 2-w eighted M RI scan.
Audiom etry
Pure tone au d iom etry  w a s  p erform ed  before and after GKRS. The PTA o f bone 
conduction w a s  assessed  for both  ears. PTA w a s  defined as th e m ean  o f th e  thresholds 
at 0.5, 1.0, 2.0, and  4.0 kHz. W hen no threshold  could be m easured , it w a s  noted at 130 
dB HL.
The m a x im u m  speech d iscrim in atio n  score (SDS) w a s  determ ined  b y  speech 
au d iom etry  m easu rem en ts w ith  D utch vo w el-con so n an t-vo w el w ord s up to a 
m a x im u m  o f 125 dB SPL.
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H earin g w a s  c lassified  according to th e 2003 consensus m eetin g  in  Tokyo.6 This 
classification  is su m m arized  in  tab le I.
Table I H earing classification consensus m eeting Tokyo 2003.6







Gam m a knife settings, procedure, and cochlear radiation dose
A  Leksell t ita n iu m  stereotactic fram e w a s  in sta lled  on each p atien t's head after 
in jectin g  local an esth esia  su b cu tan eo u sly  above th e  screw  points in  th e skull. The 
patien t w a s  th en  p laced in  a Philips T1.0 M RI scanner. A x ia l T 1 1.0  m m  M R im ages 
w e re  m ade before and  a fte r ad m in isterin g  gad o lin iu m  contrast. Then 3D TSE 0.7 m m  
im ag es w e re  produced.
U sing Leksell G am m a Plan so ftw a re  V5.34, th e  tum or w a s  delineated  on the 
corresponding im ag es usin g  th e  TSE and  T 1-w eighted gad olin ium  contrast enh anced  
im ages. The tum or vo lu m e w a s  th en  calcu lated  usin g  th e 3D so ftw are . A  rad iation 
p lan  w a s  m ade b y  p lacing  'isocenters' or 'shots' in  th e tum or volum e, gu ided  b y  
prescribed dose (PD), m a rg in a l dose, and  conform ity. The rad iation  dose w as 
prescribed to th e isodose covering 90%  of th e tum or volum e. In patients w h o  w ere  
still able to u se  th eir a ffec ted  ear on th e telephone, a dose o f 12.5 G ray (Gy) w as 
prescribed. The PD for patients w h o  declared th e ir a ffected  ear to be useless w as 
13.0 Gy. The resu ltin g  m a rg in a l dose w a s  on average  11.0  G y for a ll patients (range 
9 .3-12.5 Gy).
The cochlea w a s  pointed  out on each a x ia l M R im age, and also its vo lu m e w a s  
calcu lated  usin g  th e sam e gam m a-p lan  so ftw are . In th e sam e procedure the 
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Figure 1 The lim its o f the VS are depicted b y  the y e llo w  line and th e cochlea is 
outlined  in red.
Stereotactic su rgery  w a s  perform ed u sin g  a Leksell 4C G am m a K nife. Patients w ere  
d ischarged  from  the h osp ital the sam e day.
Statistics
The d ifferen ce in  PTA b etw een  before and a fte r GKRS w a s  calcu lated  for each patient. 
Correlations b etw e e n  the cochlear rad iation  dose and the PTA d ifferen ce w ere 
calcu lated  in SPSS (version 14.0) u sin g  a one-tailed Pearson's test. Scatter plots and 
regression lines w e re  also calcu lated  u sin g  SPSS. The sign ifican ce o f tum or in vasion  
in  the fu nd u s w a s  determ ined  u sin g  an  in dependent sam ple T-test.
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Results
O f th e in itia l 1 1 1  VS patients w h o  w e re  referred  for GKRS, 20 w e re  excluded since 
th e ir pre-SRS PTA w a s  >90 dB. Four patients h ad  neurofibrom atosis and w ere  
excluded  as w ell. Two patients w e re  not able to partic ipate  in  e xam in atio n s because 
o f h ea lth  problem s u n re lated  to th e  VS. S ixteen  patients w e re  lost to fo llow -up at the 
tim e  th e control aud io gram  w a s  scheduled. E v en tu a lly  69 patients entered the 
s t udy.
Forty-four o f th ese  patients w e re  referred  because o f docum ented  tum or g ro w th  
(>2mm) after 'w ait-and -scan ' m an agem en t. T w enty-tw o patients w ere  referred  for 
GKRS for vario u s other reasons (e.g., tum o r size com bined w ith  other factors 
in flu en cin g th e  in itia l decision-m aking). Three patients w h o  w ere  in it ia lly  advised  
to take  p art in  th e 'w ait-and -scan ' p rogram  received  GKRS because of th e ir personal 
preference
Descriptive statistics
A n  o v e rv ie w  o f d escriptive statistics is su m m arized  in  tab le II.
Table II Descriptive statistics of the study group.
Sex
M ean age at VS diagnosis 
M ean age at SRS 
Tumor side (right / left)
Tumor location (extrameatal / intrameatal) 
Fundus IAM (empty / filled)
M ean tumor size Tokyo 2003 guidelines 
M ean tumor size AAO-HNS 1995 guidelines 
M ean tumor volume
38 male / 31 female
51 years (range 17-73 years)
53 years (range 24-76 years)
42 right (61%) 27 left (39%)
66 extram eatal (96%) 3 intrameatal (4%) 
40 em pty (58%) 29 filled (42%)
17 m m  (range 6-32 mm)
17 m m  (range 6-33mm)
2281 m m 3 (range 24-10200 m m 3)
The doses in  th e tum or and  cochlea are g iven  in  tab le III and IV.
Hearing preservation
PTA w a s  calcu lated  before and a fte r GKRS. The m ean  tim e  b etw e e n  pre-GKRS audio 
and  GKRS w a s  8.0 m onths (range 1-31 m onths). B etw een  th e GKRS and post-GKRS 
audio th e m ean  duration w a s  14.2 m onths (range 3-56 m onths). There w a s  no 
sign ifican t correlation b etw e e n  th e PTA d ifferen ce (= PTA pre-GKRS m in us PTA
1 0 5
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Table III D o s e s  i n  t h e  t u m o r .
M ean Range SD
Dose 90% 12.7 Gy 12-13.2 Gy 0.33
Isodose 90% 64% 51-75% 4.5
M arginal dose 11.0 Gy 9.3-12.5 Gy 0.46
M axim al dose 19.7 Gy 16-25.5 Gy 1.73
Dose 90% is the minimal amount of Gy received by 90% of the tumor. The marginal dose is the minimal dose
in the tumor. The maximal dose is the maximal dose within the tumor.
Table IV Doses in the cochlea.
M ean Range SD
Cochlea min 2.6 Gy 0.9-7.4 Gy 1
Cochlea 90% 3.4 Gy 1.3-8.8 Gy 1.1
Cochlea 50% 4.9 Gy 2.1-10.5Gy 1.55
Cochlea max 10.3 Gy 3.1-16.1 Gy 2.9
Cochlea min is the minimal dose within the cochlea. Cochlea 90% is the minimal amount of Gy received by 
90% of the cochlea. Cochlea 50% is the minimal amount of Gy received by 50% of the cochlea. Cochlea max is 
the maximal dose within the cochlea.
post-GKRS) and the tim e b e tw ee n  GKRS and post-GKRS h earing test (p = 0.7). 
The m ean  PTAs are illustrated in table V.
Table V M ean PTA, range, and the standard deviation before and after GKRS.





Tumor ear before GKRS 43 0
&
5 20
Contralateral ear before GKRS 18 -1 - 130 19
Tumor ear after GKRS 63 -1 - 130 31
Contralateral ear after GKRS 20 030 20
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The h earin g  c lassification  before and a fte r GKRS is sh o w n  in figure  2. 
Figure 2 H earing c lassification  (Tokyo 2003) before and a fte r  GKRS.
The number of patients is given per class in each first bar. The black bars indicate the distribution of these 
patients after GKRS.
No sign ifican t correlation w a s  found b etw e e n  the m a x im a l dose at the tum or and 
the w o rsen in g  o f h earin g  (r=0.i6, p = 0.2). H ow ever, there w a s  a clear correlation 
b etw een  the m a x im a l cochlear dose and the d ifference in PTA before and  a fte r  GKRS 
(Spearm an correlation, r= 0.3, p < 0.05, tw o -ta iled  test). See Figures 3 and 4.
No correlation w a s  found b etw e e n  the tum or vo lum e (p= 0.36) or size (p= 0.29) and 
the PTA d ifference. If the VS w a s  fillin g  the fu n d u s o f the in tern al aud itory  canal, 
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Figure 3 The correlation b etw e e n  PTA d ifferen ce and  m a x im a l cochlear dose (r=0.3, 
p<0.05).
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Figure 4 The correlation b etw e e n  PTA d ifferen ce and  m a x im a l tum or dose (r= 0.16, 
p = 0.2).
Table VII The m ean PTA difference betw een before and after GKRS w a s  significantly 
higher in  the group of patients w ith  an occupied fundus (p<0.005).
M ean PTA Standard Standard error
difference (dB HL) deviation mean
Fundus free (n=39) 11.3 dB 18.1 2.9
Fundus filled w ith  tumor (n=3o) 29.5 dB 2 3 5.2
A  notable fin d in g w a s  th e correlation b etw e e n  tum or size and pre-GKRS hearing. 
Sm all tum ors w e re  correlated w ith  h igh er PTA (r=0.3, p<0.05). See Figure 5.
Complications
Five patients reported a tem p o rary  decrease in  fac ia l m uscle fu n ction  (< 3 m onths). 
None su ffe red  p erm an en t fac ia l n erve  problem s. Six  patients com plained about 
sen sib ility  d istu rbances in  th e face, but in  a ll cases th is w a s  tran sien t (<3 m onths).
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Figu re 5 The correlation b etw e e n  PTA before GKRS and  tum or size (r=0.3, p<0.05).
Discussion
In th is stu d y  w e  v a lid ated  th e relation  b etw e e n  cochlear rad iation  dose and h earing 
deterioration in  a group o f patients treated  w ith  a m ean  m a rg in a l tum or dose o f 11 
G y (9.3-12.5). We also confirm ed th e h yp oth esis th at patients w ith  tum ors occupying 
th e  fu nd u s of th e  in tern a l aud itory  can al are at greater risk  o f h earin g  loss after 
GKRS th a n  patien ts w ith  a fu nd u s free  o f tum or. H earin g w a s  considered to be 
p reserved  (M ax +1 class, Tokyo classification) in  52 (75%) o f th e  69 patients. H owever, 
ju st 32 of a ll th e  patients h ad  a Tokyo class A, B, or C (serviceable hearing) before 
GKRS. W ith in  th is  selected  group w ith  a Tokyo Class A, B, or C before GKRS, on ly  13 
patients (41%) h ad  a h earin g  class A, B, or C a fter GKRS. In other w ords, w h en  
serv iceab le  h earin g  w a s  present, th is could be p reserved  in  on ly  41%  o f th e  cases.
The path ogenesis o f sen sorin eu ra l h earin g  loss in  patients w ith  VS is still not fu lly  
understood. Pressure on th e aud itory n erve  or on th e blood vesse ls su p p ly in g  the 
n erve  and cochlea m igh t e xp la in  p art o f th is process. H ow ever, som e follow -up 
studies in patients w h o  h ad  n on -gro w in g tum ors also sh ow ed  a progressive  h earing 
loss.8 A  possible exp lan atio n  m a y  lie in  ototoxic d isp ersing  tum or m etabolites, a
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process w h ich  is not clarified  yet. A fter GKRS, a tem p o rary  sw e llin g  o f th e  VS can 
occur. A longside th e h igh er rad iation  dose, th is  sw e llin g  could p a rtly  e xp la in  the 
greater risk  o f h earin g  loss w h e n  th e fu nd u s o f th e  M A I is occupied b y  tum or.
In th e present stu d y  w e  found  th at h ig h  PTA before GKRS w a s  correlated w ith  sm all 
tum or size, w h ich  is d ifficu lt to e x p la in  in  relation  to som e o f th e theories m entioned 
above. A  possible exp lan atio n  could be th at som e tum ors cause h earin g  loss earlier, 
for w h a te ve r reason, and  th ereb y  trigger a v is it to a doctor at an  early  stage.
Over th e past decade, a num ber o f authors h ave  addressed  h earin g  p reservation . Yet 
despite th e m eetin g  in Tokyo, th ere  is still no consensus on system s for reporting 
resu lts in  VS research. This o b vio u sly  m akes com parison m ore d ifficu lt. To be able to 
com pare our results, w e  fo llow ed  th e Tokyo gu id elin es for reporting h earin g  and 
tum or size, hoping other authors w o u ld  do th e  sam e.6
A s th e  exp erien ce w ith  GKRS increased, th e dose delivered  to th e tum or and 
e sp ec ia lly  to th e surrou nd in g tissu e  h as declined. In order to com pare our results, w e  
looked for studies th at used a s im ilar rad iation  dosage.
Paek et al. studied  25 VS patients w ith  serv iceab le  h earin g  (PTA < 50 dB, SDS > 50%) 
before GKRS.9 The m ean  m a rg in a l dose used  w a s  12 Gy. They found a serviceable 
h earin g  p reservation  o f 52%. Chopra et al. stud ied  h earin g  preservation  in a group of 
110  patients a ll w ith  a fo llow -up >3 years.10 Their m a rg in a l dose w a s  b etw een  12.5 and 
13 Gy. They fo und  a serv iceab le  h earin g  preservatio n  o f 77%. The classification 
'serviceable  h earin g ' used  in  th ese  studies is com parable to our class A, B, C, and  D 
com bined. M ore in  line  w ith  Chopra et al., w e  found  a h earin g  p reservation  o f 68% in 
th is  group o f patients (class A, B, C, and  D com bined) even  th ough  our follow -up 
period w a s  shorter.
Recently, M assager et al. pub lished  a paper about th e in flu ence o f th e  rad iation  dose 
on th e cochlea.11 In a group o f 60 patients w ith  serv iceab le  h earing , 32 patients (53%) 
m ain ta in e d  serv iceab le  h earin g  a fter GKRS. In th e ir s tu d y  a m a rg in a l tum or dose of 
12 G y w a s  prescribed at th e  50% isodose level. A s in  our study, th e  m a x im u m  dose at 
th e cochlea w a s  determ ined. The m ean  m a x im u m  rad iation  dose w a s  8.51 Gy 
(3-15Gy). In our stu d y w e  found 10.27 G y (3-16 Gy). They also found a strong sign ificant 
relation  (p = 0 .0005) b etw e e n  m a x im a l cochlear dose and  h earin g  p reservation , a 
relation  th at w a s  even  stronger th a n  in  our stu d y (p = 0.02). Their find ing is 
rem arkab le and  indicates th e sign ifican ce  o f cochlear rad iation  dose. U nfortu n ate ly
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th e y  do not discuss th eir results in  light o f a possible relation  b etw e e n  th e dose on 
th e  tum or itse lf and  h earin g  p reservation . We could not d em onstrate such a 
correlation in our stu d y group (p = 0.2).
G am m a k n ife  irrad iation  tech niques w ere  developed to targ et th e rad iation  effects 
m ore p recise ly  so as to avoid collateral d am age in  h e a lth y  tissues. D ue to the 
re la tive ly  sm all d istan ce b etw e e n  tum or and  cochlea and  th e steep cu rve o f th e dose 
vo lu m e h istogram , even  a slight im provem ent in poin tin g out th e tum or can have 
sign ifican t e ffects on th e m a x im u m  cochlear dose.
A lth o u gh  a longer fo llow -up period  is required  to eva lu ate  th e long-term  results, 
th ere  is in creasing  evidence th at th e first y e a r a fter th e GKRS treatm en t is an 
im p o rtan t predictor for later h earin g  deterioration.9, 12, 13
Due to th e se ttin g  o f th is study, it w a s  im possib le to stand ard ize  th e tim in g  of 
au d iom etry  before and  a fte r GKRS. This m igh t h ave  in flu enced  our results. H owever, 
due to th e m eticu lous reg istration  and  th e detailed  data set, th e results o f th is study 
re a lis tica lly  docum ent th e im pact o f GKRS in  general and  cochlear dose in  p articu lar 
on h earin g  preservation . W e h yp oth esize  th at it is possible to low er th e m ax im u m  
dose on th e  cochlea i f  th e rad iation  p lan n in g  protocol for VS is fu rth e r optim ized.
Conclusion
H earin g p reservatio n  is not correlated to th e m a x im a l rad iation  dose at th e tum or 
but on ly  to th e m a x im a l dose at th e  cochlea. The purpose o f developing GKRS 
tech n iques w a s  to avoid  collateral d am age in  h e a lth y  tissues. This stu d y  em phasizes 
th e  need for exact rad iation  p lan n in g  in  order to reduce th e cochlear rad iation  dose 
i f  th e  h earin g  is to be preserved.
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Abstract
Introduction: This stu d y  eva lu ates th e im pact o f g a m m a  k n ife  rad io su rgery  (GKRS) 
on th e q u a lity  o f life  (OOL) o f patients w ith  a sporadic vestib u lar sch w an n o m a (VS).
M ateria ls and  m ethods: This stud y pertains to 108 VS patients w h o  had GKRS in  the 
years  2003 th ro u gh  2007. Two d ifferen t OOL question naires w e re  used: M edical 
O utcom e Study Short Form  36 (SF36) and  G lasgo w  Benefit In ven to ry (GBI). 
R ad io su rgery  w a s  p erform ed  u sin g  a Leksell 4C ga m m a  knife. The resu lts o f th e OOL 
question naires in  relation  to pro sp ective ly  and retro sp ective ly  gathered  data o f the 
VS patients treated  b y  GKRS.
Results: E v en tu a lly  97 patients could be included in th e study. Their m ean  tum or 
size w a s  17 m m  (range 6-39 m m ); the m ean m axim u m  dose on th e tum or w a s  19.9 Gy 
(range 16-25.5 Gy) and  th e m ean  m a rg in a l dose on th e tum or w a s  11.1 (range 9.3 -  12.5 
Gy). SF36 scores sh ow ed  results com parable to those for a n orm al D utch population. 
GBI sh ow ed  a m a rg in a l decline in OOL. No correlation w a s  found b etw e e n  OOL and 
gender, age, tum or size, or rad iation  dose. Increased aud io vestibu lar sym p tom s after 
GKRS w ere  correlated w ith  a decreased GBI score, and  decreased  sym p tom s w ere  
correlated w ith  a h igher OOL post-GKRS.
Conclusion: This stu d y show s th at GKRS for VS has little  im pact on th e general OOL 
o f the VS patient. H owever, there is a w id e  ran ge in  in d iv id u al OOL results. Individual 
OOL w a s  in fluenced b y  th e aud iovestibular sym ptom s. No predictive patient, tumor, 
or treatm ent factors for OOL outcom e a fte r GKRS could be determ ined. Com parison 
w ith  m icro su rgery  is d ifficu lt because o f in tra  group variab ility .
Q U ALITY OF LIFE A FT ER GKRS
A  vestib u lar sch w an n o m a (VS) is a b en ign  tum or arisin g  from  th e vestib u la r p art of 
th e 8th cran ia l nerve. U nilateral h earin g  loss, tin n itu s, and  un stead in ess are  the 
m ost com m on sym p tom s at th e tim e  o f d iagn osis.1 These sym p tom s in flu ence the 
q u a lity  o f life  (QOL) o f th e  VS patient, as has been  described in  earlier papers.2, 3 Tumor 
size is not found to be related  to th e am oun t and se ve rity  o f aud iovestibu lar 
sym p tom s.3 The g ro w th  p attern  of VSs is unpredictable. A  large  proportion o f a ll VSs 
sh o w  no g ro w th  in  th e first years  a fter diagnosis, and  a regression  of tum or size has 
even  been  described in  som e cases. W hen diagnosed, a VS is ra re ly  a life-th reaten ing 
condition, but large  VSs n eed  treatm ent to prevent b ra in stem  com pression. D ue to 
th e in creased  a v a ila b ility  o f m agn etic  resonan ce im a g in g  (MRI), VSs can  n o w  be 
d iagn osed  at an  earlier stage  and  th eir g ro w th  can  be m onitored at reg u lar in tervals.
The treatm ent stra te g y  a fter th e in itia l d iagnosis is a im ed  at controlling tum or 
gro w th  and  p reserv in g  cran ia l n erve  functions. Treatm ent options include 
c o n servative  m an agem en t (w ait and  scan, W &S), m icro su rg ery  (MS), and stereo­
tactic  rad iation  therapy.
A  w e ll-k n o w n  ty p e  o f stereotactic rad iation  th erap y  is g a m m a  k n ife  rad io su rgery  
(GKRS).
It has becom e a prom inent treatm ent option for VS <3 cm. Its tum or control rate is 
assu m ed  to be com parable to th at ach ieved  b y  m icrosurgery, but th e im pact on QOL 
appears to be less.4, 5 U ntil th e  end of th e  20th century, th e m in im a l (12-20 Gy) and 
m a x im a l (24-50 Gy) tum or doses w e re  re la tive ly  h igh  and  th e p lan n in g  w a s  less 
precise b y  current stan d ard s.6 W hereas side-effects and com plications related  to 
GKRS seem ed to be sign ifican t in  th e past, n o w ad ays th e  GKRS seem s to be a 
treatm en t option th at does not pose a n y  serious risks.
This stu d y  w a s  carried  out to eva lu ate  th e  im pact o f GKRS on th e  QOL o f VS patients. 
The a im  w a s  to eva lu ate  aud io vestibu lar sym p to m s and  to correlate th is  data w ith  
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Patients and methods
Study population and study design
This stu d y  p erta in s to 108 patients w h o  h ad  GKRS in th e years  2003 th ro u gh  2007. 
They w ere  in it ia lly  seen  and ex a m in ed  at th e  D epartm ent o f O torhinolaryngology, 
H ead and  N eck Su rgery  of our te rt ia ry  referral center. A m ong th e reasons to proceed 
to GKRS w e re  M RI-proven tum or g ro w th  (>2 m m  d ifferen ce in  m a x im a l d iam eter of 
th e  tu m o r in  either d irection on seq uen tia l M R im ag es in  th e a x ia l plane) and the 
patien t's  p erson al preference a fter consultation.
Together w ith  an  in fo rm atio n  letter and  q uestion n aire  about aud iovestibu lar 
sym p to m s before and  a fte r treatm en t w ith  GKRS, tw o  d ifferen t QOL questionnaires 
w e re  sent to th e patients a fter GKRS. Those un able  to an sw er th e q uestion naires 
w e re  excluded from  th e study.
Quality of life questionnaires
Two question naires w e re  used: th e M edical O utcom e S tu d y Short Form  36 (SF36) and 
th e  G lasgo w  B enefit In ven tory  (GBI).
The first questionnaire, th e  SF36, w a s  o rig in a lly  con structed  to su rv e y  h ealth  status 
in  th e M edical Outcom es Study.7 The Short Form  36 h ealth  su rv e y  com prises 36 item s, 
non-specific for disease, w ith  tw o  to s ix  response choices per item . The pre-coded 
responses are recoded in percentages. Item s fa llin g  into th e  sam e category are 
averaged  to create eight h ealth  concepts: ph ysica l fu n ction in g , b o d ily  pain , role 
lim itatio n s due to p h ysica l h ea lth  problem s, role lim itation s due to p erson al or 
em otion al problem s, em otion al w ell-be in g, socia l fu n ctio n in g , v ita lity , and  general 
h ea lth  perceptions. The scores are presented  w ith  a m in im u m  o f zero and  a 
m a x im u m  o f 100 . A  h igh er score m ean s a h igh er h ea lth  state. D utch norm  scores are 
ava ilab le  for reference p u rp o ses.8
The second q uestion n aire  is th e G lasgo w  Benefit In ven tory  (GBI), a tool to m easure 
patien t benefit th at w a s  developed esp ec ia lly  for o torh inolaryn gological in ter­
ven tio n s.9 The q uestion n aire  contains 18 post-intervention  item s, elic iting responses 
based  on a five-point Likert scale. This scale ran ges from  a lo w  h ealth  status, 
exp ressed  in  a low  score, to a h igh  h ealth  status. In th is case, th e item s p erta in  to 
GKRS. V arious scores can  be calcu lated  from  th e item  responses: th e  to ta l score, 
general subscale score, social support subscale score, and p h ysica l h ea lth  subscale 
score. The scores ran ge from  -100 to 100, w ith  a score o f 0 indicating no h ealth  change 
a fte r an  in terven tio n  and -100 a w orsen ed  h ealth  state a fte r treatm ent.
118
Q U ALITY OF LIFE A FT ER GKRS
Tumor size
Tumor size w a s  determ ined  according to th e consensus reached in  Tokyo on 
N ovem ber 7th 20 0 1.10 In th e case of e x tram eata l tum ors, th is  in vo lved  m easu rin g  the 
largest e x tra m e a ta l d iam eter on a x ia l MR im ages. In tram eata l tum ors w ere  
m easu red  p ara lle l to th e in tern a l acoustic m eatus (IAM). The intra- and  e xtram eata l 
portions of th e tum or w e re  c learly  delineated  b y  th e  continuation  o f th e  line  o f the 
petrous ridge depicted on seria l a x ia l M R im ages. A  tum or w a s  c lassified  as an 
in tram eata l lesion w h e n  there w a s  no tum or exten sio n  beyond that plane. A ll other 
tum ors w e re  recorded as e x tram eata l lesions.
Complications and audiovestibular symptoms
There are  severa l possible com plications o f GKRS: sen sorin eu ra l im pairm ent, 
vestib u la r disorders, fac ia l n erve  p aresis (including lacrim al g lan d  dysfunction), 
tr ig e m in a l n erve  d ysfu n ction  (disturbances o f fac ia l sen sib ility  and fac ia l pain), 
recurrent tum o r gro w th , headache, and  com plications due to in sta llin g  th e  stereo­
tactic  fram e on th e head.
Since m ost o f th ese  com plications could also be caused b y  th e VS itself, th e  sym ptom s 
before GKRS w e re  com pared to th ose a fter GKRS. Patients w ere  retro sp ectiv ly  asked 
to ind icate an  increase, decrease, or no ch an ge  of sym ptom s. Furtherm ore, a ll patient 
charts w e re  checked for other com plications or side-effects o f GKRS.
Gam m a knife settings, procedure, and cochlear radiation dose
A  Leksell t ita n iu m  stereotactic fram e w a s  in sta lled  on each p atien t's head after 
in jectin g  a local an esth etic  su b cu tan eou sly  at th e screw  points in  th e skull. The 
patien t w a s  th en  p laced in  a Philips T1.0 M RI scanner. A x ia l Ti 1.0  m m  M R im ages 
w e re  m ade before and  a fter ad m in isterin g  gad olin ium  contrast. Then 3D TSE (Turbo 
Spin Echo) 0.7 m m  im ag es w ere  constructed.
U sing Leksell g am m a-p lan  so ftw a re  V5.34, th e tum o r w a s  delineated  on the 
corresponding im ag es usin g  th e  TSE and  T 1-w eighted gad olin ium  contrast enh anced  
im ages. The tum or vo lu m e w a s  th en  calcu lated  usin g  th e 3D so ftw are . A  rad iation 
p lan  w a s  m ade b y  p lacing  ‘isocenters' or 'shots' in  th e tum or volum e, gu ided  b y  
prescribed dose (PD), m a rg in a l dose, and  conform ity. The cochlea w a s  pointed  out on 
each a x ia l M R im age, and  th e  m a x im a l rad iation  dose on th e cochlea w a s  calculated.
Stereotactic su rg e ry  w a s  perform ed  usin g  a Leksell 4C g a m m a  knife. Treatm ent tim e 
depended on th e ra d io a ctiv ity  o f th e  sources and th e num ber of shots. That num ber
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w a s  determ ined  on th e grounds o f th e  tum or's vo lu m e and  configuration . Patients 
w e re  d ischarged  from  th e h osp ital th e sam e day.
Statistics
Statistica l an a ly sis  w a s  perform ed  w ith  SPSS (16.0). Statistical s ign ifican ce w a s  set 
at th e 5% level. S u m m a ry  statistics (m ean, SD, range) w e re  exp ressed  as a frequency 
distribution. A s th e results o f th e  question naires w ere  skew ed, n on -param etric  tests 
w e re  carried  out to describe th e d ifferen ce b etw e e n  groups. The M an n -W h itn ey U 
test w a s  used  to com pare tw o  groups, th e  K ruskal-W allis test to com pare m ore th an  
tw o. Spearm an 's rho w a s  used  for continuous data. Even i f  th e  patients fa iled  to 
com plete th e entire questionnaire, th e  ava ilab le  data w a s  used  in  th e calculations.
Results and analysis
Group characteristics
Of th e  in itia l 108 patients w h o  u n d erw en t GKRS b etw e e n  2003 and  2007, one patient 
h ad  to be excluded since he w a s  un ab le  to an sw er th e questions due to dem entia, 
presum ab ly not related to the VS or GKRS. Q uestionnaires w ere  returned  b y  97 o f the 
rem ain in g  10 7  patients. (91% response rate)
The responders had received th e questionnaires after an  average period o f 21 m onths 
(range 2-55 m onths) fo llo w in g  GKRS. The stu d y  group's ch aracteristics are outlined  
in  Table 1.
Table 1 Descriptive statistics of the study group.
52 male / 45 female
53 years (range 23-81 years)
56 years (range 24-84 years)
27 months (range 2-126 months)
58 right (59.8%) 39 left (40.2%)
94 extram eatal (96.9%) 3 intram eatal (3.1%) 
17 m m  (range 6-39 mm)
2721 m m 3 (range 25-17700 m m 3)
12 0
Sex
Mean age at VS diagnosis 
Mean age at GKRS
Mean tim e between diagnosis and GKRS
Tumor side
Tumor location
Mean tumor size extrameatal
Mean tumor volum e before GKRS
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T h e  g a m m a  k n i f e  s e t t i n g s  a n d  t u m o r  r a d i a t i o n  d o s e s  a r e  g i v e n  i n  T a b l e  2.
Table 2 G am m a knife settings and dosages at the tumor.
M ean Range SD
Marginal dose 11.1 Gy 9.3-12.5 Gy 0.45
Tumor dose 90% 12.7 Gy 12-13.2 Gy 0.33
M axim al tumor dose 19.9 Gy 16-25.5 Gy 1.7
M axim al cochlea dose 10.4 Gy 5-16.1 Gy 2.69
The marginal dose is defined as the minimal dose received by 100% of the tumor. Tumor dose 90% is 
the amount of Gy minimally received by 90% of the tumor.
General quality of life after GKRS
The general QOL a fter GKRS o f our stu d y group w a s  assessed  w ith  th e SF36 
questionnaire. Here, th e results are com pared to th ose for a n orm al D utch p op ulation .8 
A  t  test sh ow ed  that th e RP and  GH d om ains w ere  sig n ifican tly  low er in  our study 
group com pared to th e n orm al population. The p opulation  ch aracteristics and SF36 
resu lts for th e n orm al p opulation  and  th e stu d y p opulation  are g iven  in  Table 3.
Quality of life change after treatment
The GBI com pared retrosp ective ly  th e QOL o f patients before and  a fte r treatm ent 
w ith  GKRS. Table 4 outlines the results o f th e  stud y population for th is questionnaire. 
The total scores and  th e th ree  subscale scores are show n.
The m ean  total GBI score of -0.1 indicates a slight negative  change in th e overall QOL 
afte r GKRS. The m ean  social support score w a s  above zero, w h ich  indicates better 
social support a fte r treatm ent. There w a s  no sign ifican t d ifferen ce in  m ean  to ta l GBI 
score b etw e e n  patients w h o  received  th e question naires w ith in  12 m onths after 
GKRS treatm ent and  those w h o  received  th e question naires later ^ = 0 .4 0 9 , 
M an n -W h itn ey  U  test).
No sign ifican t d ifferen ce w a s  fo und  b etw e e n  m en  and  w o m a n  for th e m ean  total 
GBI score (P=0.516, M an n -W h itn ey  U  test). The GBI scores for patients yo u n ger th an  
40 years, patients from  40 to 60, and patients over 60 are sh o w n  in  Figure 1. There 
seem s to be a ten d en cy  tow ard s better QOL in  older patients. H ow ever, sign ifican ce 
w a s  not reached in  a n y  o f th e  dom ains.
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Table 3 S F 3 6  s t u d y  p o p u l a t i o n  a n d  D u t c h  n o r m a l  p o p u l a t i o n .
Study population Normal population(8) Unpaired t test
N=97 N=1742 (P value)
Age receiving 
questionnaire






PF mean (SD) 82.5 (20.9) 83.0 (22.8) 0.83
RP m ean (SD) 68 (40.6) 76.4 (36 .3) 0.03
RE mean (SD) 80.7 (36.2) 82.3 (32.9 ) 0.64
VT mean (SD) 66.3 (22.4) 68.6 (19.3) 0.25
MH m ean (SD) 80.1 (15.8) 76.8 (17.4) 0.06
SF mean (SD) 81.3 (22.1) 84.0 (22.4) 0.24
BP mean (SD) 78.4 (22.1) 74.9 (23.4 ) 0.15
GH mean (SD) 65.5 (20) 70.7 (2 0 .7) 0.01
Domains: Physical functioning (PF), Role limitations physical (RP), Role limitations emotional (RE), 
Vitality (VT), General mental health (MH), Social functioning (SF), Bodily pain (BP), General health 
(GH), Physical health (PH), and Emotional health (EH). Standard deviation (SD).
Table 4 GBI total and subscale scores.
Study population (n=97)
M ean (n) SD Range
Total score -0.1 (71) 14.6 -33.3 to 52.8
General subscale score -1.4 (78) 19.3 5 O t O 6 5
Social support subscale score +6.7 (9 4 ) 18.8 -33.3 to 100
Physical health subscale score -4.9 (91) 12.5 5 O t O 3 3
1 2 2
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Figure 1 GBI to ta l and subscale scores for patients yo u n ger th a n  40 years, patients 
b etw e e n  40 and 60 years, and patients older th a n  60 years.
(p=o,237) score (p =o ,62o ) su b sca le  score 
(p -0 ,2 07 )
su b sca le  score 
(p -0 ,7 12)
I <40 yrs (n-10) 
40-60 yrs (n-47) 
>60 yrs (n-40)
Significance assessed by the Kruskal-Wallis test.
The GBI scores calcu lated  for patients w ith  tum ors sm aller th a n  10  m m , b etw e e n  10 
and  20 m m , and larger th a n  20 m m  did not sh o w  a sign ifican t correlation b etw een  
th e m ean  total score (P=0.57 K ruskal-W allis test) and  other scores. F igure 2 show s the 
d ifferen t GBI scores for patients c lassified  b y  tum or size.
Figure 2 GBI to ta l and  subscale scores for patients w ith  tum ors sm aller th a n  10 
m m , 10  m m  th ro u gh  20 m m , and  larger th a n  20 m m .
(p=o,57o) score (p=o,6 su b sc a le  score 
(p -0 ,9 0 1)
su b sca le  score
(p -0 ,725)
< io m m  (n -14 ) 
io m m -2 o m m  (n -55) 
> 2o m m  (n -28 )
Significance tested by the Kruskal-Wallis test.
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No correlation w a s  found b etw e e n  th e m ean  to ta l GBI score for m a x im a l cochlea 
(P=0.060, Spearm an 's rho) or m a x im a l tum or rad iation  dose (P=0.365, Spearm an 's 
rho). Also, no sign ifican ce w a s  reached for th e m ean  to ta l GBI score and  in itia l 
m an agem en t; W & S or im m ed iate  GKRS a fte r d iagnosis (P=0.201, M an n -W h itn ey U 
test).
The outcom e o f th e  aud iovestibu lar sym p tom  q uestion n aire  is presented in Table 5. 
In retrospect, th e  patients h ad  th eir sym p tom s both before and a fte r GKRS. Patients 
w h o  did not h ave  a specific sym p tom  before treatm en t but did h ave  it a fter treatm ent 
w e re  p laced in  th e  'in creased ' group.












Tinnitus 78 (80%) 84 (87%) 6 (6%) 67 (69%) 24 (25%)
Hearing impairment 89 (92%) 93 (9 6 %) 6 (6%) 70  (72%) 21 (22%)
Unsteadiness / vertigo 64 (66%) 73 (75%) 7 (7%) 69  (71%) 21 (22%)
Facial function 3 (3.1%) 10 (10%) 0 89 (92%) 8 (8%)
Trigeminal function 17 (18%) 28 (29%) 4  (4 %) 78 (80%) 15 (16%)
Headache 47(4 9 %) 55 (57%) 6 (6%) 76 (78%) 15(16%)
Based  on th e aud io vestibu lar questionnaire, th e  stu d y group w a s  d ivid ed  into three 
subgroups. F igure 3 show s th e GBI scores o f th e patients w ith  increased, decreased, 
or u n altered  se ve rity  o f th e  m ost com m on aud iovestibu lar sym p tom s in the 
population : tin n itu s, h earin g  im p airm ent, and  un stead in ess / vertigo . The m ean 
general and  to ta l GBI scores w e re  sign ifican tly  h igher w h e n  th ere  w a s  a total 
decrease in  th e se ve rity  o f th e  th ree  sym ptom s. In case of an  in crease  in  severity, the 
social support score w a s  h igh er and  th e p h ysica l score w a s  lower, a lth ough  th is  w a s  
not sign ifican t for both  findings.
Com pared w ith  th e m a x im a l dosages at th e  tum or and  th e cochlea, th ere  is no 
p ositive  relation  w ith  th e groups reportin g  decreased, unaltered , or increased 
sym ptom s. A  h igh er dose w a s  not related  to an  in crease  in  sym p tom s as assessed  
w ith  th e aud io vestibu lar sym p tom  questionnaire.
1 2 4
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Figure 3 M ean  GBI scores for to ta l decrease, increase, or no ch ange in  tin n itu s, 
h earin g , and  u n stead iness.
Decreased sym ptom s 
U naltered sym ptom s 
Increased sym ptom s
(p = 0,000) score (p =0 ,00 0) su b scale  score 
(p = 0,226)
su b scale  score 
(p =0,080)
**= P<o.oi (Kruskal-Wallis test).
No secondary in terventions because of recurrent tum or gro w th  h ave occurred so far.
Discussion
In our stu d y  population, w e  fo und  th at GKRS has a sm all im pact on th e general QOL 
in  VS patients. The QOL o f VS patients a fter GKRS w a s  com parable to th at o f a norm al 
D utch population, as m easu red  w ith  th e SF36 questionnaire. O nly th e RP and GH 
dom ains w e re  sign ifican tly  low er in  our stu d y group com pared to th e norm al 
population.
A ccording to th e m ean  to ta l GBI score, th e  im pact o f GKRS on th e QOL w a s  negligible. 
H ow ever, there is a w id e  ran ge  in  in d iv id u a l QOL results and  a clear correlation w a s  
fo und  b etw een  th e ch an ge  in  se v e rity  o f aud iovestibu lar com plaints and th e total 
GBI score. Our m easu rem en ts d em onstrated  th at h earin g  sym p tom s w ere  un altered  
in  about 72%, in creased  in  22%, and decreased in  7% of th e VS patients after GKRS.
M easu rin g  QOL and com paring QOL stu d y  outcom es is d ifficu lt. The t im in g  o f the 
in te rv ie w  and  th e questions asked m a y  be decisive for th e p atien t's responses. Tumor 
size o ften  d iffers  b etw e e n  stu d y  groups. The post-treatm ent QOL outcom e could be 
in flu enced  b y  th e doctor's social and surgical skills as w e ll as b y  recurrent tum or
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g ro w th  a fte r GKRS or MS. In general each selection  bias or com orbidity d ifference 
b etw e e n  d ifferent groups m akes com parison  o f th ese  groups questionable.11 D espite 
th ese  draw backs, w e  th in k  it is u se fu l to take  note o f som e other studies w h ich  used 
th e  sam e question naires, as th e y  put our find ings in  perspective.
SF36
The SF36 results m easu red  in  our stu d y group are  g iven  in  Table 6 together w ith  
va lu es  for th e n orm al D utch population. These results are p laced alongside th e SF36 
resu lts fo und  b y  other authors a fter MS, and  after M S w ith  a VS larger th a n  20 m m  
e x tra m e a ta l diam eter.
Table 6 SF36 results for four study populations.






Tufarelli et al.(io) Nicoucar et al.(2) 
n=386 n=72 




Mean (SD) 47.6 (18.0) 57.6 (13.3) 4 9 (12.1) 50.8(-)






Female 44% 46% 4 6 %
yO%75
Mean tumor size 17 mm (6-39) Not mentionned >20 mm
Elapsed mean
time since 21 months 49 months 91 months
treatment
SF36
Mean(SD) Mean (SD) Mean(SD) M ean
PF 83.0 (22.8) 82.5 (20.9) 77.8 (27.7) 72.5
RP 76.4 (36.3) 68 (40.6) 66.7(40.6) 56.6
RE 82.3 (32.9 ) 80.7 (36.2) 67.7(25.1) 67.1
VT 68.6 (19.3) 66.3 (22.4) 55.1(23.9 ) 55.1
MH 76.8 (17.4 ) 80.1 (15.8) 61.7(26.9) 66.8
SF 84.0 (22.4) 81.3 (22.1) 73.2(25.4) .85.6
BP 74.9 (23.4 ) 78.4 (22.1) 67.9(25.1) -
GH 70.7 (20.7) 65.5 (20) 60.6(25.5) 68.2
Domains: Physical functioning (PF), Role limitations physical (RP), Role limitations emotional (RE), 
Vitality (VT), General mental health (MH), Social functioning (SF), Bodily pain (BP), General health 
(GH), Physical health (PH), and Emotional health (EH). Standard deviation (SD).
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Our scores on th e SF36 q uestion n aire  a fter GKRS w e re  v e r y  s im ilar to th ose  for a 
n orm al D utch population. This suggests th e presence o f a sm all im pact on the 
g e n e r a l OOL for VS patients w h o un d erw ent GKRS and therefore also for VS patients 
in  general.
In th e other tw o  studies after M S in  VS patients, low er scores w ere  fo und  in  all 
dom ains com pared to our post-GKRS group.2, 12 Conclusions b ased  on com parisons 
b etw e e n  th ese groups and our stu d y group are questionable because of d ifferences 
in  tum o r size and  fo llow -up tim e. M yrseth  et al. recen tly  pub lished  a prospective 
nonrandom ised study.13 They also used th e SF-36 to com pare OOL b etw een  GKRS and 
M S and did not find a n y  trend tow ard  a better or w orse  outcom e for either treatm ent 
group after tw o  years  o f follow-up.
GBI
The m ean  total GBI score w e  m easu red  in  our stu d y group w a s  -0.1, w h ich  suggests a 
v e ry  sm all im pact o f GKRS on th e OOL. H ow ever, th e  stan d ard  d eviation  (14.6) and 
th e ran ge  (from  -33.3 to 52.8) point at th e  presence o f large in ter-in d iv id u al variations. 
W e h ave  tried  to id en tify  in d iv id u a l variab les  th at could exp la in  th ese  variation s. In 
th is  search  w e  fo und  som e in d ication  of a better OOL after treatm en t in  patients 
w h o  w e re  d iagnosed  at an  older age (>60 yrs), but th is outcom e w a s  not sign ificant. 
Like previous results reported b y  m a n y  authors in clu d ing M yrseth  et al, th e  three 
m ost com m on aud io vestibu lar sym p tom s before and  a fte r GKRS w e re  tin n itu s, 
h earin g  loss, and  u n stead in ess.1 The GBI results clearly  sh o w  th e in flu ence o f these 
sym p tom s on th e OOL.
In th e literature  w e  fo und  one stu d y th at assesed  OOL a fter M S b y  GBI.14 To com pare 
our results w e  d ivided  our stu d y  p opulation  into th ree  separate  groups: patients 
w h o se  OOL w a s  better, w o rse  or th e sam e a fte r GKRS. (Table 7.)
N ikolopoulos et al. recorded a decreased OOL in  54% o f h is patients a fte r M S com pared 
to our 37% after GKRS. The sam e applies to in creased  OOL, w h ere  th e y  found  17% 
com pared to our 39% .15 Com parable results w e re  found b y  M yrseth  et al. They retro­
sp ective ly  com pared th e ir M S and  GKRS results and  concluded th at post-treatm ent 
OOL, as w e ll as fac ia l n erve  functions, h earin g , and  com plication rate, w e re  better 
a fte r GKRS.4 In th e ir latest stu d y  th ese  resu lts couls be reconfirm ed.13
127
3.4
CH A PTER 3 .4
Table 7 Q O L  a f t e r  G K R S  o r  M S  t r e a t m e n t ,  m e a s u r e d  b y  G B I . .
Study population  
after GKRS (n=97)
Nikolopoulos et al. (13) 
after M S (n=53)
Age receiving questionnaire
M ean (SD) 57.6 (13.3) 4 9 (-)
Range 26-86 25-76
Mean Tumor size 17 mm 21.5 mm
Elapsed tim e since treatment Range 0.2-4.6 yrs (mean 1.75 yr) Range 1-3 yrs
QOL m easured by GBI
Better 39.4% 17.4 %
Same 23.9% 28.8%
Worse 36.7% 53.8%
This retrospective  stu d y suggests th at GKRS, w h e n  p erform ed  w ith  a re la tive ly  low  
rad iation  dose, has a lo w  im pact on QOL in  patients w ith  VS.
To com pare th e QOL b etw e e n  patients treated  b y  GKRS and  M S a p rospective study, 
pre ferab ly  random ised, w ith  a patientgroup m atch ed  on tum or size and 
pre-treatm ent sym p tom s is required. In th e present study, th e aud iovestibu lar 
sym p to m s w ere  assessed  retrosp ective ly  and could th erefore be biased. M oreover, 
th ese  sym p tom s w ere  not ob jectively  assessed. In th at light, th e results o f th is study 
are  not fu lly  com parable to th ose  found in  th e literature.
D espite th ese  shortcom ings, th is  data o ffers fu rth er in sigh t into th e  patien t's  opinion 
and  perspective. This is im p o rtan t since d ecision-m aking in  VS cases in creasin g ly  
tends to be determ ined  b y  th e p erson al preference o f th e  patients involved.
Conclusion
This stu d y sh o w ed  th at GKRS for VS h as little  im pact on th e general QOL. H owever, 
th e  ran ge  o f in d iv id u a l QOL results is w id e. In d iv id u al QOL is in flu enced  b y  th e au ­
d iovestib u lar sym ptom s. No pred ictive  patient, tum or, or treatm en t factors for QOL 
outcom e after GKRS can be identified.
A c k n o w le d g m e n ts : The authors th a n k  M artijn  G.H. v a n  Oijen for provid ing 
sta tistica l advice.
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G EN ERA L DISCUSSIO N
Two aspects o f vestib u lar sch w an n om as (VSs) are addressed in  th is thesis. The 
clin ical beh avior o f th ese  lesions is described in  th e  first part, w h ile  th e results of 
stereotactic rad io su rgery  are eva lu ated  in th e  second part.
The natural behavior of vestibular schwannomas
There is considerable v aria tio n  in  th e n a tu ra l beh avior o f VSs. M ost are indolent and 
a n y  g ro w th  is lik e ly  to be slow. Once diagnosed, som e tum ors m a y  rem ain  stable for 
a long tim e, and  rapid g ro w th  is un usual. It rem ain s u n k n o w n  w h ich  lesions w ill  
g ro w  and w h ich  w ill  not; so far, no reliab le predictors h ave  been  identified. Current 
treatm en t protocols call for im a g in g  at reg u lar in terva ls. W hereas w e  m a y  refra in  
from  th erap y  for stable tum ors, som e ty p e  of th erap y  has to be ad m in istered  for 
g ro w in g  lesions. Thus, th ere  is great n eed  for in sigh t into th e n a tu ra l b eh av ior o f VSs, 
as illu strated  b y  th e case described in Chapter 2.1. That patient w a s  seen  in  1989, 
w h e n  th e presence o f a large  VS w a s  revealed. At th e  tim e, clin ic ian s in  the 
N etherlands did not h ave  g a m m a  kn ife  rad io su rgery  (GKRS) devices at th eir disposal. 
M oreover, th e  idea o f treatin g  a b en ign  tum or like a sch w an n o m a w ith  rad ioth erapy 
w a s  h ig h ly  con troversial in  th e eighties. In th is  case, as th e tum or w a s  considered 
life-th reaten in g, th e  patient w a s  stro n gly  ad v ised  to h ave  m icrosurgery. D espite 
persistent e fforts to convince h im  to undergo surgery, th e  patient re fu sed  an y 
treatm en t w h atso ever. Eventually, a fter 18 years, an  M RI d em onstrated  th e absence 
o f gro w th ; now, 22 years later, he is a live  and  doing w ell. His on ly  h and icap  is his 
u n ila te ra l deafness.
U ntil n o w  it has rem ain ed  in exp licab le  w h y  deterioration o f aud iovestibu lar 
sym p tom s is not accom pan ied  b y  a progression in  tum or vo lu m e as w e ll as w h y  the 
se v e rity  o f th e  sym p tom s is u n related  to th e size o f th e  tum or. To th at end, w e  
conducted tw o  studies on patients w ith  a u n ila tera l sporadic VS w h o  w ere  being 
treated conservatively. We charted  the size o f their tum or as w e ll as the progression 
o f th eir sym p to m s usin g  data on tum or ch aracteristics and  c lin ical presentation. 
Our a im  w a s  to find a relation  b etw e e n  com binations o f clin ical data (m edical 
h isto ry  and  aud io vestibu lar exam in ation s) and  th e presence or absence o f grow th . 
Chapter 2.2 show s h o w  w e  tried  to find predictors for tum or g ro w th  at th e  tim e  of 
d iagnosis. Chapter 2.3 show s h o w  w e  tried  to find  variab les  correlating w ith  tum or 
g ro w th  in  th e years  a fte r diagnosis.
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In one stu d y on tum o r b eh av ior (Chapter 2.2), w e  tried to create a pred ictive rule for 
tum or g ro w th  d u rin g  the in itia l period a fte r d iagnosis, u sin g  the patients' m edical 
h isto ry  as w e ll as the results o f audiologic and ve stib u la r fu n ctio n  exam in atio n s at 
the tim e o f d iagnosis. The stu d y  w a s  based  on the d ata o f 240 patients w ith  a 
u n ila tera l sporadic VS w h o  w ere  m an aged  con servatively . In th is group o f patients, 
w e  could re liab ly  assess w h e th e r or not there had been  progression a fte rw ard s . The 
audiologic data consisted  o f the results o f pure-tone audiom etry, speech  audiom etry, 
aud itory brain  responses (ABR), and tran sien t evoked oto-acoustic em issions 
(TEOAE). The v e stib u la r fu n ction  data com prised e lectro n ystagm o grap h ic  (ENG) 
recordings o f spontaneous n ystagm u s, saccadic testing , sm ooth pursu it testing, 
optokinetic n ystagm u s, torsion test, and caloric exam in atio n s. Not a ll o f these 
m easu res w ere  ava ilab le  for all patients in  th is stu d y group, how ever, and the audio- 
ve stib u la r e xam in atio n s w ere  not ran d o m ly  distributed. G eneral descriptive, 
anam n estic, and im a g in g  d ata w a s  screened for predictors b y  logistic  regression, 
tak in g  tum or g ro w th  a fte r one fo llow -up  scan as a dependent variab le  and the 
patient ch aracteristics as independent variab les. From the sign ifican t variab les, w e  
w ere  able to create a sim ple rule w ith  considerable sign ificance. It can  be used 
togeth er w ith  other factors like the p atien t's age and h ealth  state to d eterm ine the 
preferred  m an agem en t. (Figure 1)
Figure 1 Param eters and their contribution to the rule.
Higher score gives increasing likelihood of tumor growth during the initial observation period. SSNHL = 
sudden sensorineural hearing loss.
134
G EN ERA L DISCUSSIO N
The area under th e cu rve  (AUC) o f th e ru le  w e  created w a s  0.72. W e could have 
in creased  th at area b y  adding data on speech au d io m etry  and e lectro n ystagm o gra­
phy, but so doing w o u ld  reduce its re lia b ility  since th ese  e xam in atio n s w ere  not 
carried  out on a ll patients in  th is group. The results o f our stu d y d em onstrate th at a 
m ore reliab le predictor o f g ro w th  at th e tim e  o f d iagnosis m a y  be obtained  w ith  th is 
m odel b y  usin g  a s im ilar set o f aud iovestibu lar data th at h as b een  m eticu lously  
reg istered  for a ll patients.
The other stu d y  on clin ical tum or beh avior (Chapter 2.3) su ggested  th at th e risk of 
gro w th  in  th e  years a fter d iagnosis w o u ld  be m a x im a l in  patients h a v in g  a VS w ith  
an  extra m e a ta l com ponent and  a short duration o f h earin g  loss in  com bination w ith  
v ertigo  and/or no sudden onset o f h earin g  loss. These patients appeared  to h ave  a 
risk  of g ro w th  o f 36.9% in  th e first y e a r and  64.6% in  th e second year after d iagnosis 
(Table 1).
Table 1 Risk profile of patients w ith  VS.
H igh risk Low risk
1. VS w ith  an extram eatal component and 1. VS w ith  an extram eatal component and
•  short duration of hearing loss and •  no other predictor
•  at least one of the other two predictors
(unsteadiness/vertigo or no SSHL)
2. VS w ith  intram eatal localisation and 2. VS w ith  an intram eatal localisation and
•  all three other predictors •  at most one other predictor.
The predictors for growth are extrameatal localization and, among symptoms, short duration of hearing loss 
(1-24 months), unsteadiness/vertigo, no SSHL.
Strengths and weaknesses of the study: the clinical perspective
The com position o f th e  stu d y  p opulation  w a s  a m ajor h in d ran ce to generalizing 
from  th ese  tw o  studies. Eth ical considerations prevented  a proper ran dom ization  of 
th e patients, w h e re b y  som e w o u ld  get treatm ent and  others con servative  
m an agem en t. Patients included in  a w ait-an d -scan  (W &S) reg im en  tend  to have 
sm aller tum ors; in  th is group, th e num ber o f in tram eata l tum ors is re la tive ly  high. 
In contrast, patients w ith  larger lesions are u su a lly  treated  right a fte r diagnosis. 
A ccording to th e  literature, in tram eata l tum ors h ave  a lesser ten d en cy  to grow  
com pared to larger e x tra m e a ta l lesions.1, 2 B y  extension , th e c lin ical profile o f th e  VSs
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in  our stu d y  p opulation  w o u ld  not be rep resen tative  for a ll patients w ith  a VS. One 
m igh t argue th at our conclusions w o u ld  thus h ave  little  or no c lin ical relevance. 
W hile w e  concede th at th is is a rea listic  possibility, it should be noted th at the 
negative  in flu ence o f th e com position o f th e  stu d y group is a c tu a lly  lim ited. A fter 
all, th e  a im  o f our stu d y  w a s  to in vestigate  possible relationships b etw een  
an am n estic  data and  aud iovestibu lar sym ptom s, on th e one hand, and  th e size of 
th e  tum or at th e  tim e  o f d iagnosis and  its subsequent grow th , on th e other hand. By 
doing so, w e  tried  to fo rm ulate  a risk  profile for gro w th . W hether w e  are dealing 
w ith  sm aller or larger tum ors goes beyond th e scope o f th e  research  question and  is 
th erefore less relevant.
A no th er d raw b ack  is th e  inconsistent application o f audiologic and  vestib u lar 
fu n ctio n  exam in atio n s. The fact that not a ll patients in  th e stu d y  group had been 
subjected  to th e sam e set o f in vestigatio n s reduced th e stren gth  of our conclusions 
m arkedly. In our stu d y  o f th e  risk  profile at th e tim e  o f d iagnosis, w e  fo rm ulated  a 
ru le  b ased  on an am n estic  and  aud io vestibu lar data. Due to m issin g  data, how ever, 
its re lia b ility  w a s  rather w eak . We did d em onstrate th at p red icting th e g ro w th  o f a 
VS at th e  tim e o f d iagnosis w o u ld  be feasib le  once fu tu re  studies h ave  refin ed  the 
m odel and  set n u m erica l standards.
The advent o f M RI has revolutionized diagnostics in  VS. Form erly an  exten sive  
b a tte ry  o f in itia l audiologic in vestigation s h ad  to be carried  out in  order to increase 
th e  chance o f fin d in g a VS. The subsequent step consisted  o f vestib u la r function  
testin g , u su a lly  b y  m eans of e lectro nystagm ography. These exam in atio n s provided 
a rather large  am ount of data, w h ich  w a s  used  to proceed to som e ty p e  of im aging. 
In th e M RI era, m ost o f th ese  aud io vestibu lar exam in atio n s h ave  been  considered 
outdated and un n ecessary . W ith a se n sitiv ity  o f 100% , m odern  im a g in g  techniques 
like M RI h ave  la rg e ly  replaced aud io logy tests and  electro nystagm ography. But it 
should  be noted th at M RI is not able to id en tify  predictors o f fu tu re  grow th . As w e 
h ave  dem onstrated, ex ten siv e  aud io vestibu lar exam in atio n s are neither outdated 
nor redundant. On th e contrary, w e  argue, th e y  do rem ain  usefu l. B y  g iv in g  insight 
into th e  b eh av ior o f VSs, th eir results m a y  lead to th e identification  o f predictors of 
fu tu re  g ro w th  w ith  th e m odel w e  propose here. Of course, our m odel w o u ld  h ave  to 
be refined in  fu rth er studies in  order to in crease  its reliability.
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Stereotactic radiosurgery for vestibular schwannomas
U sing rad io su rgery  (RS) as a th erap y  for VSs has long been  a subject o f in-depth 
discussion. The a im  o f RS is tw ofold : to stabilize or reduce th e size o f th e  tum or but 
also  to arrest th e  progression o f c lin ical sym ptom s. U ntil n o w  it has been  un clear to 
w h a t exten t th ese  a im s can be achieved. The opponents o f its u se  did not hesitate to 
point out th e d isad van tages o f RS, em ph asizin g th e risk  o f rad iation-induced 
m a lig n a n c y  in  later life  and  problem s en su in g  from  su rg e ry  on tum ors th at had 
b een  irrad iated  and continued to grow. M oreover, th e tum o r does not d isappear after 
RS, so life-long fo llow -up w ith  seria l im a g in g  should  be m andatory.
W e an a ly zed  our exp erien ce w ith  gam m a  kn ife  rad io su rgery  (GKRS) w ith  respect to 
tum or control, h earin g  p reservation , and  q u a lity  o f life. In th at light, w e  tried  to 
fo rm ulate  a risk  profile for continued g ro w th  a fte r GKRS and to determ ine the 
in flu ence of docum ented  tum or g ro w th  prior to GKRS on th e  outcome.
Study of tumor control
U ntil recently, assessin g  th e size o f a tum or has been  problem atic. Severa l m ethods 
h ave  been  proposed in  th e past, no tab ly  th e one recom m ended b y  th e A m erican  
A cad em y o f ORL -  H ead and  N eck Surgery.3 The m ost recent m ethod  is th at o f the 
2003 Tokyo con sensu s.4 A lth ou gh  th e latter m ethod is v e ry  practical, it has 
considerable draw backs. In particu lar, it focuses on a single param eter, th e  m a x im u m  
diam eter in  th e a x ia l p lane on MRI. A n  a lte rn ative  m ethod is vo lum etry. V olum etric 
assessm ents o f tum or size h ave  b een  m ade possible b y  sophisticated  so ftw a re  
applications. Both  m ethods w e re  used  in  our stud ies: w e  m easu red  th e m ax im u m  
diam eter and calcu lated  th e vo lu m e o f th e  tum or d u rin g fo llow -up a fter GKRS. 
W hen ta k in g  th e  m a x im u m  diam eter as th e outcom e m easure, our results w e re  in 
line  w ith  th ose  in th e literature.5-7 We could confirm  th at GKRS is an  adequate 
m eth od  to control tum or g ro w th  in  th e great m ajo rity  of patients w ith  a VS. H owever, 
w h e n  u sin g  vo lum etric  assessm ents, our resu lts w e re  less convincing. W e conclude 
th at th e occurrence o f continued g ro w th  a fte r GKRS is u n d erestim ated  w h en  only 
th e m a x im a l d iam eter is taken  into account. Sm aller tum ors in  p articu lar can 
in it ia lly  sh ow  an  im p ressive  p ercen tage vo lu m e increase. A fter longer follow-up, 
how ever, stab ilization  or vo lu m e decrease is seen  in  m ost cases. In our population, a 
successfu l result w a s  establish ed  in  92% of th e patients a fte r a m ean  observation  
period  o f 38 m onths and a m in im a l ob servation  period  o f 24 m onths (<2mm increase 
in  largest ex tern a l diam eter). 4
The m ost appropriate w a y  to ind icate th e size o f a tum or w o u ld  seem  to be volum etry.
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Though a rational choice, it does h ave  som e draw backs th at m a y  in flu ence the 
outcom e. For in stan ce, in  sm all tum ors, an  in sign ifican t in crease  in  size is 
exaggerated  w h e n  exp ressed  as a percen tage of th e volum e. W e suppose th at th is 
d eviation  is -  at least p a rt ly  -  responsible for th e d ifference in  outcom e th at w e  
fo und  b etw e e n  th e m easu rem en ts o f largest ex tra m e a ta l d iam eter and  th e 
vo lum etric  assessm ents. N evertheless, m easu rin g  th e a x ia l tum or d iam eter m ust be 
considered outdated and  should  be abandoned. A s w e  h ave  dem onstrated, tum or 
vo lu m e try  m easu rem en ts are m ore reliab le.8
The re la tive ly  sm all num ber o f patients and a rather short fo llow -up tim e  w ould  
appear to be w e a k  points in  our stu d y design. H ow ever, our stu d y  w a s  concerned 
w ith  m ore th a n  tum or control; it a lso  addressed other aspects o f GKRS as a th erap y  
for VSs. Concerning th e in flu ence o f GKRS on th e size of th e  tum or, our results concur 
w ith  th e figures in  th e literature. Indeed, our find ings support th e  idea th at GKRS 
has a re la tive ly  large  degree o f success. A no th er w e a k  point m igh t be th e  exact 
m a rg in  o f error in  our vo lum etry. The extent to w h ich  vo lum etric  figures th at are 
based  on graysca les o f M R im ages w o u ld  correspond to th e actu a l vo lu m e o f a tum or 
rem ain s u n k n o w n . Further research  is im p erative  to determ ine th e m arg in s o f error 
in  volum etry.
Predictors of success
The m ajo rity  o f th e tum ors in  th e w ait-an d -scan  group did not grow. There w ere, 
how ever, a num ber o f g ro w in g  tum ors in  th is  group, and th ese  w e re  treated, som e of 
th em  b y  GKRS. A s a consequence, w e  h ad  access to a separate  group o f patients w h o 
had  undergone GKRS a fte r a period w ith  proven  gro w th , as docum ented b y  serial 
M RI studies. W e could th en  com pare th is group w ith  th e rest o f th e  patients w h o  had 
undergone GKRS soon a fte r diagnosis. U ndoubtedly th e latter category includes 
patients w ith  stable tum ors as w e ll as w ith  g ro w in g  lesions. W e com pared data from  
th e  patient h isto ry  and th e results o f th e  audiologic and  vestib u la r fu nction  
exam in atio n s o f th ese  tw o  groups in  order to id en tify  predictors for success of GKRS. 
W e found no indication  th at g ro w th  at th e  tim e of GKRS is correlated w ith  the 
outcom e o f GKRS. We did find th at th e m ean  tum or vo lu m e reduction after GKRS is 
less pronounced in  th e patients in  w h o m  tum or g ro w th  w a s  d em onstrated  before 
treatm ent. H ow ever, th is  d ifferen ce w a s  not sign ifican t. Furtherm ore, w e  did not 
find  a n y  other predictors for th e outcom e a fter GKRS in  VS patients. Yet w e  found 
ind ications that a g ro w in g  tum or h as a d ifferent rad io sen sitiv ity  com pared to a 
non -gro w in g tum or. Therefore, it is desirable for tum or g ro w th  prior to stereotactic 
rad io th erap y  to be docum ented and  published  togeth er w ith  th e overall results.
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Study of hearing preservation
GKRS is assu m ed  to cause less m orb id ity  th a n  m icrosurgery. In p articu lar, residual 
h earin g  tends to be better preserved, even  com pared to th e results ach ieved  b y  the 
best surgeons. We an a ly zed  our resu lts o f h earin g  preservatio n  a fte r GKRS for VSs in 
relation  to th e cochlear rad iation  doses. In m ost centers n ow ad ays, there is a 
ten d en cy  to reduce th e rad iation  dose o f GKRS in  patients w ith  a VS.
W e stud ied  a group o f patients w h o  h ad  undergone GKRS at a re la tive ly  lo w  rad iation 
dose. Their outcom es confirm  th e data in  th e literature  in d icatin g  th at there is a 
relation  b etw e e n  th e m a x im u m  dose on th e cochlea and  th e degree of h earin g  
p reservation .9 Patients w ith  a tum or occupying th e fu n d u s o f th e in tern a l aud itory 
can a l h ad  a greater risk  o f h earin g  loss th a n  patients w ith  a fu nd u s free  of tum or. 
Our o vera ll resu lts d em onstrated  th at h earin g  could be preserved  in  75% of the 
patients. H ow ever, w h e n  focusin g  on th e subgroup o f patients w h o  had serviceable 
h earin g , th is  level could be p reserved  in  ju st 41%  o f th e patients. These outcom es 
seem  to be better th a n  th e  best results th at can  be ach ieved  w ith  m icrosurgery .10 
Som e surgeons prefer to operate on patients w ith  serv iceab le  h earin g  as soon as 
possible, arg u in g  th at th ere  is a w in d o w  o f o p p o rtu n ity  not to be m issed .11 The 
n a tu ra l c lin ical course includes a grad u al progression o f deafness, so w a it in g  an y  
longer w o u ld  reduce th e chance o f p reserv in g  hearing. The sam e argum en t seem s to 
hold tru e  in  en v isa g in g  GKRS as a treatm ent m odality.
W e also  in vestigated  a possible correlation b etw een  th e dose o f rad iation  on the 
tum or itse lf and h earin g  p reservation . In our stu d y  group w e  could not dem onstrate 
such  a correlation. A p p aren tly  th e cochlea is m ore vu ln erab le  to rad iation  d am age 
th a n  th e a fferen t cochlear neurons. The results o f our stu d y  underscore th e w isd om  
o f op tim izin g  th e rad iation  p lan n in g  protocol in  order to m in im ize  th e dose on the 
cochlea and m a x im iz e  th e dose on th e tum or.
The re la tive ly  short fo llow -up period (14.2 m onths) w o u ld  seem  to be a w eak n ess of 
our study. There is, how ever, firm  evidence th at th e condition in  th e first ye a r after 
GKRS is a key predictor o f later h earin g  p reservation .12-14 A no th er argum en t raised  
a g a in st th e gen era lizab ility  o f our results is th at our group o f patients d iffers from  
th e w h o le  p opulation  o f VS patients, th e  d ifferen ce being  th at on ly  sm aller tum ors 
are u su a lly  treated  w ith  GKRS. But th is arg um en t does not hold tru e; in  general, 
th ere  is no relation  b etw e e n  th e degree o f h earin g  loss and  tum or size. H earing loss 
a fte r GKRS appeared  to be related  to d am age to th e cochlea in stead  o f d am age to the 
tum or. Therefore, th e  size o f th e tum or is irre levant. In conclusion, our results 
ind icate th at p reservation  o f h earin g  is a realistic  p o ssib ility  w h e n  VSs are treated 
w ith  GKRS.
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Study of quality of life
A  VS gives rise  to a v a r ie ty  o f sym p tom s th at n e g a tive ly  in flu ence one's q u a lity  o f 
life  (QOL). A ll th erap eutic  e fforts are a im ed  at rem ovin g  th e tu m o r or arrestin g  its 
progression. These efforts do not include re liev in g  sym p to m s th at determ ine the 
q u a lity  o f life. On th e contrary, a deterioration o f sym p tom s w a s  freq u en tly  accepted 
as th e price of h a v in g  one's tum or rem oved. A lth o u gh  GKRS is considered to h ave 
fe w e r u n w a n te d  side-effects, there is still n eed  for m ore d ocum entation  and 
quan tification  o f its im pact on QOL. To th is end, w e  conducted a stu d y on th e QOL of 
th e  patients w h o  w e re  treated  w ith  GKRS. U sing tw o  d ifferent question naires, w e  
found  th at gender, age, tu m o r size, and  rad iation  dose w e re  not correlated w ith  QOL 
a fter treatm ent. A s could be expected, QOL b efore GKRS w a s  less th a n  norm al, due to 
th e  aud iovestibu lar sym ptom s. But th e ch ange in  QOL a fter GKRS appeared  to be 
m a rg in a l or even  negligible. The ran ge  o f in d iv id u a l varia tio n  in  outcom e, how ever, 
w a s  rather w id e, perhaps in  response to tw o  factors. First, th e in trinsic pow er of the 
question naires m a y  not be su ffic ient to e x a ctly  q u a n tify  an  en tity  as en igm atic  as 
QOL. A  second p o ssib ility  is th at th e in flu ence o f GKRS on th e sym p tom s o f VS 
p atients m a y  v a r y  considerably, th ereb y  a ffe c tin g  th e results o f our study. It rem ains 
u n certa in  i f  and to w h a t extent th ese  tw o  factors h ave  p layed  a role in  th e v a r ia b ility  
o f our results. Our m ost strik in g  find ings w ere  th at th e QOL scores o f our patients are 
com parable to th ose o f th e  D utch n orm al p opulation  at large  and that, as m entioned 
earlier, GKRS for VSs has little  im pact on o vera ll QOL. The p atien t's p ersp ective  is 
n o w  o f param o u n t im p ortan ce since h is/her w ish e s  often  p lay  a decisive role in  the 
choice of th erap y  for a VS. The results o f our stu d y  m a y  contribute to th e process of 
choosing a m an agem en t strategy. M ost sa lient is th at our results are in  line  w ith  the 
data in  th e literature, sh o w in g  th at GKRS does not induce sign ifican t m orbid ity 
a ffe c tin g  QOL.
Our stu d y  w o u ld  seem  to h ave  tw o  other w e a k  points: th e non-random ized 
com position of th e group o f p atien ts; and a stu d y  design lack ing  controls and  som e 
ty p e  of com parison  w ith  another th erap y  like m icrosurgery. It is possible th at the 
profiles o f tu m o r size and  sym p tom s w ill  not m atch  up w ith  th e data on VS patients 
in  general. So far, GKRS is p referab ly  applied  to sm aller tum ors and  in  patients w ith  
serv iceab le  h earin g  (vide supra). A s m entioned  above, how ever, th e  size o f th e  tum or 
is not an  argum en t either for or a ga in st GKRS, since h earin g  loss tends to be equ ally  
d istributed  am ong patients w ith  a ll sizes o f tum or. The presence o f serviceable 
h earin g  is a prerequisite  to stu d y  h earin g  preservation . Studies on th e  resu lts of 
h earin g  a fte r other ty p e s  o f th erap y  w ill  requ ire a sim ilar group o f patients w ith  
serv iceab le  h earin g  as w ell. QOL is determ ined  b y  aud io vestibu lar sym ptom s,
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in clu d ing deafness. So m ore h earin g  deterioration in  a group of patients o ffers a 
better o p p o rtu n ity  to stu d y  th e effects on QOL. The n eg ative  in flu ence o f h earing 
loss on QOL w a s  exp ected  to be m ore pronounced in our group o f patients. This puts 
our resu lts in  perspective. Our fin d in g  that QOL is h ard ly  d im in ish ed  after GKRS is 
notew orthy, g iven  th e presum ed  overrepresentation  o f patients w ith  serviceable 
h earin g  loss in  our stu d y  group. Thus, it m a y  be exp ected  th at th e decrease in  QOL 
after GKRS am ong th e w h o le  group o f patients w ill  be even  low er, perhaps even 
non-existent.
Recommendations for future research
M ost studies attem p tin g  to eva lu ate  and  com pare d ifferent treatm ent m odalities 
are h am p ered  b y  patient selection bias. For m a n y  years, a proper random ization  
w ith  respect to m icrosurgery, W &S, and  stereotactic rad io th erap y  has been 
precluded b y  th e in a b ility  to predict fu tu re  g ro w th  and  th e fear o f tum o r progression. 
G iven  th e  u rgent need for m ore in sigh t in  th e biologic and clin ica l b eh av ior o f VSs, it 
w o u ld  be desirable to focus fu tu re  research  on th ese  aspects. One exam p le  is our 
study, described in  Chapters 3 and 4, b ased  on variab les  read ily  ava ilab le  at th e  tim e 
o f d iagnosis. M eticu lous data a rch iv in g  and  large patient groups are essen tia l to 
in crease  th e pow er of pred ictive  m odels. If data on biologic b eh av ior could be 
com bined w ith  tum or-specific find ings at th e  DNA level, th is  research  could lead to a 
m ore reliab le m ean s o f p red icting fu tu re  grow th .
A lon g w ith  ad vances in  th e field o f rad iosurgery, a problem  has arisen  in  the 
ran dom ization  of recipients o f GKRS versu s m icrosurgery. W hereas th e  patients 
m ore or less fo llow ed  th e ad vice  o f th e  otologist in  th e past, th e ir opin ion is now  
bein g in fluenced  b y  in fo rm atio n  on th e in ternet. D em an d  for GKRS has increased 
due to its re la tive ly  lo w  risk  profile and th e accu m u latin g  evidence of good tum or 
control, but also due to good m ark etin g  strategies. This is another factor h am p erin g  
a random ized controlled tria l com paring th e th ree  treatm ent m od alities (W&S, 
m icrosurgery, and  rad iosurgery) for th e general VS population.
A  ran dom ized  controlled tr ia l com paring GKRS, m icrosurgery, and  W & S for a large 
group o f VS patients w o u ld  be o f great value. N o w ad ays GKRS is in creasin g ly  used  to 
treat large VSs. This is, how ever, not gen era lly  accepted practice, since tem p orary  
progression of th e tum or after GKRS m a y  occur. Therefore strict inclusion  criteria 
w ill  be m an d ato ry  in  th e design  o f a random ized  study.15, 16
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A no th er issue is th e treatm en t o f patients in  w h o m  GKRS h as failed . U ntil now, only 
case reports and  case series h ave  been  published  on th is  m atter.17, 18 Future research 
should  elucidate th e ind ications for su rg e ry  or repeated GKRS in  th ese  cases. 
Com pletely n e w  therapies b ased  on m olecu lar science could a lso  be a prom ising 
direction  for fu tu re  research. For instance, it w o u ld  be u se fu l to id en tify  m olecular 
ta rg ets  for th e developm ent o f tum or-specific ph arm acotherapeutics. So far, ErbB 
inhib itors h ave  b een  proven  to decrease th e tum or g ro w th  o f VS xen o g ra fts  in  nude 
m ice.19
Synopsis of key findings and conclusions
There are ind ications th at th e risk  o f g ro w th  o f a VS is m a x im a l w h e n  th e  tum or has 
an  e x tra m e a ta l com ponent and w h e n  there is a h isto ry  o f a short duration o f h earing 
loss, in  com bination w ith  vertig o  and/or no sudden onset o f h earin g  loss. B ased  on 
th e  aud io vestibu lar profile and  an am n estic  data, a m odel can be developed to predict 
th e  fu tu re  g ro w th  o f a VS. W e recom m end p erform in g  exten sive  audiologic and 
vestib u la r fu n ctio n  e xam in atio n s in patients w ith  a VS. The results o f these 
in vestigatio n s can be used  to im prove th e re lia b ility  o f th e  pred ictive  m odel o f 
gro w th . W hen assessin g  th e  size o f a VS, vo lum etric  m easu rem en ts are preferable to 
m ethods usin g  th e d iam eter of th e tum or.
The p lan n in g  o f a random ized controlled tr ia l to in vestig ate  th e preferred  th erap y  
for VSs is severe ly  h am p ered  b y  eth ica l considerations. A s a consequence, it w a s  
im possib le for us to d irectly  com pare m orbid ity  a fte r m icro su rgery  and  a fte r GKRS. 
N onetheless, th e resu lts o f our stu d y are in  line  w ith  th e data in  th e literature  and 
ind icate th at GKRS has a m ore favorab le  outcom e. This applies in  p articu lar to the 
preservatio n  o f residual h earin g  and th e m ain ten an ce  o f QOL. In th at regard, our 
stu d y  is im p ortant since patients tend  to p la y  a decisive role in  th e choice o f their 
m an agem en t strategy. We fo und  th at th e QOL o f patients w ith  a VS a fte r GKRS does 
not d iffer s ig n ifican tly  from  th e QOL o f th e D utch p opulation  at large. A fter GKRS, 
th e  ch ange in  QOL is negligible.
In a su b stan tia l proportion o f th e  patients w ith  a VS, th e  size o f th e tum or rem ains 
stable after diagnosis. This m eans th at after GKRS, stab ilization  o f th e  tum or cannot 
be ascribed  to th is  treatm ent alone and  cannot be considered a th erap eutic success. 
In th ese  patients, th e tum or w o u ld  h ave  h ad  th e sam e dim ensions w ith o u t being
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irrad iated. A fter GKRS, th e patients w ith  a tum or fillin g  th e fu nd u s o f th e  in tern al 
au d itory  can al h ave  a greater risk  o f h earin g  deterioration com pared to th e patients 
w ith  a fu n d u s free  o f tum or. There are indications th at th e vo lum e reduction after 
GKRS is less pronounced in  th e patients in  w h om  tum or g ro w th  has been 
d em onstrated  in  th e period preceding GKRS.
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Each y e a r th e d iagnosis vestib u lar sch w an n o m a (VS), fo rm erly  called  acoustic 
neu rom a or acoustic neurinom a, is m ade in around 250 persons in  th e  N etherlands. 
The w a y  of th in k in g  about th is tum or lon gtim e has been  d om inated  b y  the 
com parison  w ith  other th reaten in g  in tracran ia l space occupying lesions. A  VS, 
how ever, is a s trictly  b en ign  tum or. M odern  im a g in g  techniques, such as MRI, have 
dem onstrated  th at VSs o ften  do not g ro w  and m a y  rem ain  (m eta)stable during 
years, possib ly even  for life. A s a consequence co n servative  m an agem en t w ith  serial 
im ag in g , “w ait-an d -scan ” (W &S), has becom e an  attractive  a ltern ative  to in vasive  
therapies, p a rticu la rly  in  patients w ith  a sm all tum or. M icrosurgical rem oval used 
to be th e m a in sta y  o f therapy. In recent years  rad io th erap y  has ga in ed  w id esp read  
p opularity , since th e risks and  th e load for th e  patients are m inor com pared to 
m icrosurgery. R ad ioth erap y for VSs is m o stly  p erform ed  b y  com puter aided single 
dose cobalt irrad iation , th e so-called  g a m m a  k n ife  rad io su rgery  (GKRS). Since 2002 a 
GKRS fa c ility  is present in  Tilburg, th e N etherlands.
The introduction  o f th is th esis is g iven  in  C h ap ter 1. M an ag em en t strategies on 
d iagnosis and  th erap y  for VSs are discussed. Form erly ex ten sive  aud iovestibu lar 
e xam in atio n s used to be p erform ed  as th e first step in  th e  d iagnostic  process. Since 
M RI has becom e ava ilab le  th e benefit o f th ese  tests has becom e controversial. Until 
n o w  th ere  is no consensus on w h a t should be th e best th erap y  for a VS. This thesis 
addresses som e aspects o f th e  d iagnosis and  th e th erap y  o f VSs. The first issue is the 
c lin ical behavior. K now led ge o f th e  n atu re  o f th e  tum or is o f u tm ost im p ortan ce in 
th e p lan n in g  o f th e m an agem en t: is it g ro w in g  or is it stable? One a im  o f th is  study 
w a s  to seek for predictors o f c lin ical behavior. The second a im  w a s  to eva lu ate  the 
resu lts o f GKRS concerning tum o r control, h earin g  preservatio n  and q u a lity  o f life. 
The question w h eth er success or fa ilu re  o f GKRS can  be predicted  is addressed as 
w e ll. The stu d y  d esign  is exp lained .
C h ap ter 2 .1 describes the h istory  o f a patient in  w h om  a giant VS w a s  d iagnosed 18 
years ago. B y that tim e the tum or w a s  considered as a serious threat and su rgery w as 
thought to be the only w a y  to survive  for the patient. We strongly advised the patient 
to have the operation, but he refused. Im agin g 18 years later dem onstrated that the 
size o f the tum or w a s  the sam e. M oreover, his sym ptom s (unilateral deafness and 
tinnitus) had not changed either. This case h istory  is illustrative for the unpredictable 
clin ical course of a VS, and for the problem s in  p lann ing an  appropriate m anagem ent.
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In Chapter 2.2 w e  describe a stu d y  in  patients w h o  w e re  treated  con servatively, the 
W & S group. W e tried  to create a pred ictive  ru le for tum or g ro w th  at th e  m om ent of 
diagnosis. The fact th at th is  stu d y w a s  carried  out in  th e W & S group is an  im p airm ent 
in  th e va lid atio n  o f th e  results. The resu lts o f an  exten siv e  set o f aud iovestibu lar 
in vestigatio n s on th e m om ent o f d iagnosis w e re  com pared w ith  presence or absence 
o f g ro w th  about one year later, at th e first fo llow -up scan. Logistic regression  m odels 
w e re  fitted  w ith  g ro w th  as th e dependent va ria b le  and  patient ch aracteristics and 
aud io vestibu lar data as independent variab les, in  order to fo rm ulate  a predictive 
m odel. The m odel th at w e  con structed  appeared  to be, how ever, not su ffic ien tly  
satisfactory, due to incom plete and  in consistent a v a ila b ility  o f aud iovestibu lar data. 
The results o f th is  stu d y d em onstrate th at th e re lia b ility  o f th is pred ictive  ru le can 
be im proved  b y  p erfo rm in g an  id en tical set o f ex ten siv e  aud iovestibu lar 
exam in atio n s in  a ll patients. A  consistent application  o f au d io m etry  and vestib u lar 
tests has rem ain ed  u se fu l in  th e d iagnostic  w ork-up o f patients w ith  a VS, or 
suspected  to h ave  a VS.
In Chapter 2.3 w e  tried  to find a correlation b etw e e n  fu tu re  g ro w th  o f th e  tum or and 
data o f audiom etry, h isto ry  and  localization  o f th e  lesion. Four predictors o f grow th  
could be id entified : tum or localization, vertigo , absence o f sudden onset o f deafness 
(“sudden d eafn ess” ) and short duration o f h earin g  loss. E xtram eata l localization  of 
th e  tum or in  com bination w ith  short duration o f h earin g  loss and at least one o f the 
rem ain in g  predictors w a s  sig n ifican tly  related  to a larger chance o f g ro w th  in the 
tw o  years  a fte r d iagnosis. A n  in tram eata l localization  in  com bination  w ith  all three 
predictors h ad  a s im ilar result. The chance o f g ro w th  w a s  sign ifican tly  sm aller in  
e x tra m e a ta l tum ors w ith o u t predictors and  in  in tram eata l tum or w ith  ju st one 
predictor.
The results o f GKRS on tum or control are described in C h ap ter 3.1. A ssessm ent o f the 
exact size o f th e  tum or has rem ain ed  problem atical. A ccording to th e  so-called  Tokyo 
gu idelines, estab lish ed  in  2001, th e size o f th e tum or has to be exp ressed  as the 
m a x im u m  e x tra m e a ta l d iam eter in  th e a x ia l p lane on M R-im ages. H owever, 
a fte rw a rd s  sophisticated  so ftw a re  for vo lum etric  m easu rem en ts has becom e m ore 
e a s ily  availab le. O bviously, th e  vo lu m e o f a lesion has to be considered to be a better 
m easu re  for its size th a n  ju st th e  m a x im a l diam eter. A ccording to th e Tokyo 
gu id elin es th e resu lts o f GKRS in  our patients w a s  in  line  w ith  data in  th e literature. 
H ow ever, usin g  vo lum etric  m easu rem en ts our results appeared  to be in ferior to
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w h a t is m entioned in th e literature. It is concluded th at un d oub ted ly  GKRS is a 
va lu a b le  m ethod  to stabilize a VS or to bring about a reduction in  its size, but in  the 
fu tu re  results should  be p referab ly  reported u sin g  m odern  vo lum etric  techniques 
in stead  o f th e  som e d iam eter o f th e  lesion.
Chapter 3.2 describes th e stu d y on th e  pred ictive factors o f success o f GKRS. It has 
b een  su ffic ien tly  d em onstrated  th at a su b stan tia l part o f th e VSs is (m eta)stable at 
th e m om ent o f d iagnosis. Therefore in  m a n y  patients th e “success” o f GKRS is not a 
th erap eutic result, but ju st p art o f th e  n a tu ra l beh avior o f th e  tum or. In other w o rd s : 
in  m a n y  patients th ere  w a s  no need for GKRS, since arrest o f tum or progression 
w o u ld  also h ave  happened  w ith o u t th is therapy. To stu d y  th e real e ffect o f GKRS w e 
fo cused  at th e  th erapeutic result in  th e group o f patients w ith  a g ro w in g  tum or, as 
dem onstrated  during a fo llow -up period. The results in  th ese  patients w ere  com pared 
to th e rem ain in g  patients w h o  had GKRS and in w h o m  th e h isto ry  o f g ro w th  w a s  
u n k n o w n . The data o f history, tum or ch aracteristics and  aud iovestibu lar 
exam in atio n s of both  groups w ere  com pared, but no sign ifican t d ifferences could be 
dem onstrated. H ow ever, th e reduction o f th e  size of th e  tum or a fte r GKRS seem ed to 
be less pronounced in  patients w ith  a g ro w in g  tum or, but th is find ing w a s  not 
sign ifican t. Future research  is needed  to elucidate th e  fa c tu a l in flu ence o f GKRS on 
gro w th  o f a VS, to id en tify  predictors for success and  to refine th e in dications for this 
therapy.
The subject o f Chapter 3.3 is h earin g  preservation  a fte r GKRS for VSs. Special 
attention  is paid  to rad iation  doses on th e  cochlea. H earing rem n an ts could be 
p reserved  in 75% of th e patients. H ow ever, in  ju st 41% patients w ith  u se fu l h earing 
th is  level o f h earin g  could be preserved  after GKRS, according to th e defin itions of 
preservatio n  and  u se fu ln ess o f h earing . Our results are in  line  w ith  data reported in 
th e literature. Even th e best results o f m icro su rgery  do not com e up to th is  level of 
h earin g  preservation . The rad iation  dose on th e cochlea appeared  to be related  to the 
degree o f h earin g  loss, w h ereas th e dose on th e  tum or did not h ave  such an  effect. 
A p p aren tly  th e se n s it iv ity  for rad iation  induced d am age  is m ore pronounced in  the 
cochlea th a n  in  th e tum or and  a fferen t p ath w ays. We conclude th at p lan n in g  of 
GKRS should pre ferab ly  be p erform ed  m a x im iz in g  th e rad iation  dose on th e tum or 
and  reducing as m uch as possible rad iation  on th e cochlea.
The th erap y  of VSs m a y  h ave  serious consequences for th e q u a lity  o f life  (QOL). 
Therefore w e  conducted a retrospective  stu d y  on th e QOL after GKRS, usin g  tw o
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different questionnaires, described in Chapter 3.4. The QOL before treatm ent w as 
lower than in the general Dutch population, as could be expected, although 
considerable variations w ere found. This variab ility  presum ably is caused by the 
m ultiform  symptoms that go along w ith  a VS. For instance serious vertigo and 
debilitating tinnitus m ay significantly contribute to the scores in some patients. It is 
remarkable that this study reveals that the QOL rem ained unchanged after GKRS. 
We presum ed that loosing hearing after GKRS would seriously affect the QOL, but 
this w as not observed in our study. Our results are m ostly in line w ith  data in the 
literature. We conclude that GKRS hardly affects the QOL. This inform ation is of 
param ount im portance in the process of decision m aking in patients w ith  a VS.
In the general discussion, Chapter 4, w e  sum m arize our results and conclusions and 
w e elaborate on what w e  have learned. There is one major im pairm ent in the 
research on the clinical behavior as w ell as on the value of m anagem ent strategies. 
That is the im practicability to perform a randomized controlled study. The VS is an 
intracranial tum or w ith  an unknow n grow th potential, w hich m eans that in 
individual cases w e are not able to estim ate whether the tumor is growing or not. As 
a consequence ethical principles preclude randomization of patients in groups 
receiving GKRS, m icrosurgery or conservative m anagem ent. The variety  of 
sym ptom s of a VS constitute another problem, since imponderables m ay interfere in 
the evaluation of the results of treatment. And there are also variations in types of 
radiotherapy, radiation planning and technique and quality of surgery. These 
intrinsic drawbacks and im pairm ents certain ly have affected the strength of our 
study. Nevertheless the results of the studies described in this thesis have elucidated 
aspects of clinical behavior of VSs and the value of GKRS, leading to suggestions for 
guidelines in clinical practice. In conclusion recommendations for future research 
are made.
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De d iagnose vestib u la ir  sch w an n o o m  (VS), ook w e l genoem d brugh oektum or of 
acousticus neurinoom , w ordt in  N ederland ongeveer 250 m a a l per ja a r  gesteld. In 
het verled en  w e rd  bij o p vattin gen  over de b eh an d elin g  v a n  deze aan d o en in g  v a a k  
de verge lijk in g  getrokken m et andere, ve e la l k w a a d a a rd ig e  in tracran ië le  tum oren. 
Het VS is echter een vo lstrekt go ed aard ige tum or en m ede dankzij de kom st v a n  
m oderne beeldvorm ende tech nieken  zoals de M RI is kom en v a st  te staan  dat deze 
tu m o ren  v a a k  jaren , en som s zelfs leven slan g , stabiel v a n  grootte ku n n en  blijven. 
H ierm ee is het a fw a ch te n d  beleid  m et reg elm atige  beeldvorm ing, het zogenaam de 
“w ait-an d -scan ” (W &S), een  aantrekkelijk  a lte rn atie f gew orden  voor b eh an delin g, 
vo oral bij kleinere, n iet bed reigen de tum oren. V anouds bestond de b eh an d elin g  uit 
ch iru rg isch e  ve rw ijd e rin g  v a n  de tum or. D aarn aast w a s  er de m ogelijkheid  om  de 
tum or te b estralen . In de laatste  decenn ia  is de b estra lin g sb eh an d elin g  m ede door 
de verbeterde bee ld vo rm in g  en betere technieken, n au w k eu riger gew orden. De 
laatste  decenn ia  is het aan d eel v a n  VS p atiën ten  dat is b estraa ld  sterk toegenom en. 
Een v a n  de gesch ik te  b estra lin g sm eth od es is een een m alige  stereotactische 
b estra lin g  m et het zogenaam d e g a m m a  knife. Deze tech n iek  w ordt sinds 2002 ook 
in  N ederland toegep ast in  het G am m a K n ife  Center bij het St E lisabeth  Ziekenhuis te 
Tilburg. Deze b eh an d e lin g sw ijze  w ordt ook w e l rad io ch iru rg ie  o f g a m m a  kn ife  
rad io su rgery  (GKRS) genoem d.
In H oofdstuk 1, de Inleid ing, w ordt de m et de d iagn ostiek  en beh an d elin g  
sam en h an g en d e  p roblem atiek  behandeld . Tot op heden b estaat er in  ons lan d  en ook 
in tern atio n aa l nog geen  consensus over w a t de beste b eh an d elin g  is. Uit deze 
problem atiek  is voor het in  dit p ro efsch rift b esch reven  onderzoek een  keuze 
gem aakt. Dit onderzoek h eeft b etrekking op tw e e  aspecten  v a n  het VS. Ten eerste 
w e rd  gezocht n aar factoren die eventu ele  groei zouden ku nnen  voorspellen . Ten 
tw e ed e  w erd  de w a a rd e  v a n  de GKRS onderzocht voor w a t b etre ft tum orcontrole, 
behoud v a n  gehoor en k w alite it v a n  leven . Ook w erd  onderzocht o f er voorspellende 
factoren  ku n n en  w ord en  geïdentificeerd  voor het slagen  of m islu kken  v a n  GKRS. 
Tevens w ordt de opzet v a n  het onderzoek in dit h oofdstuk u iteengezet.
In H oofdstuk 2.1 w ordt de ziektegesch iedenis b esch reven  v a n  een patiënt bij w ie  18 
ja a r  geleden een groot VS w erd  vastgeste ld . D estijds w e rd  de tum or v a n w e g e  zijn 
o m van g als leven sb ed reigend  b esch ou w d  en w a s  ch iru rg isch e  ve rw ijd e rin g  de 
en ige behandeloptie. Deze patiën t kreeg toen dus het d ringen d  ad vies zich te laten
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opereren. Hij w eigerd e  dit echter en onttrok zich aan  verdere controle. Na 18 ja a r  kon 
b eeldvorm en d onderzoek w orden h erh aald  en toen bleek dat zow el de tum orgrootte  
als de sym p tom en  onverand erd w aren . Deze ziektegesch iedenis is il lu stra tie f voor 
het o n verw ach te  en onvoorspelbare beloop v a n  het ziekteproces als problem en bij de 
ju iste  keuze v a n  behan delin g.
H oofdstuk 2.2 besch rijft een studie  w a a r  w ordt geprobeerd, om op basis v a n  
va riab e len  die reeds bekend zijn op het m om ent v a n  diagnose, te  voorspellen  o f de 
tu m o r gedurende de eerste periode n a  d iagnose groeit. In dit deel v a n  het onderzoek 
m oest gebruik  gem aakt w o rd en  v a n  de gegeven s v a n  de p atiën ten  uit de W &S-groep, 
een  in trin siek  nad eel bij het onderzoek en een beperkende factor bij het form uleren  
v a n  conclusies. R etrosp ectief w erd  gekeken n aar enerzijds het vóórkom en v a n  groei 
bij de eerste vervo lg sc an  en anderzijds de resu ltaten  v a n  een groot a a n ta l u itgebreide 
aud iologische en vestib u la ire  onderzoeken op het tijdstip  v a n  het ste llen  v a n  de 
diagnose. A an  de h an d  v a n  au d iovestibu la ire  data als o n afh an kelijk e  va ria b e le  en 
bew ezen  tum orgroei bij de eerste vervo lg scan  als a fh an k e lijk e  va ria b e le  w e rd  een 
voo rsp ellin gsm o d el geconstrueerd. Het bleek dat tum or locatie, duizeligheid, 
plotsdoofheid  en gehoorverlies < 2 ja a r  de groei v a n  de tum or in het eerste ja a r  n a  de 
d iagnose tot op zekere hoogte konden voorspellen . Het bleek echter dat de b etro u w ­
b aarh eid  v a n  dit m odel nog niet o p tim aa l w a s . Dit k w a m  doordat de om van g  v a n  de 
ten  tijde v a n  het ste llen  v a n  de d iagnose verrich te  au d io vestib u la ire  onderzoeken 
niet altijd  dezelfde w a s : er w a s  dus een versch il in  de b esch ikbare  aud iovestibu laire  
data. M et dit onderzoek is even w el aan getoon d  dat de b etro u w b aarh eid  v a n  dit 
voo rsp ellin gsm o d el nog verbeterd  kan  w ord en  door op consequente w ijze  telkens bij 
elke patiënt m et een VS ten tijde v a n  het stellen v a n  de d iagnose een identieke set 
(uitgebreide) au d iovestibu la ire  d iagn ostiek  te verrich ten . Op term ijn  zal h ierm ee 
een  b elan grijk  hulpm iddel ter besch ikk ing ku n n en  kom en bij de beslu itvorm in g 
over het te vo lgen  beleid  bij een patiënt m et een VS. De d iagnose VS kan  tegenw oordig 
m et behulp v a n  M RI gem akkelijk  gesteld  w orden. Echter, het u itvo eren  v a n  
uitgebreide audiologische en vestib u la ire  onderzoeken, zoals die in  het verleden 
w erd en  gedaan , is dus niet oud erw ets o f overbodig.
Het vo orsp ellen  v a n  de groei v a n  het VS op lan ge  term ijn  w ordt in  H oofdstuk 2.3 
onderzocht. H ier w ordt een  pro sp ectie f onderzoek in  de W & S groep p atiën ten  naar 
een m ogelijke sam en h an g  tu ssen  enerzijds groei v a n  het proces en anderzijds de 
lo kalisatie  v a n  de tum or en audiologische en an am n estisch e  data. Het blijkt dat net 
als bij het vo orsp ellen  v a n  groei op de korte term ijn , v ier factoren  als groeivoorspel-
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lers ku n n en  w ord en  b eschouw d: de locatie  v a n  de tum or (intra- v s  extram eataa l), de 
aan w ezig h eid  v a n  duizeligheid, de a fw ez igh e id  v a n  plotsdoofheid  en een korte duur 
v a n  het gehoorverlies. E xtram eata le  ligg in g  v a n  de tum or in com binatie  m et een 
korte duur v a n  het gehoorverlies en m in sten s een v a n  de tw e e  overige groeivoor- 
spellers blijkt vergezeld  te  g a a n  m et een  sign ifican t grotere kan s op groei v a n  de 
tum or in  de ja ren  vo lgen d  op het stellen  v a n  de diagnose. Dit is ook het geva l bij de 
com binatie  in tram eata le  lig g in g  v a n  de tum or en aan w ezig h eid  v a n  alle  h ierboven  
genoem de groeivoorspellers. Bij ex tra m e a ta le  tum oren  zonder de aan w ezig h eid  v a n  
groeivoorspellers en in tram eata le  processen m et aan w ezig h eid  v a n  hoogstens één 
groeivoorspeller is de kans op groei sign ifican t lager.
H oofdstuk 3.1 b esch rijft de resu ltaten  v a n  GKRS voor w a t b etreft stabilisatie , re s­
pectieve lijk  reductie v a n  de grootte v a n  de tum or. Een b elan grijk  probleem  bij deze 
studie  w a s  het n au w k eu rig  vastste lle n  v a n  de om van g  v a n  de tum or. In 200 1 w erd  
h iertoe in  Tokyo een in tern atio n aal geldende richtlijn  afgesproken om  de grootte 
v a n  een  VS v a st te stellen. Hierbij w e rd  de m a x im a le  d iam eter v a n  het proces in  het 
a x ia le  v la k  op de M RI-beelden als m aat genom en. N adien  is even w el verfijn de 
so ftw a re  ter b esch ikk in g gekom en, w a a rm e e  het vo lu m e v a n  de tum or eenvoudiger 
kan  w ord en  vastgeste ld . W anneer w e  het resu ltaat v a n  GKRS b esch ou w en  aan  de 
h an d  v a n  de tum orgrootte  gem eten  vo lgens de Tokyo m ethode blijken onze 
resu ltaten  overeen  te  kom en m et die u it andere centra, b esch reven  in  de literatuur. 
Echter, w a n n e e r  w e  gebruik  m aken  v a n  het berekende vo lu m e v a n  de tu m o ren  voor 
en n a  GKRS dan zijn onze resu ltaten  m inder goed, echter nog altijd  bevred igend. 
G econcludeerd w ordt dat het tegen w oord ig  de voorkeur verd ien t resu ltaten  v a n  
b eh an d elin g  te presenteren  aan  de h an d  v a n  deze vo lu m etrie  en de Tokyo m ethode 
niet m eer toe te passen . Voorts zal verder onderzoek m et grotere aan ta lle n  patiënten  
d an  m oeten  u itw ijzen  bij w e lk e  vo lu m e veran d erin g  er sprake is v a n  een  succesvolle 
b eh an d elin g  en op w e lk  m om ent een a an vu llen d e  th erap ie  is geïndiceerd.
H oofdstuk 3.2 b esch rijft het onderzoek n aar vo orspellende factoren  voor het te 
ve rw a ch te n  succes v a n  de b eh an d elin g  m et GKRS. Het is in m iddels kom en v a st  te 
s ta a n  dat bij een b e lan grijk  deel v a n  de patiën ten  m et een VS de tum or stabiel is en 
de groei dus is gestopt op het m om ent v a n  het stellen  v a n  de diagnose. Het is daarom  
onm ogelijk  om n a  een beh an d elin g  m et GKRS v a st  te stellen  o f s tab ilisatie  v a n  de 
tu m oro m van g  het gevo lg is v a n  de b eh an d elin g  o f onderdeel vorm t v a n  het 
natu urlijk  beloop. M en zou ook ku nnen  stellen  dat GKRS in  een b elan grijk  deel v a n  
de p atiën ten  een overbodige b eh an d elin g  is: im m ers, ook zonder deze therap ie zou
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de tumor niet zijn gegroeid. De vraag is dus in hoeveel patiënten GKRS feitelijk in 
staat is tumorgroei tot stand te brengen. Daarnaast zijn w ij op zoek naar mogelijke 
verschillen tussen het bestralen van een actief groeiende tum or en het bestralen 
van  een tumor die zich in een stabiele fase bevindt. Om dit te onderzoeken richtten 
w ij ons op de groep patiënten bij w ie  tumorgroei w erd vastgesteld na een observa­
tieperiode in het kader van  een W&S-beleid. De resultaten van  GKRS in deze groep 
werden vergeleken met die van  de overige met GKRS behandelde patiënten, dus die 
patiënten w aarbij de groeipotentie onbekend was. Vervolgens w erd onderzocht of er 
verschillen tussen beide groepen w aren voor w at betreft anam nestische data, tu- 
morkarakteristieken en audiovestibulaire onderzoeksresultaten. In dit onderzoek 
konden tussen beide groepen geen significante verschillen worden vastgesteld. Wel 
leek de verm indering van  het tum orvolum e na GKRS meer uitgesproken bij de groep 
patiënten w aarbij de voorafgaande groei niet bekend w as. Anders gezegd: na 
bewezen groei leek de tumor minder te kunnen worden verkleind met GKRS. Echter 
deze onderzoeksbevinding w as niet significant; verder onderzoek zal over deze 
kw estie uitsluitsel moeten geven.
In H oofdstuk 3.3 wordt de mogelijkheid onderzocht om met GKRS het (rest)gehoor te 
sparen bij patiënten met een VS, dit met nam e in relatie tot de hoeveelheid straling 
die op de cochlea w as gericht. Gehoorsparen bleek mogelijk bij 75% van  de op deze 
wijze behandelde patiënten. Echter bij die patiënten die voor de behandeling nog 
een bruikbaar gehoor hadden w as dit slechts m ogelijk in 41% van  de gevallen, een en 
ander volgens vooraf geformuleerde definities van  een bruikbaar gehoor en 
gehoorsparen. Onze behandelresultaten zijn hierm ee in overeenstem m ing met 
hetgeen wordt verm eld in de literatuur en zijn m instens zo goed en overtreffen 
m eestal de in de literatuur verm elde chirurgische resultaten. De m ate w aarin  het 
gehoor gespaard kon worden stond in relatie met de stralingsdosis op de cochlea en 
niet met die op de tumor. De cochlea is gevoeliger voor bestralings gerelateerde 
schade dan de gehoorzenuw. Voor de praktijk betekent dit dat de bestraling zeer 
nauwkeurig gepland moet worden om de stralingsdoses op de cochlea zo laag 
mogelijk te houden.
Behoud en zomogelijk verbetering van  de kw aliteit van  leven (Oualitiy of Life, QOL) 
is een belangrijk aspect bij de behandeling van  het VS. Daarom w erd onderzoek 
gedaan naar de QOL na GKRS, dat is beschreven in H oofdstuk 3.4. Aan de hand van 
tw ee verschillende vragenlijsten werd de QOL voor en na behandeling met GKRS 
retrospectief vastgesteld. Zoals verw acht kon worden bleek de QOL bij patiënten met
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een VS voor behandeling minder te zijn dan die in de gezonde Nederlandse populatie, 
zij het dat de variatie in de gemeten w aarden aanzienlijk w as. Deze vrij grote 
spreiding van  m eetresultaten zou verklaard kunnen worden door de pluriforme 
symptomatologie van  het VS. Zo kunnen invaliderende duizeligheid en ernstige 
tinnitus een belangrijke invloed hebben op de scores. Een opvallende bevinding w as 
dat de QOL na behandeling met GKRS niet of nauwelijks veranderd bleek te zijn. 
Voorstelbaar is dat verlies van  het (rest)gehoor een belangrijke invloed gehad zou 
kunnen hebben op de QOL na behandeling, m aar dit bleek niet het geval te zijn. Onze 
onderzoeksresultaten komen in grote lijnen overeen met hetgeen in de literatuur 
hierover kan worden aangetroffen. De conclusie lijkt gew ettigd dat GKRS als 
behandeling van  het VS geen of hooguit een gering gevolg heeft voor de QOL. Dit 
gegeven is van  groot belang bij de besluitvorm ing over het te voeren beleid bij 
patiënten met een VS.
In H oofdstuk 4 worden de conclusies van  dit proefschrift op een rij gezet. Bij het 
plannen en uitvoeren van  patiëntgebonden onderzoek naar aspecten van  het 
biologisch gedrag van  het VS en het evalueren van  behandelingsresultaten, blijkt 
telkens dat er één grote belem m ering is. Dat betreft de onmogelijkheid om 
prospectief gerandom iseerd onderzoek te doen. Het VS is een intracraniële tumor die 
in principe progressief kan zijn, hoewel inm iddels aannem elijk is gem aakt dat dit bij 
een groot aantal patiënten niet het geval is. Dit impliceert dat op grond van  ethische 
overw egingen het niet mogelijk is patiënten voor wetenschappelijk onderzoek te 
randomiseren in groepen met een afw achtend beleid, een operatie of een 
behandeling met GKRS. Hier komt nog bij dat het VS aanleiding kan geven tot naar 
aard en ernst gevarieerde symptomatologie. Ook bestaan er verschillen in 
chirurgische kw aliteit en vorm  en inhoud van  de bestralingsbehandelingen. Het te 
bereiken wetenschappelijke bewijs bij het evalueren van  behandelingsstrategieën 
zal dus nooit m axim aal worden. Dit vormt ook de zwakte van  het in dit proefschrift 
beschreven onderzoek. Niettem in zijn grote lijnen herkenbaar en op grond van  de in 
dit proefschrift beschreven onderzoeksresultaten zijn bruikbare aanbevelingen 










Het schrijven van  dit dankwoord besef ik dat er vele situaties zijn w aar je, naast je 
eigen inzet, afhankelijk bent van  de inzet van  anderen. Met het voltooien van  dit 
proefschrift en de opleiding tot KNO-arts is de basis van  m ijn loopbaan af. Hiervoor 
ben ik aan vele personen dank verschuldigd m aar enkele daarvan w il ik graag 
persoonlijk bedanken.
Prof. dr. K. Graam ans. Beste Kees, nadat je mij het vertrouw en gaf om te starten met 
de opleiding tot KNO-arts in Nijmegen vroeg je mij om het voorliggende onderzoek 
naar het vestibulair schwannoom  op te pakken. Jouw  jarenlange ervaring op het 
gebied van  de schedelbasis en de patiënten die daarvoor naar Nijmegen kwam en 
w aren  voor dit onderzoek de ideale uitgangssituatie. De m anier waarop je me 
begeleidde heb ik va n a f het begin als zeer prettig ervaren. Door mij geproduceerde 
m anuscripten werden door jou steevast binnen enkele dagen teruggestuurd en zo 
nodig door jou persoonlijk bij mij thuis afgegeven. Je inhoudelijke commentaren 
w aren  altijd duidelijk en de correcties naar fatsoenlijk Engels overvloedig. Ik kan me 
voorstellen dat je m enigm aal hebt gelachen (of gehuild) om de Engelse teksten van 
m ijn hand... Met veel plezier kijk ik terug op de werkbesprekingen die w e hadden op 
“Het Rijk van  Nijmegen” en de m aandelijkse werkbespreking bij jou thuis aan de 
keukentafel. Een, twee, drie en “one for the road” ! Ik hoop je nog vaak  te spreken en 
ik w ens jou en Donny al het goede toe. Hartelijk dank!
Dr. J.J.S. Mulder. Beste Jef, dat jij mijn co-promotor zou worden w as gezien het 
onderwerp va n a f het begin duidelijk. De gestructureerde m anier waarop jij naar 
problemen kijkt m aakt ze overzichtelijk. W anneer ik een onderzoeksopzet of patiënt- 
gebonden probleem met je bespreek kom ik steeds tot de conclusie dat ik nog niet ben 
uitgeleerd. Gedurende m ijn opleiding ben jij ook m ijn mentor geweest, het feit dat ik 
je als mentor nooit met problemen heb hoeven benaderen is een bevestiging van  de 
fantastische tijd die ik de laatste v ijf  jaar in Nijmegen heb gehad. Hartelijk dank voor 
je adviezen en de prettige samenwerking!
Prof. dr. C.W.J.R. Cremers. Hooggeleerde heer, tijdens mijn promotietraject en 
opleiding tot KNO-arts heb ik veel geleerd van  uw  nauwkeurigheid, enthousiasme 
en niet te evenaren werkethos. De m etaforen die u gebruikt, om situaties in de 
kliniek en gedurende het onderzoek te verduidelijken, zal ik niet snel vergeten. 
Hartelijk dank voor de plezierige samenwerking!
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Dr. R.T. Donders en W. Lemmens. Beste Roger en Wim, het hoofdstuk w aar ik mee 
begon (2.2) is tevens het hoofdstuk dat als laatste klaar w as. Dat lag zeker niet aan 
ju llie inzet! Zonder ju llie hulp w as er waarschijnlijk  w einig van  terecht gekomen. 
Hartelijk dank voor de hulp en het geduld!
Drs. P.E.J. Hanssen. Beste Patrick, als radiotherapeut bij het Gam m a Knife Centrum 
heb je een belangrijke rol gespeeld bij de behandeling van  alle Gam m a Knife 
Patiënten in mijn studie. Hartelijk dank voor je  hulp bij het verzamelen van  de 
follow-up gegevens voor mijn onderzoek en veel succes met het afronden van  je 
eigen promotie.
Prof. dr. J.J. van  Overbeeke. Hooggeleerde heer, v ia  u verliep het initiële contact met 
het Gam m a Knife Centrum in Tilburg. Hartelijk dank voor de samenwerking.
Dr. A.J. Beynon. Beste Andy, hartelijk dank voor je hulp bij de audiologische aspecten 
van  dit proefschrift.
Drs. J.C.J.M. Artz. Beste Janneke, toen ik met het onderzoek begon had jij reeds het 
nodige voorwerk gedaan. Hartelijk dank hiervoor en veel succes met je verdere carrière.
Drs. A.E. van  Haren. Beste Anniek, hartelijk dank voor jouw  enorme inzet tijdens je 
wetenschappelijke stage!
Drs. R.R.C. Timmer. Roderick, mijn broertje en mijn beste vriend. Ik ben er trots op dat 
je bij de verdediging van  dit proefschrift als paranim f naast me staat. Ook al w as het 
v a n a f het moment dat ik begon met schrijven aan dit proefschrift een uitgem aakte 
zaak...
Drs. A.B. Rinia. Beste Bas, w ij begonnen sam en aan onze KNO-carrière. Sinds onze 
start in het laboratorium van  het AMC ging het mij niet alleen m aar voor de wind. 
Je w as er gedurende deze periode en daarna. Je bent een trouw e vriend en dat 
w aardeer ik zeer. Geweldig dat je paran im f w ilt zijn bij m ijn prom otie!
Prof. dr. H.A.M. M arres &  dr. F.J.A. van  den Hoogen. Beste Henri en Frank, ondanks 
dat jullie niet direct bij mijn promotie betrokken waren, w il ik jullie in het dankwoord 
van  dit proefschrift toch zeker noemen. Hartelijk dank voor het vertrouwen en de 
fantastische opleiding in Nijmegen!
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S.D. Rauch, M.D. Dear Steve, you taught me the basics of w riting a scientific paper. 
And now  see w hat is has lead to.. Thank you for being the enthusiastic supervisor 
that you are, I had a great tim e in Boston!
Drs. P.A.A. Struyvenberg. Beste Paul, nadat ik mede onder jouw  supervisie begon als 
arts-assistent KNO in het m ilitair hospitaal te Utrecht heb ik je ook nog enkele malen 
gesproken toen ik twijfelde over de KNO. Hartelijk dank voor je steun en inspanningen, 
je ziet dat het niet voor niets is geweest!
Dr. N. de Vries. Beste Nico, in het Lucas Andreas ziekenhuis gaf je mij de gelegenheid 
om even goed na te denken over de toekomst. Je creëerde de mogelijkheid voor deze 
mooie revanche. Hartelijk dank daarvoor!!
Beste collega AIOS van  de afdeling KNO in het Radboud ziekenhuis. De afgelopen v ijf 
jaar w aren  jullie niet alleen m ijn collega's m aar ook mijn “Nijmeegse vrienden” en 
die van  Frederike. Hartelijk dank voor deze mooie periode! Speciale dank aan mijn 
collega's die in hetzelfde jaar begonnen aan de opleiding; Robert Jan, Godelieve, 
Sylvia (onze eigeste huisvriendin!) en Ilse. Hans, jij ook bedankt, door te dreigen 
met een inhaalm anoeuvre zorgde je voor een goede stimulans richting het afronden 
van  dit proefschrift.
B. Quist &  T. Quist-Xristidou. Lieve vader Bas en Fil, een bezoek aan Oisterwijk voelt 
altijd als een vakantie. Veel dank voor jullie oprechte interesse en m eeleven de 
afgelopen jaren. Fil, in het bijzonder dank voor jouw  bijdrage aan dit proefschrift, in 
de vorm  van  de prachtige illustratie op de k a ft!
J.C.A.M. Timmer &  G.C.E. Timmer-Mur. Lieve papa en m am a, met trots draag ik dit 
boekje aan ju llie op. Jullie hebben mij altijd gestim uleerd en geholpen om net een 
stap extra te zetten. Ik hecht veel w aarde aan jullie m ening en ben blij dat jullie die 
ook nooit achterhouden. Zoals jullie m eeleven is geweldig en ik hoop dat ju llie dat 
nog heel lang blijven doen!
Lieve Frederike, de laatste woorden in dit boekje zijn voor jou. De afgelopen jaren zijn 
behoorlijk hectisch geweest. Ik kan hier een opsom ming geven van  alle clichés die 
mij op het moment van  dit schrijven te binnen schieten, dat doe ik niet. Je kent ze 
allem aal.. en w e kunnen ze sam en beamen. Het belangrijkste dat ik je  w il zeggen is 
dat ik veel respect voor je heb en heel veel van  je houd. Ik kijk enorm uit naar de 
toekomst met jou en onze grote schatten Quirijn en Aemilia!
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Ferdinand Christiaan Alexander Timmer w erd geboren op 5 December 1978 te 
Utrecht. In 1997 haalde hij zijn VWO diploma aan het Kalsbeek college te Woerden. 
Na een tussenjaar w aarin  hij Farmacie studeerde ving hij in 1998 aan met de 
studie Geneeskunde aan de Universiteit van  Utrecht. In November 2004 werd 
de Geneeskunde bul behaald. Direct hierop volgde een onderzoeksstage van  drie 
m aanden in het M assachusetts Eye and Ear In firm ary dat is verbonden aan de 
H arvard University in Boston, onder leiding van  dr. S.D. Rauch. Na terugkom st uit 
Boston werden de beginselen van  de KNO-heelkunde geleerd als assistent KNO 
in het Centraal M ilitair Hospitaal te Utrecht. Hierna volgden enkele m aanden 
onderzoek in het AMC te Am sterdam  en een leerzame tijd als assistent KNO in het 
Lucas Andreas ziekenhuis te Amsterdam . In 2006 startte hij met de opleiding tot 
KNO-arts in het UMC St Radboud, met prof. dr. K. Graam ans als opleider. Prof. dr. K. 
Graam ans initieerde het voorliggende onderzoek naar het vestibulair schwannoom. 
In 2009 werd prof. dr. K. Graam ans als opleider opgevolgd door prof. dr. H.A.M. 
M arres. De perifere stages van  de KNO opleiding werden gelopen in Arnhem  en 
Venlo onder respectievelijk dr. H. Boum an en dr. E.J.J.M. Theunissen. Op 12 november 
2011 werd de opleiding tot KNO-arts voltooid. Per 1 januari 2012 zal Ferdinand 
aanvangen met een fellowship aangezichtschirurgie onder supervisie van  dr. PJ.F.M. 
Lohuis. Ferdinand trouwde in 2008 met Frederike Quist, geboren op 29 juni 1979 te 
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The m anagem ent of a unilateral sporadic vestibular  
schw annom a is still subject to controversy, m ain ly  
due to its unpredictable grow th pattern. Over the past 
decades, better understanding of th is  pattern has 
prompted a more conservative approach. In particular, 
improved im aging techniques have facilitated insight 
into vestibular schw annom a growth. W hen selecting  
a m anagem ent strategy, careful clinical assessm ent is 
m andatory since m ultiple factors are relevant.
This thesis addresses some issues in the diagnosis and 
therapy of vestibular schw annom as. The m ain focus 
is on clinical behavior. Understanding the nature of 
the tum or is of utm ost im portance in  p lanning the 
m anagem ent: is it grow ing or is it stable? The first 
aim  of th is study w as to seek predictors of its clinical 
behavior. The second w as to evaluate the results of 
Gamma Knife Radiosurgery concerning tum or control, 
hearing preservation and quality of life. The study  
also considers whether the success or failure of Gamma 
Knife Radiosurgery can be predicted.
